PATH: Form 990, tax year 2022

View the entire original 990 at ProPublica ↗

Organization: PATH (EIN 91-1157127)
Tax period: 2022-01-01 to 2022-12-31
Filed: 2023-11-09
IRS object ID: 202323139349305152
Schema version: 2022v5.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2023-11-09T15:23:09-06:00	ReturnTs
Tax Period End	2022-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	521392008	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	GELMAN ROSENBERG & FREEDMAN	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	4550 MONTGOMERY AVE SUITE 800N	AddressLine1Txt
City	BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	208142930	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2022-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	911157127	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PATH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	PATH	BusinessNameControlTxt
Phone	2062853500	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVENUE 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	KELLY PRIESTLEY	PersonNm
Person Title	CONTROLLER & PRIN. FIN. OFFICER	PersonTitleTxt
Phone	2062853500	PhoneNum
Signature	2023-11-09	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	KELLY	PersonFirstNm
Person Last	PRIESTLEY	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	0	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	RICHARD J LOCASTRO CPA	PreparerPersonNm
PTIN	P00288314	PTIN
Phone	3019519090	PhoneNum

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	2	TrustedCustomerCd
Authentication Assurance Level	AAL1	AuthenticationAssuranceLevelCd
Identity Assurance Level	IAL1	IdentityAssuranceLevelCd

Field	Value	IRS element (for citing)
Tax	2022	TaxYr
Build TS	2023-04-26 12:10:37Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	KELLY PRIESTLEY	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVENUE 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$389,969,297	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.PATH.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1981	FormationYr
Legal Domicile State	WA	LegalDomicileStateCd
Activity Or Mission	SEE PART III, LINE 1.	ActivityOrMissionDesc
Voting Members Governing Body	15	VotingMembersGoverningBodyCnt
Voting Members Independent	15	VotingMembersIndependentCnt
Total Employee	667	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$333,068,959	PYContributionsGrantsAmt
CY Contributions Grants	$347,720,581	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$9,205,357	PYInvestmentIncomeAmt
CY Investment Income	$4,226,978	CYInvestmentIncomeAmt
PY Other Revenue	$843,270	PYOtherRevenueAmt
CY Other Revenue	$869,980	CYOtherRevenueAmt
PY Total Revenue	$343,117,586	PYTotalRevenueAmt
CY Total Revenue	$352,817,539	CYTotalRevenueAmt
PY Grants And Similar Paid	$75,961,955	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$90,575,790	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$135,407,327	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$138,417,115	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$2,510,590	CYTotalFundraisingExpenseAmt
PY Other Expenses	$123,975,347	PYOtherExpensesAmt
CY Other Expenses	$117,640,612	CYOtherExpensesAmt
PY Total Expenses	$335,344,629	PYTotalExpensesAmt
CY Total Expenses	$346,633,517	CYTotalExpensesAmt
PY Revenues Less Expenses	$7,772,957	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$6,184,022	CYRevenuesLessExpensesAmt
Total Assets BOY	$307,073,332	TotalAssetsBOYAmt
Total Assets EOY	$335,091,155	TotalAssetsEOYAmt
Total Liabilities BOY	$253,115,813	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$282,616,412	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$53,957,519	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$52,474,743	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$129,569,809	ExpenseAmt
Grant	$38,931,915	GrantAmt
Desc	THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION AND DATA USE, PRIMARY HEALTH CARE, DIAGNOSTICS, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, MALARIA AND NEGLECTED TROPICAL DISEASES, AND MORE.(CONTINUED ON SCHEDULE O)CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2022, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED COUNTRY-LED DIGITAL HEALTH TRANSFORMATION IN NUMEROUS WAYS. WORK CONTINUED ON THE DATA USE PARTNERSHIP, A PROJECT FUNDED BY THE BILL & MELINDA GATES FOUNDATION THROUGH WHICH PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS AND USE OF DATA. WITH SUPPORT FROM THIS PROJECT, THE GOVERNMENT PUBLISHED A REFRESHED DIGITAL HEALTH INVESTMENT ROADMAP, AN IMPORTANT STEP TO ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE PROJECT LAUNCHED AN IMPROVED HUMAN RESOURCES FOR HEALTH INFORMATION SYSTEM TO BETTER TRACK CREDENTIALS AND ALLOCATE HEALTH WORKERS ACROSS THE COUNTRY. THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - AND DEVELOPED A MODEL FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE FINDINGS AND RECOMMENDATIONS WERE PUBLISHED IN A REPORT AND A SERIES OF COMMUNICATIONS MATERIALS AND WERE SHARED AT EVENTS INCLUDING THE WORLD HEALTH SUMMIT.DIGITAL SQUARE, A PATH-LED INITIATIVE BACKED BY A UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO $170 MILLION THROUGH 2026, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES. HIGHLIGHTS FROM 2022 INCLUDED UPDATING THE DIGITAL SQUARE GLOBAL GOODS GUIDEBOOK, LAUNCHING A NEW DIGITAL HEALTH TECHNOLOGIES FUNDING CALL (NOTICE G), AND RELEASING A NEW TOTAL COST OF OWNERSHIP TOOL. IN 2022, DIGITAL SQUARE ALSO ANNOUNCED THE DIGITAL RESULTS IMPROVE VACCINE EQUITY AND DEMAND (DRIVE DEMAND) PROJECT, A TWO-YEAR, $5 MILLION PARTNERSHIP WITH THE ROCKEFELLER FOUNDATION TO DEPLOY AND EXPAND THE USE OF DIGITAL HEALTH TOOLS IN FIVE COUNTRIES.PATH, WITH US CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING OVERALL HEALTH INFORMATION SYSTEM (HIS) SUPPORT ACTIVITIES AS PART OF THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM (TAP), WHICH PARTNERS WITH COUNTRIES TO BUILD LASTING DIGITAL HEALTH CAPACITY. IN 2022, THE TEAM BEGAN IMPLEMENTING THE THIRD YEAR OF THE PROJECT, WITH A FOCUS ON NATIONAL HEALTH DATA POLICIES AND GOVERNANCE, HEALTH INFORMATION SYSTEM STANDARDS, AND HEALTH INFORMATION SYSTEM WORKFORCE STRENGTHENING. THROUGH TAP, PATH WORKED TO STRENGTHEN HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN BOTSWANA, COTE D'IVOIRE, DEMOCRATIC REPUBLIC OF THE CONGO (DRC), ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, UGANDA, VIETNAM, AND ZAMBIA.IN 2022, PATH LAUNCHED THE DIGITAL HEALTH ECOSYSTEM (DHE) PROJECT IN PARTNERSHIP WITH MEDIC AND FUNDED BY THE BAYER FOUNDATION. THIS PROJECT SUPPORTS SUSTAINABILITY AND EXPANSION OF DIGITAL TOOLS FOR HEALTH BY HELPING LOCAL ENTREPRENEURS MORE EASILY ACCESS FINANCING, TECHNICAL RESOURCES, AND OPPORTUNITIES FOR SCALE. IN 2022, DHE LAUNCHED ITS FIRST ACCELERATOR PROGRAM AND IDENTIFIED AND FUNDED FOUR AFRICAN DIGITAL HEALTH ORGANIZATIONS TO EXPAND ACCESS TO TOOLS FOR COMMUNITY HEALTH. PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS, INCLUDING: TRANSFORM HEALTH; THE WORKING GROUP FOR RECOMMENDATIONS FOR G20 LEADERS; THE DIGITAL CONNECTED CARE COALITION; THE DIGITAL PUBLIC GOODS ALLIANCE, OF WHICH PATH BECAME A MEMBER IN MAY 2022; AND THE DIGITAL PUBLIC GOODS CHARTER CAMPAIGN.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.IN 2022, PATH SUPPORTED THE ADVANCEMENT OF AFFORDABLE, RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES; CONDUCTED PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATED A G6PD (GLUCOSE-6-PHOSPHATE DEHYDROGENASE) OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHED NINE PEER-REVIEWED ARTICLES. WE CONTINUED TO CONTRIBUTE TO THE AVAILABILITY OF COST-EFFECTIVE AND DEPENDABLE DIAGNOSTIC SOLUTIONS IN LOW-RESOURCE SETTINGS, ENSURING THAT COMMUNITIES IN NEED HAVE ACCESS TO TOOLS FOR AN ACCURATE AND TIMELY DIAGNOSIS.IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS). THIS INCLUDED DESIGNING AND PRODUCING 100 COVID-19 BENCHMARKING PANELS AND FACILITATING INDEPENDENT EVALUATION OF COVID-19 DIAGNOSTICS FOR THE WORLD HEALTH ORGANIZATION'S (WHO) EMERGENCY USE LISTING (EUL); COLLABORATING TO DEVELOP A PUBLICLY AVAILABLE INTERACTIVE DASHBOARD THAT STREAMLINED INFORMATION ON TECHNICAL SPECIFICATIONS, REGULATORY STATUS, AND SUPPLY OF COVID-19 TESTS, AIDING PROCUREMENT DECISIONS; SUPPORTING NATIONAL RESPONSES IN MULTIPLE COUNTRIES,INCLUDING QUANTIFYING SARS-COV-2 IN WASTEWATER AND ASSESSING COST-EFFECTIVENESS; COLLABORATING WITH MULTIPLE DIAGNOSTICS DEVELOPERS TO DEVELOP BLINDED PANELS TO TEST MOLECULAR DIAGNOSTIC ASSAYS AND ASSESS THE BEST-IN-CLASS CANDIDATES VIA IN-HOUSE STUDIES TO ENSURE UNBIASED PERFORMANCE EVALUATION; AND, CONDUCTING FEASIBILITY STUDIES IN BRAZIL TO EVALUATE THE EFFECTIVENESS OF CONTACT TRACING WITH SERIAL SELF-TESTING AND GENERATING EVIDENCE AND RESOURCES FOR IMPLEMENTATION. WE ALSO LAUNCHED THE DIAGNOSTIC IMAGE REPOSITORY, OFFERING OVER 35,000 OPEN-SOURCE IMAGES OF COVID-19 RAPID DIAGNOSTIC TESTS TO SUPPORT DEVELOPMENT OF ARTIFICIAL INTELLIGENCE-BASED SMART READERS, AND ESTABLISHED PARTNERSHIPS TO IMPROVE THE OPERATIONAL ASPECTS OF WHO'S EUL PROCESSES.WE CONDUCTED A CLINICAL TRIAL FOR ASSESSING PRESUMPTIVE TUBERCULOSIS (TB) CASES IN A LOW HIV PREVALENCE REGION (HANOI, VIETNAM) FOR THE PRESENCE OF A TB BIOMARKER, LIPOARABINOMANNAN, IN URINE. THIS WAS THE LARGEST COHORT OF ITS TYPE TO DATE (N=780) AND PATH WAS ABLE TO ASSESS THE PERFORMANCE OF TWO HIGHLY SENSITIVE IMMUNOASSAYS ON THESE SAMPLES. URINE SAMPLES WERE COLLECTED UNDER FULL ETHICAL APPROVAL AND WERE MADE AVAILABLE FOR USE BY OTHER DIAGNOSTIC DEVELOPERS WHO AIM TO IMPROVE OR DEVELOP NEW PRODUCTS.TO ENHANCE THE SECURITY OF LOCAL DIAGNOSTIC SUPPLY CHAINS IN LMICS, PATH CONDUCTED A COMPREHENSIVE LANDSCAPE ANALYSIS TO DETERMINE KEY MARKET FAILURES AND IDENTIFIED MARKET-SHAPING INTERVENTIONS NEEDED TO EXPAND ACCESS TO HIGH-QUALITY DIAGNOSTICS. THIS INCLUDED THE DEVELOPMENT OF AN INTERACTIVE DASHBOARD THAT CONSOLIDATED PUBLICLY AVAILABLE DATA ON DIAGNOSTIC COMPANIES WITH A MANUFACTURING PRESENCE IN AFRICA, LATIN AMERICA, AND SOUTHEAST ASIA. THE DASHBOARD INCREASED THE VISIBILITY AND AWARENESS OF THESE COMPANIES WITHIN EACH REGION WHILE PROVIDING AN OVERVIEW OF THEIR PRODUCT PORTFOLIOS AND QUALITY SYSTEMS.TO INCREASE ACCESS TO G6PD TESTING, ESSENTIAL FOR TREATING PLASMODIUM (P.) VIVAX MALARIA PATIENTS, WE BROKERED A VOLUME GUARANTEE FOR THE SD BIOSENSOR STANDARD G6PD TEST, THE SOLE QUANTITATIVE POINT-OF-CARE DIAGNOSTIC FOR THIS TYPE OF MALARIA. THIS GUARANTEE, PROVIDED BY MEDACCESS, SUPPORTS SD BIOSENSOR IN REDUCING THE PRICE OF THEIR POINT-OF-CARE G6PD DEVICE AND TESTING STRIPS FOR LMICS AND MORE IMPORTANTLY ENSURES SUPPLY SECURITY OF THE TEST THROUGH COMMITMENTS FROM THE SOLE MANUFACTURER.IN COLLABORATION WITH THE UK NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 29 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT THE DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW COST, SEROTYPE SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$94,042,875	ExpenseAmt
Grant	$36,699,439	GrantAmt
Desc	ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.IN 2022, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY PROVIDING EXPERTISE TO THE COVID-19 VACCINES GLOBAL ACCESS (COVAX) FACILITY, SUPPORTING VACCINE SUPPLY CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE MANUFACTURERS, STRENGTHENING COUNTRY DELIVERY READINESS, AND TRAINING PHARMACISTS IN GHANA AS VACCINATORS. WE ALSO COORDINATED GRANTS TO RESEARCH GROUPS CONDUCTING TRIALS OF COVID-19 VACCINES AT FRACTIONAL DOSES IN LOW-RESOURCE SETTINGS. WE SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL, THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, WE SUPPORTED STUDIES IN AUSTRALIA, BRAZIL, INDONESIA, MONGOLIA, AND PAKISTAN. IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED LMIC VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL MANUFACTURERS PREPARING FOR WHO PREQUALIFICATION SUBMISSION OR INSPECTION; SUPPORTED MANUFACTURERS IN CLINICAL TRIAL DESIGN AND REGULATORY FILINGS; BEGAN MAPPING THE CURRENT VACCINE MANUFACTURING CAPACITY IN AFRICA; AND SUPPORTED CLINICAL ASSAY DEVELOPMENT AND TECHNOLOGY TRANSFERS, AMONG OTHER ACTIVITIES. PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. IN 2022, PATH DISSEMINATED COLLABORATIVE STUDY RESULTS ON UNIVERSAL REAGENTS FOR SABIN INACTIVATED POLIO VACCINES. THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH CONTINUED STUDIES ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. PATH WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING AND SUBMITTED AN APPLICATION FOR JE VACCINE INTRODUCTION TO GAVI, THE VACCINE ALLIANCE, IN SEPTEMBER 2022. INTRODUCTION OF JE VACCINE IN BANGLADESH IS ANTICIPATED IN 2025.ALSO IN 2022, WE COMPLETED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE (MMCV). THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTINUED TO CONTRIBUTE TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE ROLLOUT OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP. PATH ALSO SERVED AS A COORDINATOR BETWEEN WHO, GAVI, AND GLOBAL PARTNERS TO IDENTIFY PATHWAYS TO ACCELERATE MMCV INTRODUCTION ONCE THE VACCINE IS MADE AVAILABLE. PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN JULY 2022, WHO PREQUALIFIED THE RTS,S MALARIA VACCINE, HAVING RECOMMENDED IT FOR BROADER USE IN 2021 TO CURB P. FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. IN NOVEMBER 2022, MALAWI BECAME THE FIRST OF THE THREE COUNTRIES TO EXPAND VACCINATION INTO THE SO-CALLED "COMPARATOR" AREAS OF THE PILOT PROGRAM. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO CONTINUED TO RESEARCH USE OF THE VACCINE ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION TO AVERT MALARIA IN HIGHLY SEASONAL SETTINGS.THE DEFEAT DIARRHEAL DISEASE INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2022 WAS THE NEED TO CONTINUE TO STRENGTHEN ROUTINE IMMUNIZATION COVERAGE DURING COVID-19 RECOVERY, USING ROTAVIRUS VACCINE AS AN EXAMPLE OF THE CHALLENGES AND OPPORTUNITIES.TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE THROUGH A PHASE III EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO CONTINUED A PHASE II STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL. PATH CONTINUED TO SUPPORT RESEARCH RELATED TO VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST SHIGELLA, ONE OF THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS, FOR WHICH THERE IS NO LICENSED VACCINE. WE CONDUCTED PRECLINICAL RESEARCH ON THE NOVEL, ORALLY ADMINISTERED, INACTIVATED WHOLE CELL SHIGELLA TRUNCATED MUTANT VACCINE CANDIDATE. WE ALSO INITIATED A CLINICAL TRIAL TO TEST TWO EXPERIMENTAL CHALLENGE STRAINS OF SHIGELLA TO INFORM THE FUTURE DEVELOPMENT OF SHIGELLA VACCINES. FINALLY, WE COMPLETED A SERIES OF STUDIES TO BETTER UNDERSTAND THE PUBLIC HEALTH VALUE OF POTENTIAL SHIGELLA VACCINES AND HELP INFORM DECISIONS BY INTERNATIONAL AGENCIES, FUNDERS, VACCINE DEVELOPERS, AND NATIONAL POLICYMAKERS.WE ALSO HOSTED THE 2022 VACCINES AGAINST SHIGELLA AND ENTEROTOXIGENIC ESCHERICHIA COLI CONFERENCE IN WASHINGTON, DC. THIS THREE-DAY INTERNATIONAL MEETING BROUGHT TOGETHER 270 ATTENDEES FROM 29 COUNTRIES TO SHARE RESEARCH RELATED TO THE DEVELOPMENT OF VACCINES AGAINST NEGLECTED DIARRHEAL PATHOGENS.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRISE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS. WE ALSO INITIATED WORK ON A PROJECT TO EVALUATE TWO DIFFERENT MEASLES AND RUBELLA MICROARRAY PATCHES. CLINICAL STUDY PREPARATIONS WERE UNDERWAY THROUGHOUT 2022. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WE PROVIDED SUPPORT TO THE GOVERNMENT OF NEPAL TO INTRODUCE TCV IN APRIL 2022 AND TO MAKE THE TRANSITION TO HAVE TCV IN ROUTINE IMMUNIZATION; WE CONTINUED TO SUPPORT THE GOVERNMENT OF MALAWI TO PLAN FOR TCV INTRODUCTION; AND PATH WORKED WITH NATIONAL DECISION-MAKERS TO ADVANCE APPLICATIONS FOR TCV INTRODUCTION. THE GOVERNMENT OF BANGLADESH, WITH PATH SUPPORT, SUBMITTED AN APPLICATION IN SEPTEMBER 2022. BURKINA FASO HAD A NEAR-FINAL APPLICATION IN 2022. IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES. TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HUMAN PAPILLOMAVIRUS (HPV) VACCINATION TO WHO AND OTHER STAKEHOLDERS. BASED ON THIS EVIDENCE, IN 2022, WHO ENDORSED A SINGLE-DOSE HPV VACCINATION SCHEDULE TO HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE III STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES. WE ALSO PUBLISHED AN HPV VACCINE PRODUCT CHOICE CALCULATOR FOR ASSESSING AND COMPARING COSTS OF HPV VACCINATION PROGRAMS.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$42,564,478	ExpenseAmt
Grant	$7,016,849	GrantAmt
Desc	AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA (DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA) WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR OFFICES INCLUDE:(CONTINUED ON SCHEDULE O)DRCIN 2022, PATH WORKED CLOSELY WITH THE MINISTRY OF HEALTH UNDER THE MASHAKO PLAN TO ADVANCE IMMUNIZATION COVERAGE AND COMBAT EPIDEMICS, PARTICULARLY POLIO. DEVELOPED BY THE MOH, THE PRIMARY AIM OF THE MASHAKO PLAN IS TO REDUCE THE NUMBER OF ZERO-DOSE CHILDREN THOSE WHO HAVE NOT RECEIVED ANY SCHEDULED VACCINES BY 35 PERCENT BY THE END OF 2025 AND TO INCREASE VACCINE COVERAGE THROUGH AN INITIAL PHASE OF VACCINATION CAMPAIGNS IN HAUT KATANGA, HAUT LOMAMI, ITURI, KASAI, KINSHASA, KWILU, MONGALA, TANGANYIKA, AND TSHUAPA PROVINCES. THESE NINE PROVINCES ARE MOST AFFECTED BY THE MEASLES AND POLIO EPIDEMICS AND ARE HOME TO HALF OF ALL CONGOLESE ZERO-DOSE CHILDREN. TO DATE, THE MASHAKO PLAN HAS BEEN GRADUALLY EXPANDED BETWEEN 2020 AND 2022 TO COVER ALL OF THE COUNTRY'S PROVINCES, GENERATING A 50 PERCENT INCREASE IN THE NUMBER OF VACCINATION SESSIONS COMPARED WITH 2018, RESULTING IN FULL VACCINATION COVERAGE RISING FROM 35 PERCENT TO 50 PERCENT BETWEEN 2018 AND 2020. IN 2022, PATH ALSO SUPPORTED THE MINISTRY OF PUBLIC HEALTH, HYGIENE, AND PREVENTION AND THE NATIONAL UNIVERSAL HEALTH COVERAGE COUNCIL IN THE FORMAL ADOPTION AND APPROPRIATION OF THE COSTED DIGITAL HEALTH INVESTMENT ROADMAP, WHICH AIMS TO ACCELERATE DIGITAL HEALTH TRANSFORMATION IN THE DRC. THE ROADMAP, SUPPORTED BY USAID AND DIGITAL SQUARE AT PATH AND ADOPTED FOLLOWING A ROUNDTABLE DISCUSSION THAT INCLUDED MORE THAN 90 PARTICIPANTS FROM THE DRC GOVERNMENT, DONOR ORGANIZATIONS, AND THE PRIVATE SECTOR WILL HELP TO PLOT A COURSE FOR STANDARDIZING THE DRC'S DIFFERENT DIGITAL PLATFORMS, TRAINING THOUSANDS OF HEALTH WORKERS, AND COMPUTERIZING THOUSANDS OF HEALTH CENTERS BY 2024.ETHIOPIAIN APRIL 2022, USAID-FUNDED SURVEILLANCE FOR MALARIA ELIMINATION (S4ME) PROJECT WAS LAUNCHED IN ETHIOPIA TO STRENGTHEN THE CAPACITY OF NATIONAL AND SUBNATIONAL MALARIA ELIMINATION EFFORTS. PATH PARTNERS WITH ADDIS CONTINENTAL INSTITUTE OF PUBLIC HEALTH IN THE IMPLEMENTATION OF THE S4ME PROJECT. THE S4ME TEAM ESTABLISHED THREE CLUSTER OFFICES IN HARAR, DEBREBERHAN, AND SHASHEMENE, OPERATING WITHIN THE HEALTH BUREAUS TO BRING SUPPORT CLOSER TO END USERS, FOSTER COLLABORATION WITH REGIONAL HEALTH BUREAUS AND ZONAL HEALTH DEPARTMENTS, AND ENSURE THE SUSTAINABILITY OF THE PROJECT. TO ASSESS THE IMPLEMENTATION STATUS OF THE NATIONAL MALARIA ELIMINATION PROGRAM (NMEP), PATH CONDUCTED A BASELINE SURVEY ACROSS 57 SUPPORTED WOREDAS (DISTRICTS) IN SEVEN REGIONAL STATES. SURVEY FINDINGS OF STRENGTHS AND GAPS IN THE NMEP WERE USED IN DESIGNING TARGETED AND TAILORED SUPPORT FOR MALARIA SURVEILLANCE AND ELIMINATION EFFORTS. AFTER USAID RECEIVED A REQUEST FOR SUPPORT FROM THE MOH AND THE GLOBAL FUND COUNTRY COORDINATING MECHANISM, UNDER THE S4ME PROJECT, PATH ALSO MANAGED THE HIRING PROCESS FOR TWO CONSULTANTS, BOTH INTERNATIONAL AND LOCAL, TO PROVIDE EXPERTISE THAT WILL STRENGTHEN ETHIOPIA'S APPLICATION FOR FUNDING FROM THE GLOBAL FUND. PATH CONTINUED RUNNING THE MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM IN ETHIOPIA. IN 2022, THE MACEPA TEAM CUSTOMIZED THE PUBLIC HEALTH EMERGENCY MANAGEMENT DISTRICT HEALTH INFORMATION SYSTEM-2 (DHIS2) TO MONITOR WEEKLY AND IMMEDIATELY REPORTABLE DISEASES (ENHANCING THE CAPACITY FOR DISEASE SURVEILLANCE), AND CREATED USER ACCOUNTS FOR 40,000 HEALTH FACILITIES. IN PARTNERSHIP WITH THE ETHIOPIAN PUBLIC HEALTH INSTITUTE, THE PROJECT INTRODUCED A DIGITAL SOLUTION USING THE DHIS2 TRACKER SYSTEM TO CAPTURE TRAVELERS' VACCINATION STATUS, FACILITATING THE RECORDING OF ADMINISTERED VACCINES AND ADVERSE REACTIONS. MOREOVER, THE MACEPA TEAM PLAYED A KEY ROLE IN MALARIA RISK STRATIFICATION FOR TARGETED INTERVENTIONS AND RESOURCE ALLOCATION. COLLABORATING WITH THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO, THE FEDERAL MINISTRY OF HEALTH (FMOH), THE ARMAUER HANSEN RESEARCH INSTITUTE, AND THE AMHARA PUBLIC HEALTH INSTITUTE, THE PROJECT CONDUCTED STUDIES TO UNDERSTAND MALARIA TRANSMISSION DYNAMICS IN HIGH-RISK POPULATIONS.PATH ALSO SUPPORTED THE GATES FOUNDATION'S HPV COST OF DELIVERY STUDY PROJECT. IN 2022, PATH CONDUCTED A COMPREHENSIVE HPV VACCINE COST OF DELIVERY STUDY IN ETHIOPIA, PROVIDING INSIGHTS INTO THE OPERATIONAL AND CONTEXTUAL FACTORS, AND THE OVERALL COSTS, OF THE HPV VACCINATION PROGRAM AMONG 14-YEAR-OLD GIRLS. RECOMMENDATIONS WERE MADE TO IMPROVE PROGRAM EFFICIENCY AND EXPAND VACCINATION TO MULTI-AGE COHORTS, TARGETING GIRLS AGED 9 TO 14 YEARS. UNDER USAID'S TARGETED AND TAILORED COVID-19 MASS VACCINATION PROJECT, PATH WORKED WITH THE ETHIOPIAN GOVERNMENT TO MITIGATE THE COVID-19 PANDEMIC BY PROVIDING SUPPORT IN COORDINATION AND PLANNING, CAPACITY BUILDING, SERVICE DELIVERY, DEMAND GENERATION, AND MONITORING AND EVALUATION OF VACCINATION CAMPAIGNS. THE PROJECT PLAYED AN ACTIVE ROLE IN FACILITATING THE INTEGRATION OF COVID-19 VACCINATION INTO THE ROUTINE IMMUNIZATION PROGRAM AND PROVIDED CAPACITY BUILDING, SUPPORTIVE SUPERVISION, AND DATA MANAGEMENT SUPPORT TO SIX REGIONS. THE PROJECT TEAM ACTIVELY CONTRIBUTED TO THE DEVELOPMENT OF GUIDELINES FOR COVID-19 VACCINATION INTEGRATION INTO THE EXISTING ROUTINE IMMUNIZATION SYSTEM WITH THE AIM TO INCREASE UPTAKE AND IMPROVE ACCESS TO THE COVID-19 VACCINE. PATH ALSO WORKED WITH THE GATES FOUNDATION'S COVID-19 VACCINE HESITANCY PROJECT IN ETHIOPIA TO ADDRESS COVID-19 VACCINE HESITANCY THROUGH DATA-DRIVEN, TAILORED, CULTURALLY SENSITIVE, AND INCLUSIVE COMMUNICATION INTERVENTIONS IN ADDIS ABABA AND BAHIR DAR CITY ADMINISTRATIONS. PATH CONTINUED WORKING AS PART OF GAVI'S TARGETED COUNTRY ASSISTANCE (TCA) PROJECT TO SUPPORT THE FMOH AND THE AFAR AND SOMALI REGIONS IN ACHIEVING INCREASED AND EQUITABLE IMMUNIZATION COVERAGE WITH A FOCUS ON IDENTIFYING, MAPPING, AND REACHING ZERO-DOSE CHILDREN, UNDER-IMMUNIZED CHILDREN, AND MISSED COMMUNITIES. THE PROJECT TEAM DEVELOPED A PLAN TO SUSTAIN HEALTH FACILITIES WHILE PREPARING TO EXIT FROM THE FOUR SUPPORTED WOREDAS IN THE AFAR AND SOMALI REGIONS. PATH'S ETHIOPIA SENIOR MANAGEMENT TEAM VISITED FACILITIES IN THE AFAR AND SOMALI REGIONS TO ASSESS THE IMPACT OF THE GAVI TCA PROJECT IN THE FACE OF PROLONGED CONFLICT IN NORTHERN ETHIOPIA. WE ALSO PROVIDED TECHNICAL SUPPORT ON LEADERSHIP, MANAGEMENT, AND GOOD GOVERNANCE TO THE NATIONAL AND REGIONAL EXPANDED PROGRAM ON IMMUNIZATION TEAMS UNDER GAVI'S COVID-19 VACCINE DELIVERY SUPPORT LEADERSHIP MANAGEMENT COORDINATION PROJECT. PATH CONTINUED IMPLEMENTING USAID'S BRUEH TESFA DEMONSTRATING PATHWAYS TO SCALE FOR NURTURING CARE THROUGH ENGAGEMENT, LEADERSHIP, AND SYSTEMS STRENGTHENING PROJECT, WORKING TO INTEGRATE ETHIOPIA'S EARLY CHILDHOOD DEVELOPMENT POLICY FRAMEWORK INTO MATERNAL AND CHILD HEALTH PROGRAMS AND PROMOTING MULTISECTORAL COLLABORATION.GHANAIN 2022, PATH WORKED IN COLLABORATION WITH THE GHANA HEALTH SERVICE (GHS) TO EXPAND THE ONSITE CHLORINE GENERATION PROJECT TO THREE ADDITIONAL REGIONS WITH 40 AQUA RESEARCH STREAM CHLORINE GENERATORS INSTALLED IN 24 HEALTH CARE FACILITIES. WE ALSO SUPPORTED REFRESHER TRAINING FOR OVER 200 HEALTH WORKERS IN INFECTION PREVENTION AND CONTROL PRACTICES AS PART OF THIS PROJECT.WITH FUNDING FROM THE UK FOREIGN, COMMONWEALTH, AND DEVELOPMENT OFFICE, PATH SUPPORTED THE INTRODUCTION OF THE ELLAVI UTERINE BALLOON TAMPONADE (UBT) INTO THE POSTPARTUM HEMORRHAGE MANAGEMENT AND SAFE MOTHERHOOD PROTOCOLS IN GHANA. PATH COLLABORATED WITH THE MANUFACTURER SINAPI BIOMEDICAL IN SOUTH AFRICA TO IDENTIFY A LOCAL DISTRIBUTER AND REGISTERED THE ELLAVI UBT IN GHANA. WE ALSO SHARED A POLICY BRIEF WITH THE GHS POLICY, PLANNING, MONITORING, AND EVALUATION DIVISION FOR COUNTRY SCALE-UP AND INCLUSION OF THE DEVICE IN THE ESSENTIAL COMMODITIES FOR MATERNAL HEALTH AND SUBSEQUENT ADDITION IN THE ESSENTIAL MEDICINES LIST AND NATIONAL HEALTH INSURANCE MEDICINES LIST.PATH DEVELOPED TRAINING MANUALS FOR INFECTION CONTROL AND MANAGEMENT AND SOCIAL BEHAVIOR CHANGE MATERIALS TO SUPPORT IMPLEMENTATION OF THE MATERNAL INFECTIOUS DISEASES CONTROL PROJECT AT ANTENATAL CARE SERVICES IN BONO EAST REGION.WITH FUNDING SUPPORT FROM THE CHILDREN'S INVESTMENT FUND FOUNDATION AND IN COLLABORATION WITH KYBELE INC. AND AFRICA HEALTH SUPPLIES THROUGH IMPLEMENTATION OF THE MEBCI 2.0 PROJECT, PATH EQUIPPED FOUR REGIONAL HOSPITALS' NEONATAL INTENSIVE CARE UNITS WITH NEWBORN EQUIPMENT. WE ALSO SUPPORTED TRAININGS ON THE CORRECT USE AND MAINTENANCE OF EQUIPMENT PER MANUFACTURER STANDARDS FOR MORE THAN 250 CLINICAL ENGINEERS, DOCTORS, AND NURSES WHO OFFER NEONATAL SERVICES FROM ALL FOUR FACILITIES.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$45,172,884	ExpenseAmt
Grant	$7,927,587	GrantAmt
Desc	ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN COUNTRIES IN AFRICA (SUCH AS THE DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS. PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2022, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE AND RECOVERY EFFORT FOR THE COVID-19 PANDEMIC.ASIA, MIDDLE EAST, AND EUROPE REGIONPATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR GLOBAL EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM, THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION AND PROGRAM DELIVERY. HIGHLIGHTS INCLUDE:IN 2022, PATH CONTINUED FORGING LOCAL PARTNERSHIPS TO ADVANCE INNOVATIVE, AGILE HEALTH SYSTEMS IN BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT THE PANDEMIC RESPONSE AND TEACHING IN EASTERN EUROPE AND SOUTH ASIA REGIONS. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE MOTHER-TO-CHILD TRANSMISSION OF VIRAL HEPATITIS B AND IMPLEMENT FACTORY-BASED PANDEMIC PREPAREDNESS PROGRAMS IN SOUTHEAST ASIA. THANKS TO OUR CONTINUOUS WORK IN IMPROVING LIVES WITH SCIENCE AND TECHNOLOGY, PATH WAS ABLE TO STRENGTHEN THE DEVELOPMENT OF COVID-19, POLIO, HPV, YELLOW FEVER, AND MEASLES, MUMPS, AND RUBELLA VACCINES IN CHINA; DEVELOP HIGH-IMPACT PUBLIC HEALTH PROGRAMS SUCH AS RICE FORTIFICATION, DIAGNOSTIC & SURVEILLANCE, AND DIGITAL HEALTH IN INDIA; AND SUPPORT MEDICATION-ASSISTED TREATMENT FOR TB, HIV, AND HEPATITIS C PATIENTS IN UKRAINE. THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING PRIMARY HEALTH SYSTEM SERVICES, CAPACITY, AND RESILIENCE USING COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO THE MOST VULNERABLE COMMUNITIES. FOR INSTANCE, IN INDIA, WE LAUNCHED A CLIMATE CHANGE STRATEGY THAT FOCUSES ON GENERATING EVIDENCE, BUILDING PARTNERSHIPS, AND ADVOCATING TO SUPPORT CLIMATE-RESILIENT HEALTH SYSTEMS IN THE COUNTRY.PATH IN THE AMEE REGION INTRODUCED ITS WORK AT THE HIGHEST POLITICAL LEVELS DURING THE COMMONWEALTH HEADS OF GOVERNMENT MEETING IN KIGALI, SUPPORTED INDIA IN ITS G20 HEALTH TRACK MEETINGS, AND BEGAN PREPARING TO PARTICIPATE IN THE 28TH MEETING OF THE CONFERENCE OF PARTIES AT THE UN CLIMATE CHANGE CONFERENCE IN THE UNITED ARAB EMIRATES TO HIGHLIGHT THE NEED FOR URGENT ACTION IN CLIMATE CHANGE AND HEALTH.PATH CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND HIV; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$45,172,884	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$7,927,587	TotalOtherProgSrvcGrantAmt
Total Program Service Expenses	$311,350,046	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	Yes (1)	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	0	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	0	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (1)	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	Yes (1)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (1)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	Yes (1)	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
Info In Schedule O Part V	Yes (X)	InfoInScheduleOPartVInd
IRP Document	190	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	667	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (1)	ForeignFinancialAccountInd
Foreign Country	BE	ForeignCountryCd
Foreign Country	CH	ForeignCountryCd
Foreign Country	ET	ForeignCountryCd
Foreign Country	GH	ForeignCountryCd
Foreign Country	IN	ForeignCountryCd
Foreign Country	KE	ForeignCountryCd
Foreign Country	MZ	ForeignCountryCd
Foreign Country	PE	ForeignCountryCd
Foreign Country	SG	ForeignCountryCd
Foreign Country	SZ	ForeignCountryCd
Foreign Country	TZ	ForeignCountryCd
Foreign Country	UG	ForeignCountryCd
Foreign Country	UK	ForeignCountryCd
Foreign Country	VM	ForeignCountryCd
Foreign Country	ZA	ForeignCountryCd
Foreign Country	CG	ForeignCountryCd
Foreign Country	MI	ForeignCountryCd
Foreign Country	BM	ForeignCountryCd
Foreign Country	SF	ForeignCountryCd
Foreign Country	UP	ForeignCountryCd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	15	GoverningBodyVotingMembersCnt
Independent Voting Member	15	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	KELLY PRIESTLEY CONTROLLER & PRINCIPAL FINANCIAL OFFICER	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	2062853500	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVE SUITE 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
BETH GALETTI MBA
CHAIR	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
DAVID KING JD
VICE CHAIR	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
SANFORD MELZER MD MBA
SECRETARY	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
BRUCE MCNAMER JD MBA
TREASURER	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
FREDERICK WERE MD MMED PHD
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
YEHONG ZHANG PHD MBA
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
JO ADDY MBA MPA
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
IREENA VITTAL
DIRECTOR (RESIGNED 9/15/22)	2.00	0.00	Yes (X)		$0	$0	$0
DEANNA OPPENHEIMER
DIRECTOR (RESIGNED 9/15/22)	2.00	0.00	Yes (X)		$0	$0	$0
JOHN-ARNE ROTTINGEN MD PHD
MSC, MPA--DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
JOEL HOLSINGER
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
HELENA WAYTH MSC
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
ABAYOMI SULE MBBS MBA
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
LISA ANDERSON
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
RACHEL SIBANDE MSC
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
SYLVANA SINHA
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
LUTZ HEGEMANN MD PHD
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
NIKOLAJ JESTED GILBERT MSC
PRESIDENT AND CEO	39.00	1.00		Yes (X)	$587,315	$0	$46,332
PHILIPPE GUINOT MBA
CHIEF OF BUSINESS, FIN. & OPS.	1.00	39.00		Yes (X)	$0	$309,656	$26,676
JESSICA MILMAN
EXEC. DIR., STRATEGY, OPS., & EFFECTIVENESS	39.00	1.00			$310,143	$0	$51,153	Yes (X)
JEFFREY D BERNSON MPH MPA
CHIEF PROGRAMS & INNOVATION OFFICER	40.00	0.00			$334,378	$0	$53,907	Yes (X)
MEISSA DIAW
CHIEF PEOPLE & DIVERSITY OFFICER	40.00	0.00			$223,533	$0	$401	Yes (X)
MOLLI M BARNES
CHIEF PEOPLE OFFICER (UNTIL 1/31/22)	40.00	0.00			$173,318	$0	$28,282	Yes (X)
CARLA ANNE COSTA SANDINE
CHIEF OF EXTERNAL AFFAIRS	40.00	0.00			$238,350	$0	$47,936	Yes (X)
SABRINA L POWERS JD
CHIEF OF LEGAL & RESEARCH AFFAIRS/GC	40.00	0.00			$282,858	$0	$46,915	Yes (X)
NANTHALILE C MUGALA MD MMED
CHIEF OF AFRICA REGION	40.00	0.00			$300,528	$0	$108,653	Yes (X)
NABEEL A GOHEER PHD
CHIEF OF AFRICA	40.00	0.00			$206,849	$0	$1,636	Yes (X)
DAVID C KASLOW MD
CHIEF SCIENTIFIC OFF. (UNTIL 10/8/22)	40.00	0.00			$356,341	$0	$64,013	Yes (X)
TRAD M HATTON MA MHS
DIR., CEN. AFRICA HUB & DRC COUNTRY PRO.	40.00	0.00			$360,453	$0	$53,782		Yes (X)
ASHLEY J BIRKETT PHD
GLOBAL HEAD, MALARIA VACCINES	40.00	0.00			$340,464	$0	$63,199		Yes (X)
BRUCE LAMONT INNIS MD FIDSA
GLOBAL HEAD, RESPIRATORY INFECTIONS	40.00	0.00			$351,046	$0	$34,748		Yes (X)
JOHN O KONZ PHD
GLOBAL HEAD OF POLIO	40.00	0.00			$360,406	$0	$69,154		Yes (X)
KIMBERLY GREEN PHD
DIRECTOR, PRIMARY HEALTH CARE	40.00	0.00			$332,684	$0	$70,010		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,758,666	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$309,656	TotReportableCompRltdOrgAmt
Total Other Compensation	$766,797	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	369	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt	CityContractorAddress/ForeignAddress/CityNm	CountryContractorAddress/ForeignAddress/CountryCd	Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd	ServicesServicesDesc	CompensationCompensationAmt	Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd
RANDSTAD INDIA PVT LTD
SUITE NO 001 002 COPIA	NEW DELHI	IN	110025	STAFFING SERVICES	$2,359,826
WMBE PAYROLLING DBA TARGETCW
				GENERAL CONTRACTOR	$835,922	9475 CHESAPEAKE DRIVE	SAN DIEGO	CA	92123
PIVOTAL CONSULTING LLC
				CONSULTING	$758,295	1631 15TH AVE W 118	SEATTLE	WA	98119
GLOBALIZATION PARTNERS INC
				STAFFING SERVICES	$670,108	175 FEDERAL ST 17TH FL	BOSTON	MA	02110
SAFEGUARD WORLD INT'L
BLDG 2 CAMPION PARK HOLMES CHAPEL	CREWE	UK	CW4 8AX	GENERAL CONTRACTOR	$595,667

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	60	CntrctRcvdGreaterThan100KCnt
Related Organizations	$7,258,047	RelatedOrganizationsAmt
Government Grants	$124,001,387	GovernmentGrantsAmt
All Other Contributions	$216,461,147	AllOtherContributionsAmt
Noncash Contributions	$817,716	NoncashContributionsAmt
Total Contributions	$347,720,581	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$4,050,778	TotalRevenueColumnAmt
Exclusion	$4,050,778	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$37,269,962	SecuritiesAmt
Other	$57,996	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$37,102,013	SecuritiesAmt
Other	$49,745	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$167,949	SecuritiesAmt
Other	$8,251	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$176,200	TotalRevenueColumnAmt
Exclusion	$176,200	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
OTHER	900099	$833,517	$833,517
REIMBURSEMENTS	900099	$36,463	$36,463

Field	Value	IRS element (for citing)
Other Revenue Total	$869,980	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$352,817,539	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$5,096,958	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$30,451,668	TotalAmt
Program Services	$30,451,668	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$60,124,122	TotalAmt
Program Services	$60,124,122	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$3,462,838	TotalAmt
Program Services	$1,396,390	ProgramServicesAmt
Management And General	$2,043,594	ManagementAndGeneralAmt
Fundraising	$22,854	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$99,251,909	TotalAmt
Program Services	$84,875,846	ProgramServicesAmt
Management And General	$13,719,320	ManagementAndGeneralAmt
Fundraising	$656,743	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$11,368,301	TotalAmt
Program Services	$9,492,195	ProgramServicesAmt
Management And General	$1,801,126	ManagementAndGeneralAmt
Fundraising	$74,980	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$16,517,455	TotalAmt
Program Services	$14,759,917	ProgramServicesAmt
Management And General	$1,687,296	ManagementAndGeneralAmt
Fundraising	$70,242	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$7,816,612	TotalAmt
Program Services	$6,551,104	ProgramServicesAmt
Management And General	$1,214,931	ManagementAndGeneralAmt
Fundraising	$50,577	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$1,290,110	TotalAmt
Program Services	$560,192	ProgramServicesAmt
Management And General	$728,347	ManagementAndGeneralAmt
Fundraising	$1,571	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$771,284	TotalAmt
Program Services	$171,127	ProgramServicesAmt
Management And General	$600,157	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$328,905	TotalAmt
Management And General	$328,905	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$18,835,671	TotalAmt
Program Services	$15,126,015	ProgramServicesAmt
Management And General	$3,634,561	ManagementAndGeneralAmt
Fundraising	$75,095	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$74,754	TotalAmt
Program Services	$69,009	ProgramServicesAmt
Management And General	$4,078	ManagementAndGeneralAmt
Fundraising	$1,667	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$6,500,259	TotalAmt
Program Services	$6,264,483	ProgramServicesAmt
Management And General	$178,126	ManagementAndGeneralAmt
Fundraising	$57,650	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$7,354,699	TotalAmt
Program Services	$5,692,257	ProgramServicesAmt
Management And General	$1,619,420	ManagementAndGeneralAmt
Fundraising	$43,022	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$239,103	TotalAmt
Program Services	$239,103	ProgramServicesAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$11,558,732	TotalAmt
Program Services	-$377,084	ProgramServicesAmt
Management And General	$11,940,032	ManagementAndGeneralAmt
Fundraising	-$4,216	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$14,531,024	TotalAmt
Program Services	$13,757,357	ProgramServicesAmt
Management And General	$771,898	ManagementAndGeneralAmt
Fundraising	$1,769	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$13,325,667	TotalAmt
Program Services	$13,037,359	ProgramServicesAmt
Management And General	$256,127	ManagementAndGeneralAmt
Fundraising	$32,181	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$4	TotalAmt
Management And General	$4	ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$1,934,824	TotalAmt
Management And General	$1,934,824	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$922,241	TotalAmt
Program Services	$243,761	ProgramServicesAmt
Management And General	$678,480	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
SUBCONTRACTORS	$27,441,134	$27,434,942	$6,192
EQUIP RENT & MAINT	$5,321,856	$5,334,266	-$12,410
FACILITIES ALLOC	$3,632,712	$13,928,149	-$10,510,003	$214,566
DIRECT AID TO BENEF.	$1,870,822	$1,870,822

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,706,811	TotalAmt
Program Services	$347,046	ProgramServicesAmt
Management And General	$147,876	ManagementAndGeneralAmt
Fundraising	$1,211,889	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$346,633,517	TotalAmt
Program Services	$311,350,046	ProgramServicesAmt
Management And General	$32,772,881	ManagementAndGeneralAmt
Fundraising	$2,510,590	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$12,911,863	BOYAmt
EOY	$12,287,583	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$10,006,728	BOYAmt
EOY	$39,962,314	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$38,296,068	BOYAmt
EOY	$37,140,905	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$555,337	BOYAmt
EOY	$303,620	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$7,454,031	BOYAmt
EOY	$7,299,862	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$37,198,207	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$30,625,474	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$7,119,705	BOYAmt
EOY	$6,572,733	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$230,729,600	BOYAmt
EOY	$198,170,250	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$33,353,888	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$307,073,332	BOYAmt
EOY	$335,091,155	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$253,115,813	BOYAmt
EOY	$240,270,829	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$42,345,583	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$253,115,813	BOYAmt
EOY	$282,616,412	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$20,653,709	BOYAmt
EOY	$23,389,854	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$33,303,810	BOYAmt
EOY	$29,084,889	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$53,957,519	BOYAmt
EOY	$52,474,743	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$307,073,332	BOYAmt
EOY	$335,091,155	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$6,184,022	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$7,666,798	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$305,316,107	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$286,808,545	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$287,454,383	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$333,068,959	CurrentTaxYearMinus1YearAmt
Current Tax Year	$347,720,581	CurrentTaxYearAmt
Total	$1,560,368,575	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$305,316,107	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$286,808,545	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$287,454,383	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$333,068,959	CurrentTaxYearMinus1YearAmt
Current Tax Year	$347,720,581	CurrentTaxYearAmt
Total	$1,560,368,575	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$702,888,681	SubstantialContributorsTotAmt
Public Support Total170	$857,479,894	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,963,587	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$6,310,221	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$12,207,084	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$8,920,472	CurrentTaxYearMinus1YearAmt
Current Tax Year	$4,050,778	CurrentTaxYearAmt
Total	$34,452,142	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$980,560	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$836,870	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,030,112	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$843,270	CurrentTaxYearMinus1YearAmt
Current Tax Year	$869,980	CurrentTaxYearAmt
Total	$4,560,792	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$1,599,381,509	TotalSupportAmt
Gross Receipts Rltd Activities	$3,538	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.53610	PublicSupportCY170Pct
Public Support PY170	0.52640	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$198,070	FilingOrganizationsTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$198,070	FilingOrganizationsTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$346,106,542	FilingOrganizationsTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$346,304,612	FilingOrganizationsTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$163,912	CurrentYearMinus3Amt
Current Year Minus2	$135,193	CurrentYearMinus2Amt
Current Year Minus1	$207,166	CurrentYearMinus1Amt
Current Year	$198,070	CurrentYearAmt
Total	$704,341	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus2	$405	CurrentYearMinus2Amt
Current Year Minus1	$29,340	CurrentYearMinus1Amt
Total	$29,745	TotalAmt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$11,742,214	BeginningYearBalanceAmt
Investment Earnings Or Losses	-$1,762,177	InvestmentEarningsOrLossesAmt
Other Expenditures	$546,557	OtherExpendituresAmt
End Year Balance	$9,433,480	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$10,930,723	BeginningYearBalanceAmt
Contributions	$2,500	ContributionsAmt
Investment Earnings Or Losses	$1,323,367	InvestmentEarningsOrLossesAmt
Other Expenditures	$514,376	OtherExpendituresAmt
End Year Balance	$11,742,214	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$10,287,113	BeginningYearBalanceAmt
Contributions	$2,745	ContributionsAmt
Investment Earnings Or Losses	$1,095,576	InvestmentEarningsOrLossesAmt
Other Expenditures	$454,711	OtherExpendituresAmt
End Year Balance	$10,930,723	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,095,917	BeginningYearBalanceAmt
Contributions	$2,100	ContributionsAmt
Investment Earnings Or Losses	$1,691,617	InvestmentEarningsOrLossesAmt
Other Expenditures	$502,521	OtherExpendituresAmt
End Year Balance	$10,287,113	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$10,056,545	BeginningYearBalanceAmt
Contributions	$1,240	ContributionsAmt
Investment Earnings Or Losses	-$494,491	InvestmentEarningsOrLossesAmt
Other Expenditures	$467,377	OtherExpendituresAmt
End Year Balance	$9,095,917	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.36000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.36000	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.28000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$23,293,061	OtherCostOrOtherBasisAmt
Depreciation	$18,151,573	DepreciationAmt
Book Value	$5,141,488	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$8,100,458	OtherCostOrOtherBasisAmt
Depreciation	$7,256,015	DepreciationAmt
Book Value	$844,443	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$5,804,688	OtherCostOrOtherBasisAmt
Depreciation	$5,217,886	DepreciationAmt
Book Value	$586,802	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$6,572,733	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp

Field	Value	IRS element (for citing)
Desc	RIGHT-OF-USE ASSET	Desc
Book Value	$33,353,888	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$33,353,888	TotalBookValueOtherAssetsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

Field	Value	IRS element (for citing)
Desc	LEASE LIABILITY	Desc
Amt	$42,345,583	Amt

Field	Value	IRS element (for citing)
Total Liability	$42,345,583	TotalLiabilityAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART V, LINE 4:	FormAndLineReferenceDesc
Explanation	PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY.	ExplanationTxt

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (61 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AFRICA	$1,749,841
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AMEE	$1,411,495
CENTRAL AMERICA AND THE CARIBBEAN	0	0	BID & PROPOSAL	BID & PROPOSAL	$87,939
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$996,160
CENTRAL AMERICA AND THE CARIBBEAN	0	0	FUNDRAISING	FUNDRAISING	$380,879
CENTRAL AMERICA AND THE CARIBBEAN	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$996,077
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	OTHER	$158,672
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$3,521,948
CENTRAL AMERICA AND THE CARIBBEAN	0	0	GRANTMAKING		$218,299
EAST ASIA AND THE PACIFIC	7	133	PROGRAM SERVICES	AMEE	$8,570,990
EAST ASIA AND THE PACIFIC	0	0	BID & PROPOSAL	BID & PROPOSAL	$49,051
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$5,627,949
EAST ASIA AND THE PACIFIC	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$1,580,273
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	OTHER	$778
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$3,253,896
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		$8,668,881
EUROPE	2	10	PROGRAM SERVICES	AFRICA	$27,178
EUROPE	0	0	PROGRAM SERVICES	AMEE	$788,225
EUROPE	0	0	BID & PROPOSAL	BID & PROPOSAL	$8,679
EUROPE	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$14,319,496
EUROPE	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$2,614,548
EUROPE	0	0	PROGRAM SERVICES	OTHER	$86,426
EUROPE	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$11,000,614
EUROPE	0	0	GRANTMAKING		$30,297,004
MIDDLE EAST AND NORTH AFRICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$17,614
MIDDLE EAST AND NORTH AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$23,500
MIDDLE EAST AND NORTH AFRICA	0	0	GRANTMAKING		$14,000
NORTH AMERICA	0	0	PROGRAM SERVICES	AMEE	$94,536
NORTH AMERICA	0	0	BID & PROPOSAL	BID & PROPOSAL	$4,574
NORTH AMERICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$515,407
NORTH AMERICA	0	0	FUNDRAISING	FUNDRAISING	$6,824
NORTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$91,368
NORTH AMERICA	0	0	PROGRAM SERVICES	OTHER	$5,455
NORTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$370,768
NORTH AMERICA	0	0	GRANTMAKING		$305,790
RUSSIA AND NEIGHBORING STATES	1	29	PROGRAM SERVICES	AMEE	$5,632,432
RUSSIA AND NEIGHBORING STATES	0	0	BID & PROPOSAL	BID & PROPOSAL	$8,363
RUSSIA AND NEIGHBORING STATES	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$723,459
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$117,906
RUSSIA AND NEIGHBORING STATES	0	0	GRANTMAKING		$1,586,535
SOUTH AMERICA	1	5	PROGRAM SERVICES	ESSENTIAL MEDICINE	$300,315
SOUTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$54,372
SOUTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$1,054,562
SOUTH AMERICA	0	0	GRANTMAKING		$806,292
SOUTH ASIA	4	222	PROGRAM SERVICES	AFRICA	$26,277
SOUTH ASIA	0	0	PROGRAM SERVICES	AMEE	$13,526,599
SOUTH ASIA	0	0	BID & PROPOSAL	BID & PROPOSAL	$186,511
SOUTH ASIA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$5,043,332
SOUTH ASIA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$2,653,797
SOUTH ASIA	0	0	PROGRAM SERVICES	OTHER	$45,474
SOUTH ASIA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$1,422,691
SOUTH ASIA	0	0	GRANTMAKING		$5,092,495
SUB-SAHARAN AFRICA	25	651	PROGRAM SERVICES	AFRICA	$30,452,212
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	AMEE	$26,415
SUB-SAHARAN AFRICA	0	0	BID & PROPOSAL	BID & PROPOSAL	$269,910
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	$9,855,670
SUB-SAHARAN AFRICA	0	0	FUNDRAISING	FUNDRAISING	$9,273
SUB-SAHARAN AFRICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	$15,391,312
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	OTHER	$1,239,879
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	$26,516,790
SUB-SAHARAN AFRICA	0	0	GRANTMAKING		$13,134,829

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	40	ContinuationTotalOfficeCnt
Continuation Total Employee	1050	ContinuationTotalEmployeeCnt
Total Office	40	TotalOfficeCnt
Total Employee	1050	TotalEmployeeCnt
Subtotal Spent	$9,303,011	SubtotalSpentAmt
Continuation Spent	$223,739,825	ContinuationSpentAmt
Total Spent	$233,042,836	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (216 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	$115,999	CHECK/WIRE	$0
CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	$102,300	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$142,553	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$129,250	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$39,000	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$11,141	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$37,125	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$78,015	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$700,000	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$99,832	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$44,751	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$125,304	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$19,007	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$13,785	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$19,492	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$8,488	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$19,523	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$116,121	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$230,241	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$130,148	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$9,028	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$200,530	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$177,521	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$174,859	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$525,853	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$220,523	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$29,062	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$273,607	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE & PROGRAM INNOVATION	$1,938,449	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$11,298	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$134,828	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$8,804	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$1,125,669	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$36,376	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$155,000	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$150,000	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$952,229	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$101,818	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$235,633	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	$45,166	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$44,100	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$97,943	CHECK/WIRE	$0
EAST ASIA AND THE PACIFIC	AMEE	$56,811	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$507,431	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$56,927	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$20,000	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$490,000	CHECK/WIRE	$0
EUROPE	AFRICA	$148,878	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$972,084	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$491,837	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$71,243	CHECK/WIRE	$0
EUROPE	OTHER	$64,838	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$65,000	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$8,000	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$118,501	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	$3,610,913	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$881,119	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$56,173	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$540,754	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$39,227	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$21,800	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$65,000	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$1,837,323	CHECK/WIRE	$0
EUROPE	AFRICA & PROGRAM INNOVATION	$1,174,052	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$15,856	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$1,930,000	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$1,311,826	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	$337,574	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$52,844	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$45,500	CHECK/WIRE	$0
EUROPE	PROGRAM INNOVATION	$19,452	CHECK/WIRE	$0
EUROPE	ESSENTIAL MEDICINE	$710,062	CHECK/WIRE	$0
EUROPE	AFRICA, AMEE, ESSENTIAL MEDICINE, OTHER, & PROGRAM INNOVATION	$9,001,439	CHECK/WIRE	$0
EUROPE	AFRICA, AMEE, ESSENTIAL MEDICINE, OTHER, & PROGRAM INNOVATION	$5,631,350	CHECK/WIRE	$0
MIDDLE EAST & NORTH AFRICA	PROGRAM INNOVATION	$14,000	CHECK/WIRE	$0
NORTH AMERICA	ESSENTIAL MEDICINE	$10,560	CHECK/WIRE	$0
NORTH AMERICA	ESSENTIAL MEDICINE	$200,000	CHECK/WIRE	$0
NORTH AMERICA	PROGRAM INNOVATION	$60,525	CHECK/WIRE	$0
NORTH AMERICA	PROGRAM INNOVATION	$34,704	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$23,990	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$33,297	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$94,947	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$17,448	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$40,544	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$14,465	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$53,731	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$34,852	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$47,176	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$39,082	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$127,064	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$186,332	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$9,689	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$9,750	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$22,763	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$48,650	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$36,137	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE & PROGRAM INNOVATION	$177,722	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$18,617	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$17,167	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$60,295	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$88,198	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$40,334	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$186,800	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$59,374	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$55,267	CHECK/WIRE	$0
RUSSIA AND NEIGHBORING STATES	AMEE	$39,536	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$100,000	CHECK/WIRE	$0
SOUTH AMERICA	AMEE	$10,000	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$61,000	CHECK/WIRE	$0
SOUTH AMERICA	ESSENTIAL MEDICINE	$46,903	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$233,991	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$32,588	CHECK/WIRE	$0
SOUTH AMERICA	ESSENTIAL MEDICINE	$248,854	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$50,604	CHECK/WIRE	$0
SOUTH AMERICA	PROGRAM INNOVATION	$19,821	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$67,629	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE & PROGRAM INNOVATION	$62,432	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$29,359	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$102,895	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$21,668	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE	$125,465	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE	$868,742	CHECK/WIRE	$0
SOUTH ASIA	PROGRAM INNOVATION	$381,744	CHECK/WIRE	$0
SOUTH ASIA	PROGRAM INNOVATION	$389,157	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$29,337	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE	$20,000	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$342,351	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE	$570,398	CHECK/WIRE	$0
SOUTH ASIA	ESSENTIAL MEDICINE	$420,108	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$188,142	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$147,113	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$57,257	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$10,026	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$140,995	CHECK/WIRE	$0
SOUTH ASIA	PROGRAM INNOVATION	$16,187	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$146,185	CHECK/WIRE	$0
SOUTH ASIA	PROGRAM INNOVATION	$37,760	CHECK/WIRE	$0
SOUTH ASIA	AMEE	$917,546	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	OTHER	$13,346	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$7,713	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$57,842	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$48,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$33,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$10,877	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$19,274	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$125,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	$14,406	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	$188,500	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$17,844	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$21,977	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$8,496	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$14,340	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$92,442	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$151,572	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$43,666	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$1,424,371	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$41,555	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$106,498	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$129,659	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$149,121	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$69,598	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	OTHER	$131,261	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$35,303	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$144,141	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$17,678	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$43,761	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$17,402	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$76,283	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	OTHER	$113,085	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$11,028	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$53,266	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	$49,843	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$20,213	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$60,936	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$44,285	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	OTHER	$20,761	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$26,101	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	$1,074,907	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$1,025,881	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$71,112	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$288,932	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$5,583	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$61,349	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$99,884	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$23,221	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$30,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$23,201	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$79,218	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$168,967	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$228,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & OTHER	$22,905	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$36,038	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$213,737	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$11,523	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$36,434	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$790,000	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$38,199	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$67,927	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$42,670	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$9,611	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$37,894	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$69,592	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$38,936	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$540,034	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$29,980	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$14,938	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$311,517	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	$409,920	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$339,204	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$1,448,986	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$1,415,829	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$76,289	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$35,251	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$148,787	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	AFRICA	$30,544	CHECK/WIRE	$0
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	$30,000	CHECK/WIRE	$0

Field	Value	IRS element (for citing)
Total501c3 Org	163	Total501c3OrgCnt
Total Other Org	53	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (1)	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 2:

PATH HAS ROBUST POLICIES, PROCEDURES, AND GUIDELINES, INCLUDING SUBRECIPIENT POLICY AND PROCEDURES, IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING (FINANCIAL AND TECHNICAL), SITE VISITS, REGULAR CONTACT, ANNUAL AUDITS, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS/DONORS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. THE AUDIT IS CONDUCTED FOR THE COUNTRY PROGRAMS AND IS EXTENDED TO THE SUBRECIPIENTS.

PART III ACCOUNTING METHOD:

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (65 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
AKROS INC
PO BOX 457	LARAMIE	WY	82073	263668995	OTHER	$176,590	$0	PROGRAM INNOVATION
BAGAMIAN SCIENTIFIC CONSULTING
222 NW 3RD AVE	GAINESVILLE	FL	32601	821347380	OTHER	$62,465	$0	ESSENTIAL MEDICINES
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZA	SAN FRANCISCO	CA	94612	741613878	501(C)(3)	$157,111	$0	ESSENTIAL MEDICINES
BUILD HEALTH INTERNATIONAL INC
100 CUMMINGS CENTER SUITE 120 B	BEVERLY	MA	01915	464300024	501(C)(3)	$14,770	$0	PROGRAM INNOVATION
CASE WESTERN RESERVE UNIVERSITY
10900 EUCLID AVE	CLEVELAND	OH	44106	341018992	501(C)(3)	$27,322	$0	PROGRAM INNOVATION
CHILDREN'S HOSPITAL BOSTON
RESEARCH FINANCE PO BOX 414413	BOSTON	MA	022414413	042774441	501(C)(3)	$526,516	$0	ESSENTIAL MEDICINES
CINCINNATI CHILDREN'S HOSPITAL
MEDICAL CENTER 3333 BURNET AVE ML	CINCINNATI	OH	452293039	310833936	501(C)(3)	$230,000	$0	ESSENTIAL MEDICINES	6014
CLINTON HEALTH ACCESS INITIATIVE
383 DORCHESTER AVE SUITE 400	BOSTON	MA	02127	271414646	501(C)(3)	$1,778,126	$0	PROGRAM INNOVATION
COOPERSMITH
4206 RIVER RD NW	WASHINGTON	DC	20016	472387850	OTHER	$201,210	$0	PROGRAM INNOVATION
DARTMOUTH-HITCHCOCK CLINIC
ONE MEDICAL CENTER DR	LEBANON	NH	03756	222715483	501(C)(3)	$310,257	$0	ESSENTIAL MEDICINES
DIMAGI INC
585 MASSACHUSETTS AVE SUITE 4	CAMBRIDGE	MA	02139	830343298	501(C)(3)	$191,827	$0	PROGRAM INNOVATION
DKT INTERNATIONAL INC
1001 CONNECTICUT AVE NW SUITE 800	WASHINGTON	DC	20036	581593137	501(C)(3)	$28,749	$0	PROGRAM INNOVATION
FOOD AND DRUG ADMINISTRATION
5600 FISHERS LANEHFA-140 ROOM 11-40	ROCKVILLE	MD	20857	530196965	GOV	$135,200	$0	ESSENTIAL MEDICINES
GET ODK INC
3288 ADAMS AVE 16043	SAN DIEGO	CA	92176	454561037	OTHER	$25,250	$0	PROGRAM INNOVATION
GLOBAL CONNECT DEVELOPMENT GROUP LLC
480 BEACH ST	BOSTON	MA	02131	823433604	OTHER	$346,390	$0	PROGRAM INNOVATION
GLOBAL HEALTH CORPS
318 WEST 39TH STREET ROOM 9L	NEW YORK	NY	10018	800512336	501(C)(3)	$8,900	$0	PROGRAM INNOVATION
GLOBAL HEALTH STRATEGIES LLC
27 WEST 24TH STREET SUITE 900	NEW YORK	NY	10010	272494697	501(C)(3)	$665,772	$0	PROGRAM INNOVATION
GUARALDI SYSTEMS LLC
97 ALGER BROOK RD	SOUTH STAFFORD	VT	05070	851148274	OTHER	$278,812	$0	PROGRAM INNOVATION
HARVARD SCHOOL OF PUBLIC HEALTH
677 HUNTINGTON AVENUE	BOSTON	MA	02215	042103580	501(C)(3)	$689,291	$0	ESSENTIAL MEDICINES & PROGRAM INNOVATION
HISP US LLC
31 ANCONA AVE	OCEAN PARK	ME	04063	850894858	OTHER	$341,904	$0	PROGRAM INNOVATION
HJF MEDICAL RESEARCH INTERNATIONAL INC
6720A ROCKLEDGE DRIVE SUITE 100	BETHESDA	MD	20817	522322791	501(C)(3)	$3,381,337	$0	ESSENTIAL MEDICINES
ICF MACRO INC
9300 LEE HIGHWAY	FAIRFAX	VA	22031	223661438	OTHER	$2,143,241	$0	PROGRAM INNOVATION
INDIANA UNIVERSITY
107 S INDIAN AVE	BLOOMINGTON	IN	47405	356001673	GOV	$158,255	$0	PROGRAM INNOVATION
INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI)
1201 EYE STREET NW	WASHINGTON	DC	20005	521041632	501(C)(3)	$40,619	$0	PROGRAM INNOVATION
INTRAHEALTH INTERNATIONAL INC
6340 QUADRANGLE DRIVE SUITE 200	CHAPEL HILL	NC	27517	550825466	501(C)(3)	$531,142	$0	AFRICA & PROGRAM INNOVATION
JHPIEGO
1615 THAMES STREET SUITE 200	BALTIMORE	MD	212313447	237424444	501(C)(3)	$773,622	$0	AFRICA & AMEE
JSI RESEARCH AND TRAINING INSTITUTE INC
1616 NORTH FORT MYER DR 16TH FLOOR	ARLINGTON	VA	222093100	042679824	501(C)(3)	$991,582	$0	PROGRAM INNOVATION
KINDEVA DRUG DELIVERY LP
11200 HUDSON RD	WOODBURY	MN	55129	844392783	OTHER	$476,030	$0	PROGRAM INNOVATION
LAST MILE HEALTH
24 SCHOOL STREET 5TH FLOOR	BOSTON	MA	02108	261401736	501(C)(3)	$40,000	$0	PROGRAM INNOVATION
LIVING GOODS
1423 BROADWAY	SAN FRANCISCO	CA	94612	205010527	501(C)(3)	$49,886	$0	PROGRAM INNOVATION
MANAGEMENT SCIENCES FOR HEALTH INC
200 RIVERS EDGE DRIVE SUITE 320	MEDFORD	MA	02155	042482188	501(C)(3)	$16,928	$0	PROGRAM INNOVATION
MASS DESIGN GROUP LTD
334 BOYLSTON ST STE 400	BOSTON	MA	02116	611659704	501(C)(3)	$35,000	$0	PROGRAM INNOVATION
MASSACHUSETTS GENERAL HOSPITAL
DEPT OF EMERGENCY MEDICINE ZERO	BOSTON	MA	02114	041564655	501(C)(3)	$46,000	$0	ESSENTIAL MEDICINES	EMERSON PL 104
MEDIC MOBILE INC
3254 19TH STREET FLOOR 2	SAN FRANCISCO	CA	94110	275104203	501(C)(3)	$677,641	$0	PROGRAM INNOVATION
MICHIGAN STATE UNIVERSITY
3900 COLLINS RD SUITE 1044	LANSING	MI	48910	386005984	501(C)(3)	$334,616	$0	PROGRAM INNOVATION
MICRON BIOMEDICAL INC
311 FERST DRIVE NW SUITE L1309	ATLANTA	GA	30332	471692844	OTHER	$181,474	$0	PROGRAM INNOVATION
NAT'L INST OF ALLERGY & INFECTIOUS DISEASES (NIAID)
6610 ROCKLEDGE DR ROOM 2800	BETHESDA	MD	208926606	520858115	GOV	$265,800	$0	ESSENTIAL MEDICINES
NICHOLAS INSTITUTE FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY
2117 CAMPUS DRIVE PO BOX 90335	DURHAM	NC	27708	560532129	501(C)(3)	$49,618	$0	PROGRAM INNOVATION
ONA SYSTEMS INC
126 E 12TH ST SUITE 4A	NEW YORK	NY	100035320	383940780	OTHER	$343,787	$0	PROGRAM INNOVATION
OPEN FUNCTION GROUP INC
66 EUCLID AVE	HASTINGS ON HUDSON	NY	10706	811412952	OTHER	$51,750	$0	PROGRAM INNOVATION
OPENMRS INC
10425 COMMERCE DR STE 110	CARMEL	IN	460327643	455316647	501(C)(3)	$430,364	$0	PROGRAM INNOVATION
PARTNERS IN HEALTH A NONPROFIT CORPORATION
800 BOYLSTON ST SUITE 300	BOSTON	MA	02199	043567502	501(C)(3)	$72,703	$0	PROGRAM INNOVATION
PHARMARON CPC INC
800 W BALTIMORE STREET 5TH FLOOR	BALTIMORE	MD	21201	208419781	OTHER	$765,054	$0	ESSENTIAL MEDICINES
POPULATION COUNCIL
ONE DAG HAMMERKJOLD PLAZA	NEW YORK	NY	10017	131687001	501(C)(3)	$38,900	$0	PROGRAM INNOVATION
POPULATION SERVICES INTERNATIONAL INC
1120 19TH ST NW STE 600	WASHINGTON	DC	20036	560942853	501(C)(3)	$482,718	$0	PROGRAM INNOVATION
REGENSTRIEF INSTITUTE INC
1101 W 10TH ST	INDIANAPOLIS	IN	46202	300007730	501(C)(3)	$1,242,154	$0	PROGRAM INNOVATION
RTI INTERNATIONAL
PO BOX 12106	DURHAM	NC	277092106	560686338	501(C)(3)	$248,661	$0	PROGRAM INNOVATION
SYSTEMONE LLC
5 BRIDGE STREET	SHELBURNE FALLS	MA	01370	461066795	OTHER	$46,966	$0	AMEE
TECHCHANGE INC
2001 13TH ST NW 2ND FLOOR	WASHINGTON	DC	20009	273358772	OTHER	$495,812	$0	PROGRAM INNOVATION
THE ALBERT B SABIN VACCINE INSTITUTE INC
2175 K STREET NW SUITE 400	WASHINGTON	DC	20037	061389829	501(C)(3)	$2,211,718	$0	ESSENTIAL MEDICINES
THE NATURE CONSERVANCY
4245 FAIRFAX DRIVE	ARLINGTON	VA	22203	530242652	501(C)(3)	$8,926	$0	PROGRAM INNOVATION
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
UCSF OFFICE OF SPONSORED RES 3333	SAN FRANCISCO	CA	94118	946036493	501(C)(3)	$196,237	$0	PROGRAM INNOVATION	CALIFORNIA ST STE 315
TULANE UNIVERSITY
6823 ST CHARLES AVE	NEW ORLEANS	LA	70112	720423889	501(C)(3)	$573,668	$0	ESSENTIAL MEDICINES & PROGRAM INNOVATION
UNITED NATIONS FOUNDATION INC
1750 PENNSYLVANIA AVE NW SUITE 300	WASHINGTON	DC	20006	582368165	501(C)(3)	$146,098	$0	PROGRAM INNOVATION
UNIVERSITY OF CALIFORNIA LOS ANGELES ( UCLA )
10889 WILSHIRE BLVD SUITE 700	LOS ANGELES	CA	90095	956006143	GOV	$213,374	$0	AFRICA
UNIVERSITY OF MARYLAND BALTIMORE
BALTIMORE PO BOX 41428	BALTIMORE	MD	212036428	526002033	GOV	$69,793	$0	ESSENTIAL MEDICINES
UNIVERSITY OF MASSACHUSETTS
MEDICAL SCHOOL 55 LAKE AVENUE NORTH	WORCESTER	MA	01655	043167352	GOV	$236,395	$0	PROGRAM INNOVATION
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
CENTER FOR INFECTIOUS DISEASES	CHAPEL HILL	NC	275993368	566001393	501(C)(3)	$528,440	$0	ESSENTIAL MEDICINES & PROGRAM INNOVATION
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
AGRICULTURAL COLLEGE 85 SOUTH	BURLINGTON	VT	05405	030179440	501(C)(3)	$457,533	$0	ESSENTIAL MEDICINES	PROSPECT STREET
UNIVERSITY OF WASHINGTON ( UW )
GRANT CONTRACT ACCOUNTING 12455	CHICAGO	IL	60693	916001537	501(C)(3)	$1,942,884	$0	ESSENTIAL MEDICINES & PROGRAM INNOVATION	COLLECTIONS DRIVE
VILLAGEREACH
2900 EASTLAKE AVE E SUITE 230	SEATTLE	WA	981023012	912088484	501(C)(3)	$94,775	$0	AFRICA & PROGRAM INNOVATION
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
300 TURNER ST NW SUITE 4200	BLACKSBURG	VA	24061	546001805	GOV	$17,267	$0	ESSENTIAL MEDICINES
VITAL STRATEGIES INC
100 BROADWAY 4TH FLOOR	NEW YORK	NY	10005	223419667	501(C)(3)	$62,898	$0	PROGRAM INNOVATION
VITAL WAVE INC
555 BRYANT STREET 226	PALO ALTO	CA	94301	203208079	OTHER	$1,315,199	$0	PROGRAM INNOVATION
WALTER REED ARMY INSTITUTE OF RESEARCH
US TREASURY 503 ROBERT GRANT AVE	SILVER SPRING	MD	20910	520664528	GOV	$1,755,399	$0	ESSENTIAL MEDICINES

Field	Value	IRS element (for citing)
Total501c3 Org	54	Total501c3OrgCnt
Total Other Org	14	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, ANNUAL AUDITS, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS/DONORS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Idemnification Gross Up Pmts	Yes (X)	IdemnificationGrossUpPmtsInd
Housing Allowance Or Residence	Yes (X)	HousingAllowanceOrResidenceInd
Written Policy Ref T And E Expnss	Yes (1)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (1)	SubstantiationRequiredInd
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (1)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (16 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
NIKOLAJ JESTED GILBERT MSC
PRESIDENT AND CEO	$586,653	$0	$0	$0	$662	$0	$35,800	$0	$10,532	$0	$633,647	$0	$0	$0
JOHN O KONZ PHD
GLOBAL HEAD OF POLIO	$342,306	$0	$0	$0	$18,100	$0	$35,800	$0	$33,354	$0	$429,560	$0	$0	$0
DAVID C KASLOW MD
CHIEF SCIENTIFIC OFF. (UNTIL 10/8/22	$322,702	$0	$0	$0	$33,639	$0	$35,800	$0	$28,213	$0	$420,354	$0	$0	$0
TRAD M HATTON MA MHS
DIR., CEN. AFRICA HUB & DRC COUNTRY	$150,306	$0	$0	$0	$210,147	$0	$18,325	$0	$35,457	$0	$414,235	$0	$0	$0
NANTHALILE C MUGALA MD MMED
CHIEF OF AFRICA REGION	$212,753	$0	$0	$0	$87,775	$0	$108,653	$0	$0	$0	$409,181	$0	$0	$0
ASHLEY J BIRKETT PHD
GLOBAL HEAD, MALARIA VACCINES	$339,564	$0	$0	$0	$900	$0	$31,367	$0	$31,832	$0	$403,663	$0	$0	$0
KIMBERLY GREEN PHD
DIRECTOR, PRIMARY HEALTH CARE	$278,794	$0	$0	$0	$53,890	$0	$24,428	$0	$45,582	$0	$402,694	$0	$0	$0
JEFFREY D BERNSON MPH MPA
CHIEF PROGRAMS & INNOVATION OFFICER	$333,778	$0	$0	$0	$600	$0	$33,630	$0	$20,277	$0	$388,285	$0	$0	$0
BRUCE LAMONT INNIS MD FIDSA
GLOBAL HEAD, RESPIRATORY INFECTIONS	$350,446	$0	$0	$0	$600	$0	$34,854	$0	-$106	$0	$385,794	$0	$0	$0
JESSICA MILMAN
EXEC. DIR., STRATEGY, OPS., & EFFECT	$292,043	$0	$0	$0	$18,100	$0	$30,064	$0	$21,089	$0	$361,296	$0	$0	$0
PHILIPPE GUINOT MBA
CHIEF OF BUSINESS, FIN. & OPS.	$0	$303,679	$0	$0	$0	$5,977	$0	$26,046	$0	$630	$0	$336,332	$0	$0
SABRINA L POWERS JD
CHIEF OF LEGAL & RESEARCH AFFAIRS/GC	$281,958	$0	$0	$0	$900	$0	$33,808	$0	$13,107	$0	$329,773	$0	$0	$0
CARLA ANNE COSTA SANDINE
CHIEF OF EXTERNAL AFFAIRS	$237,750	$0	$0	$0	$600	$0	$27,879	$0	$20,057	$0	$286,286	$0	$0	$0
MEISSA DIAW
CHIEF PEOPLE & DIVERSITY OFFICER	$200,760	$0	$0	$0	$22,773	$0	$0	$0	$401	$0	$223,934	$0	$0	$0
NABEEL A GOHEER PHD
CHIEF OF AFRICA	$206,069	$0	$0	$0	$780	$0	$1,636	$0	$0	$0	$208,485	$0	$0	$0
MOLLI M BARNES
CHIEF PEOPLE OFFICER (UNTIL 1/31/22)	$22,846	$0	$0	$0	$150,472	$0	$4,769	$0	$23,513	$0	$201,600	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 1A	HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT.
PART I, LINE 4A	LIST OF PERSONS IN FORM 990, PART VII, SECTION A WHO RECEIVED SEVERANCE PAYMENTS IN 2022: - MOLLI M. BARNES $133,674

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	14	ContributionCnt
Noncash Contributions Rpt F990	$58,935	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	SOFTWARE/SUPP.	Desc
Contribution	5	ContributionCnt
Noncash Contributions Rpt F990	$758,781	NoncashContributionsRptF990Amt
Method Of Determining Revenues	COST	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Form8283 Received	0	Form8283ReceivedCnt
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (1)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, COLUMN (B):	FormAndLineReferenceDesc
Explanation	THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (17 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:	PATH IS A GLOBAL NONPROFIT DEDICATED TO ACHIEVING HEALTH EQUITY. WITH MORE THAN 40 YEARS OF EXPERIENCE FORGING MULTISECTOR PARTNERSHIPS, AND WITH EXPERTISE IN SCIENCE, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP INNOVATIVE SOLUTIONS TO THE WORLD'S MOST PRESSING HEALTH CHALLENGES. THE LARGEST INVESTMENTS IN PATH'S PROGRAMMATIC WORK IN 2022 WERE ORGANIZED INTO THREE PRIMARY PORTFOLIOS: PROGRAMS & INNOVATION, ESSENTIAL MEDICINES, AND THE AFRICA REGION.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	IN 2022, WE ALSO ACCOMPLISHED A DESIGN LOCK AND SUBSEQUENT EXECUTION OF A TECHNOLOGY TRANSFER, LICENSE, AND COMMERCIALIZATION AGREEMENT WITH LIFEASSAY DIAGNOSTICS LTD. FOR A POINT-OF-CARE RAPID DIAGNOSTIC TEST FOR PRIMARY IMMUNODEFICIENCY (PID). PID ARE A RARE CLASS OF HEREDITARY DISEASES THAT AFFECT THE IMMUNE SYSTEM, RESULTING IN INCOMPLETE IMMUNE RESPONSES THAT MAKE INDIVIDUALS MORE VULNERABLE TO DISEASES. PEOPLE WITH SOME FORMS OF PID ARE AT RISK OF PROLONGED INFECTION AND SHEDDING OF POLIOVIRUS INTO THEIR COMMUNITIES. IDENTIFYING THOSE WITH PID CAN HELP DISRUPT COMMUNITY OUTBREAKS AND DISEASE CYCLES. MEDICAL DEVICES AND HEALTH TECHNOLOGIES THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM SUPPORTS PRODUCT DEVELOPMENT AT PATH. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD. IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE MANUFACTURED IN SOUTH AFRICA AVAILABLE IN 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN BRAZIL IN 2022, BRINGING THE GLOBAL TOTAL TO 40 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE AND MARKETED. IN THE AREAS OF VACCINE AND PHARMACEUTICAL TECHNOLOGIES, WE CONVENED A THIRD GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND US DECISION-MAKERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM INCLUDING EVALUATING THE USABILITY OF CANDIDATE PRODUCTS AND THE POTENTIAL TOTAL COST TO DELIVER MEASLES AND RUBELLA VACCINE WITH A PATCH. IN ADDITION, WE ADVISED UGANDA'S MINISTRY OF HEALTH (MOH) ON THE COUNTRY-WIDE ADOPTION OF A PATH-ADVANCED VACCINE COLD CHAIN INVENTORY AND PERFORMANCE TRACKING SYSTEM. FINALLY, SCIENTISTS IN THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A NOVEL HEAT-STABLE INSULIN FORMULATION, SUITABLE FOR ORAL ADMINISTRATION. MARKET DYNAMICS PATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, CIVIL SOCIETY ORGANIZATIONS, AND PATH'S COUNTRY PROGRAMS. IN 2022, OUR LARGEST AREAS OF WORK WERE: (1) IMPROVING ACCESS TO MEDICAL OXYGEN, RESPIRATORY CARE SYSTEMS, AND CRITICAL MEDICAL DEVICES IN LMICS. AS PART OF THAT WORK, WE SUPPORTED GLOBAL AND COUNTRY EFFORTS IN RESPIRATORY CARE CAPACITY-BUILDING AND IMPLEMENTATION, STRENGTHENED ADVOCACY TO ELEVATE OXYGEN TO GLOBAL AND NATIONAL AGENDAS, AND ENHANCED RESEARCH AND MONITORING, EVALUATION, AND LEARNING ON OXYGEN WITH A GOAL TO EQUITABLY IMPROVE ACCESS TO HIGH-QUALITY OXYGEN SERVICES AT ALL LEVELS OF THE HEALTH CARE SYSTEM. IN INDIA, KENYA, SENEGAL, AND TANZANIA, WE ADVANCED ACCESS TO AFFORDABLE AND APPROPRIATE TOOLS SUCH AS PULSE OXIMETRY AND ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHMS TO HELP HEALTH CARE WORKERS IDENTIFY CRITICALLY ILL CHILDREN AND REFER THEM FOR TREATMENT WITHOUT DELAY. AS PART OF THIS WORK, WE IMPROVED ACCESS TO TOOLS AT FACILITIES, TRAINED HEALTH CARE WORKERS, AND INFORMED NATIONAL POLICY AND ADVOCACY EFFORTS TOWARD SCALING THESE CRITICAL DEVICES AT THE PRIMARY HEALTH CARE (PHC) LEVEL. (2) SUPPORTING THE INTRODUCTION AND SCALE-UP OF MALARIA HEALTH PRODUCTS WITH THE AIM OF ELIMINATING THE P. VIVAX STRAIN OF MALARIA. WITH PARTNERS, OUR WORK INCLUDED DEVELOPING APPROPRIATE STRATEGIES TO ADDRESS P. VIVAX, SHARING HIGH-QUALITY EVIDENCE TO INFORM POLICY AND DECISION-MAKING, AND SUPPORTING THE DEVELOPMENT AND AVAILABILITY OF MEDICINES AND DIAGNOSTICS TO ENSURE SAFE AND EFFECTIVE TREATMENT OF PATIENTS. EPIDEMIC PREPAREDNESS AND RESPONSE PATH'S EPIDEMIC PREPAREDNESS AND RESPONSE (EPR) GLOBAL PROGRAM EXHIBITED UNWAVERING DEDICATION TO SUPPORTING MINISTRIES OF HEALTH, AGRICULTURE, ENVIRONMENT, AND OTHER SECTORS TO PREPARE FOR THE LOOMING THREAT OF ANTIMICROBIAL RESISTANCE (AMR), CLIMATE CHANGE, AND INFECTIOUS DISEASES THROUGH A ONE HEALTH APPROACH. AMR AND CLIMATE CHANGE POSE A PRESSING CRISIS, DISRUPTING ECOSYSTEMS, INTENSIFYING NATURAL DISASTERS, AND JEOPARDIZING THE WELL-BEING OF COMMUNITIES WORLDWIDE. IN 2022, EPR STRENGTHENED ITS EFFORTS ON HUMANITARIAN RESPONSE BY PROVIDING TECHNICAL ASSISTANCE TO ENSURE THAT POPULATIONS MOST VULNERABLE TO EMERGING HEALTH THREATS RECEIVE VITAL AID AND SUPPORT. CONCURRENTLY, THE TEAM CONTINUED TO IMPLEMENT TWO USAID PROJECTS - INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) AND DISCOVERY & EXPLORATION OF EMERGING PATHOGENS, VIRAL ZOONOSES (DEEP VZN) - IN SEVERAL COUNTRIES IN AFRICA AND ASIA. WITH SUPPORT FROM THE US CDC, PATH COLLABORATED WITH THE NATIONAL GOVERNMENTS OF SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR CAPACITY TO PREPARE FOR AND RESPOND TO EPIDEMICS. PATH'S MULTIDIMENSIONAL APPROACH TO EPIDEMIC PREPAREDNESS AND RESPONSE REMAINS AN EXEMPLAR OF PROACTIVE AND COLLABORATIVE ACTION, LEVERAGING PARTNERSHIPS AND INNOVATIONS TO SAFEGUARD GLOBAL HEALTH. THANKS TO COLLABORATION WITH USAID, CDC, AND OTHER PARTNERS, PATH WORKED WITH NATIONAL LEADERS IN 17 COUNTRIES TO ENHANCE CAPACITY FOR EPR BY STRENGTHENING DISEASE SURVEILLANCE LABORATORY SYSTEMS THROUGH A MULTISECTORAL ONE HEALTH APPROACH. MALARIA AND NEGLECTED TROPICAL DISEASES PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS AROUND THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. IN 2022, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA AND INCREASED ENGAGEMENT WITH THE DRC GOVERNMENT TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA PROVIDED TECHNICAL ASSISTANCE AND EXPERTISE TO SUPPORT SUBNATIONAL TAILORING BASED ON RISK STRATIFICATION MAPS AND MODELING OF OPTIMAL INTERVENTION MIXES ACROSS ALL GEOGRAPHIES AND SUPPORTED PRIORITIZATION OF AND FUNDING FOR EVALUATION OF TARGETED CONTROL STRATEGIES ADDRESSING HIGH-RISK POPULATIONS IN SENEGAL AND ETHIOPIA. MACEPA ALSO CONDUCTED EXPLORATORY ACTIVITIES IN MALAWI AND NIGERIA (E.G., QUANTIFYING COMMUNITY CASE MANAGEMENT NEEDS AND GAPS THROUGH LANDSCAPING AND BENCHMARKING ANALYSES IN MALAWI AND FINALIZING AND DISSEMINATING RESULTS FROM SURVEILLANCE ASSESSMENTS IN NIGERIA) TO INFORM TECHNICAL ASSISTANCE NEEDS AND RECOMMENDATIONS FOR THOSE GEOGRAPHIES. THE PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO) PLUS PROJECT, FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI), PROVIDED TECHNICAL AND MATERIAL ASSISTANCE TO THE ZAMBIA MOH IN MALARIA CASE MANAGEMENT, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, DISEASE SURVEILLANCE, AND DATA MANAGEMENT AND USE. WORK IN 2022 INVOLVED MENTORING HEALTH WORKERS IN THE PROJECT'S FOUR FOCUS PROVINCES ON ADHERENCE TO MALARIA CASE MANAGEMENT STANDARDS AS WELL AS TRAINING, DEPLOYING, AND SUPPORTING COMMUNITY HEALTH WORKERS WHO TEST AND TREAT MALARIA AT THE COMMUNITY LEVEL. ADDITIONALLY, PAMO PLUS WORKED WITH THE ZAMBIA NURSING AND MIDWIFERY COUNCIL TO INTEGRATE MALARIA IN PREGNANCY TRAINING INTO THE NURSING COLLEGE CURRICULUM AND TRAINED ANTENATAL CARE PROVIDERS AND SAFE MOTHERHOOD ACTION GROUP MEMBERS ON THE MALARIA IN PREGNANCY GUIDELINES. PAMO PLUS SUPPORTED THE DEVELOPMENT OF COMMUNITY ENGAGEMENT PLANS, ORIENTED COMMUNITY CHANGE AGENTS, CONDUCTED DATA QUALITY AUDITS, AND TRAINED MOH STAFF IN DATA MANAGEMENT AND MENTORSHIP. PAMO PLUS CONTINUED IMPLEMENTING A MALARIA PRE-ELIMINATION PROGRAM, CONDUCTING RESEARCH IN LOW-BURDEN DISTRICTS OF EASTERN PROVINCE, ZAMBIA. IN 2022, PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS WITH OUR PARTNERS UNDER PMI VECTORLINK, USAID'S FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT - FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND) - WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB).
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	WE COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. UNDER THE RAPID MALARIA ASSESSMENTS TO SUPPORT APPROPRIATELY TAILORED SUBNATIONAL INTERVENTION PACKAGES IN BURKINA FASO PROJECT, FUNDED BY THE GATES FOUNDATION, PATH ALSO PROVIDED TECHNICAL SUPPORT TO THE CENTRE NATIONAL DE RECHERCHE ET DE FORMATION SUR LE PALUDISME TO EXPLORE NEW DATA SOURCES, COLLECTION METHODS, AND INDICATORS TO PROVIDE GRANULAR AND TIMELY DATA FOR DECISION-MAKING INCLUDING TO SUPPORT SUBNATIONAL PLANNING AND GLOBAL FUND GRANT ASSESSMENTS. PATH ALSO LED A USAID INITIATIVE TO SUPPORT MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN NATIONAL POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION. IN SENEGAL AND THE GAMBIA, PATH CONTINUED TO INTEGRATE MALARIA INTO THE SCOPE OF NATIONAL EMERGENCY OPERATIONS CENTERS (EOCS). IN SENEGAL, WE SUPPORTED THE MINISTRY OF HEALTH TO CREATE AND RESOURCE REGIONAL EOC-MALARIA UNITS. WITH A REGIONAL PRESENCE, THE EOC CAN MORE RAPIDLY RESPOND TO POTENTIAL PUBLIC HEALTH THREATS. IN DRC, PATH BEGAN TO SUPPORT THE RECENTLY CREATED NATIONAL PUBLIC HEALTH INSTITUTE'S EFFORTS TO SET UP A SINGLE, CENTRAL EOC TO MANAGE THE MULTIPLE HEALTH EMERGENCIES DRC HAS TO MANAGE, INCLUDING DEVELOPING AN INTEGRATED DATA PLATFORM TO SUPPORT DECISION-MAKING. PATH'S LABORATORY TEAM AT THE NATIONAL MALARIA ELIMINATION CENTER IN LUSAKA, ZAMBIA, HAS DEVELOPED A COST-EFFECTIVE AND SCALABLE ANTIMALARIAL DRUG RESISTANCE ASSAY FOR P. FALCIPARUM MALARIA UTILIZING NANOPORE SEQUENCING. IN 2022, PATH RECEIVED FUNDING FROM THE GATES FOUNDATION TO INTEGRATE NANOPORE SEQUENCING INTO ROUTINE MALARIA SURVEILLANCE IN ZAMBIA, EXPAND NANOPORE SEQUENCING TO NEW GEOGRAPHIES THROUGH COLLABORATION AND CAPACITY BUILDING, AND OPTIMIZE EXISTING AND DEVELOP NOVEL NANOPORE SEQUENCING ASSAYS FOR MALARIA MOLECULAR SURVEILLANCE. THE VIVACTION PROJECT WORKS TO CATALYZE ADOPTION AND EVENTUAL SCALE-UP OF P. VIVAX TOOLS. IN ETHIOPIA, PATH CONTINUED STUDYING WHETHER IT IS OPERATIONALLY FEASIBLE TO PROVIDE OPTIMIZED RADICAL CURE TREATMENT TO P. VIVAX PATIENTS WHO ARE ELIGIBLE BASED ON TREATMENT GUIDELINES. IN 2022, PATH FOCUSED ON DEVELOPMENT OF THE COUNTRY PROTOCOL, INCLUDING MULTIPLE SERIES OF WORKING SESSIONS WITH THE ARMAUER HANSEN RESEARCH INSTITUTE, WHICH WERE ESSENTIAL FOR ALIGNMENT ACROSS THE DIFFERENT WORKSTREAMS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE IN THE STATE OF UTTAR PRADESH, SUPPORTING THE NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAM IN DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION THROUGH CAPACITY BUILDING, OUTBREAK INVESTIGATION, AND DATA MANAGEMENT. PATH HAS SUPPORTED THE STATE IN SUSTAINING ELIMINATION LEVEL OF VISCERAL LEISHMANIASIS (VL) TRANSMISSION IN THE VL-ENDEMIC DISTRICTS, THROUGH EFFECTIVE DISEASE SURVEILLANCE AND VECTOR CONTROL MEASURES BY THE STATE HEALTH SYSTEM. PATH PROVIDED TECHNICAL SUPPORT FOR SUCCESSFUL IMPLEMENTATION OF A PHASED MASS DRUG ADMINISTRATION CAMPAIGN, AS WELL AS MORBIDITY MANAGEMENT AND DISABILITY PREVENTION SERVICES ACROSS ALL LYMPHATIC FILARIASIS-ENDEMIC DISTRICTS IN THE STATE. PATH HAS ALSO SUPPORTED THE STATE HEALTH SYSTEM IN MAINTAINING A CASE FATALITY RATIO OF <10 PERCENT FROM ACUTE ENCEPHALITIS SYNDROME IN UTTAR PRADESH. IN THE STATE OF BIHAR, PATH SUPPORTED SUCCESSFUL IMPLEMENTATION OF THE JAPANESE ENCEPHALITIS VACCINATION CAMPAIGN IN 14 NEW ENDEMIC DISTRICTS, FOLLOWED BY INTRODUCTION IN THEIR ROUTINE IMMUNIZATION PROGRAM. THE GOAL OF THE ZAMBIA DIGITAL COMMUNITY HEALTH PROJECT IS TO DEVELOP A UNIFIED PLATFORM TO COORDINATE HEALTH SERVICE DELIVERY BY COMMUNITY HEALTH WORKERS. IN 2022, THE TEAM CONTINUED TO DEVELOP A DIGITAL COMMUNITY HEALTH WORK PLATFORM THAT ADDRESSES SERVICE DELIVERY AND DECISION SUPPORT, DATA QUALITY AND MANAGEMENT, AND A DATA CULTURE THAT CONTRIBUTES TO ADDRESSING CHALLENGES IN DATA USE. IN 2022, THE USAID SURVEILLANCE FOR MALARIA ELIMINATION (S4ME) ACTIVITY SUPPORTED MALARIA ELIMINATION EFFORTS IN ETHIOPIA BY DESIGNING AND TESTING EFFECTIVE SURVEILLANCE ACTIVITIES FOR ELIMINATION AT THE WOREDA LEVEL, INCLUDING HEALTH FACILITIES AND COMMUNITY PLATFORMS; SUPPORTING THE IDENTIFICATION AND TIMELY REPORTING OF MALARIA CASES BY UTILIZING REAL-TIME DATA FROM DIGITAL SYSTEMS TO INVESTIGATE AND CLASSIFY MALARIA CASES; AND SUPPORTING THE IMPLEMENTATION OF TARGETED MALARIA ELIMINATION INTERVENTIONS. IN NOVEMBER 2022, THROUGH FUNDING FROM GIVEWELL, PATH LAUNCHED A PILOT PROJECT IN THE DRC TO DELIVER PERENNIAL MALARIA CHEMOPREVENTION (PMC) TO CHILDREN UNDER TWO YEARS OF AGE AT ROUTINE VACCINATION VISITS. PROJECT IMPLEMENTATION IS ANTICIPATED TO BEGIN IN SUMMER 2023. UNDER THE LEADERSHIP OF WHO AND WITH FUNDING FROM THE GATES FOUNDATION, PATH CONTINUED WORKING WITH NEGLECTED TROPICAL DISEASE (NTD) PROGRAMS AND OTHER STAKEHOLDERS TO DESIGN AN INTEGRATED SURVEILLANCE PLANNING TOOLKIT FOR NTDS WITH A SPECIFIC FOCUS ON ONCHOCERCIASIS AND LYMPHATIC FILARIASIS. PATH ALSO SUPPORTED IMPLEMENTATION OF PMI'S ELIMINATE MALARIA PROJECT, WHICH AIMS TO CONTRIBUTE TO ELIMINATION OF INDIGENOUS TRANSMISSION OF P. FALCIPARUM MALARIA BY 2023 AND PUT MYANMAR ON THE PATH TO ELIMINATE ALL HUMAN MALARIA BY 2030. IN 2022, THE TEAM CONTINUED TO DEVELOP AN UPDATED MALARIA INFORMATION SYSTEM AND MALARIA CASE-BASED REPORTING AND SURVEILLANCE SYSTEM TO INFORM ELIMINATION EFFORTS. EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK IN 2022, THE EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK (ECDAN), HOSTED BY PATH, CONTINUED TO ADVOCATE FOR YOUNG CHILDREN AND THEIR CAREGIVERS. THROUGH THE GLOBAL CHILDCARE CAMPAIGN ECDAN CONTINUED TO ADVANCE ITS ENGAGEMENT BY DEVELOPING TACTICAL STRATEGIES TO CONNECT MORE CLOSELY WITH COUNTRY-LEVEL ACTIVITIES. JOINT ADVOCACY EFFORTS BY ECDAN AND PARTNERS CONTRIBUTED TO THE INCLUSION OF CHILDCARE IN THE WORLD BANK INTERNATIONAL DEVELOPMENT ASSOCIATION'S (IDA) 20TH REPLENISHMENT AND THE ESTABLISHMENT OF A WORLD BANK'S INVEST IN CHILDCARE INITIATIVE BY BILATERAL GOVERNMENTS AND FOUNDATIONS THAT LEVERAGES IDA FUNDING AT THE COUNTRY LEVEL. THE GLOBAL INITIATIVE TO SUPPORT PARENTS WAS FORMALIZED AND QUICKLY MOBILIZED, TRANSLATED, AND MADE KEY RESOURCES AVAILABLE TO HUNDREDS OF LOCAL IMPLEMENTING PARTNERS RESPONDING TO BOTH THE WAR IN UKRAINE AND THE FLOODS IN PAKISTAN. REGIONAL CONVENINGS WERE ALSO HELD FOCUSED ON PARENTING IN AFRICA, ASIA, AND LATIN AMERICA. ECDAN ALSO LAUNCHED AND HOSTED A NEW FUNDERS COLLABORATIVE INITIATIVE TO DEVELOP AND SCALE UP SUCCESSFUL MODELS OF HOME-BASED CHILDCARE IN KENYA, RWANDA, AND INDIA. THE FIVE INITIAL KNOWLEDGE FELLOWS COMPLETED AND DISSEMINATED THEIR KNOWLEDGE PRODUCTS. SIX OTHER KNOWLEDGE FELLOWS (2022 COHORT) WERE SELECTED, PAIRED WITH MENTORS, AND SUPPORTED TO DESIGN KNOWLEDGE PROJECTS. ECDAN CONTINUED TO PRODUCE GLOBAL PUBLIC GOODS IN COLLABORATION WITH THE HARVARD UNIVERSITY T.H. CHAN SCHOOL OF PUBLIC HEALTH AND THE MURDOCH CHILDREN'S RESEARCH INSTITUTE, INCLUDING A SYSTEMATIC EVIDENCE REVIEW OF THE POTENTIAL APPLICATIONS OF SYSTEMS THINKING IN SCALING EFFORTS TO ENABLE EVERY CHILD TO THRIVE. PRIMARY HEALTH CARE PATH'S PRIMARY HEALTH CARE (PHC) PROGRAM EMPLOYS A COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PHC MODEL THAT ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. PHC AT PATH IS COMPOSED OF SIX TEAMS, DESCRIBED BELOW. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION TOGETHER WITH PARTNERS AROUND THE WORLD, PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) TEAM DEVELOPS, ADAPTS, AND SCALES UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AMONG MOTHERS AND CHILDREN AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. TO ENSURE OPTIMAL NEWBORN NUTRITION, PATH FOCUSES ON BREASTFEEDING PROMOTION, PROVISION OF SPECIALIZED LACTATION SUPPORT FOR MOTHERS OF SMALL AND SICK NEWBORNS, AVAILABILITY OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS, AND UPTAKE AND USE OF GLOBAL STANDARDS FOR HUMAN MILK BANKING. IN 2022, USING HUMAN-CENTERED DESIGN, WE FINALIZED A PROTOTYPE FOR A DIGITAL ADAPTATION KIT FOR DIGITIZING NEWBORN FEEDING AND LACTATION SUPPORT DATA. THIS TOOL WAS DEVELOPED IN KENYA AND IS NOW PUBLICLY AVAILABLE AS A GLOBAL GOOD FOR ALL SETTINGS. PATH CONTINUED SUPPORTING ARIADNE LABS AS A SUBJECT MATTER EXPERT AND SUPPORTED THE GLOBAL DISSEMINATION OF RESEARCH FINDINGS THROUGH MULTIPLE PEER-REVIEWED PUBLICATIONS AND AN INTERNATIONAL CONFERENCE. PATH ALSO WAS SELECTED AS THE COORDINATION BODY FOR THE WHO HUMAN MILK BANKING AND DONOR HUMAN MILK GUIDELINES. THIS INVOLVED SUPPORTING THE WHO STEERING COMMITTEE AND CREATING A GUIDELINE DEVELOPMENT GROUP.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	PATH ALSO COORDINATED THE SAMPLE COLLECTION FOR A GLOBAL DONOR MILK COMPOSITION STUDY FROM FOUR COUNTRIES' HUMAN MILK BANKS. IN GHANA, PATH IS LEADING A FOUR-YEAR EFFORT, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS SPECIFICALLY THE RIDGE HOSPITAL (ALSO KNOWN AS THE GREATER ACCRA REGIONAL HOSPITAL), TEMA GENERAL HOSPITAL, EASTERN REGIONAL HOSPITAL (KOFORIDUA), AND BONO REGIONAL HOSPITAL (SUNYANI). AS PART OF THIS INITIATIVE, THE GHANA HEALTH SERVICE (GHS) AND PATH ARE RESPONSIBLE FOR ADVOCACY, POLICY, AND PROCUREMENT OF LIFESAVING NEONATAL EQUIPMENT TO IMPROVE ADVANCED NEONATAL CARE IN ALL FOUR HOSPITALS. PATH PROCURED AND INSTALLED EQUIPMENT WITHIN THE FOUR FACILITIES AND SUPPORTED TRAININGS OF HOSPITAL STAFF ON THE PROPER USE OF THE NEONATAL EQUIPMENT. ADDITIONALLY, PATH AND GHS SUCCESSFULLY DEVELOPED A COMPREHENSIVE TRAINING MANUAL (WITH INPUT FROM KYBELE, OUR IMPLEMENTING PARTNER) TO ORIENT NURSES AT ANTENATAL AND POSTNATAL CARE DELIVERY POINTS WITHIN THE MEBCI 2.0 FACILITY CATCHMENTS. THE MANUAL WAS ALSO USED TO ORIENT FACILITY AND DISTRICT HEALTH PROMOTION OFFICERS, AS WELL AS REGIONAL NEWBORN CHAMPIONS, ON THE IMPORTANCE OF RAISING AWARENESS AND PROVIDING EDUCATION ON THE CONTINUUM OF CARE FOR SMALL AND SICK NEWBORNS, CREATING DEMAND FOR HIGH-QUALITY NEWBORN CARE. IN COLLABORATION WITH THE GHS AND WITH FUNDING FROM THE PFIZER FOUNDATION, PATH CONTINUED IMPLEMENTING THE INTEGRATED ANTENATAL CARE PROJECT IN THE BONO EAST REGION OF GHANA. THE PROJECT AIMS TO AVERT INFECTIOUS DISEASE MORTALITY AND MORBIDITY IN NEONATES AND MOTHERS BY IMPLEMENTING AN IMPROVED, COMPREHENSIVE INFECTIOUS DISEASE SCREENING PROGRAM DURING PREGNANCY. AS OF DECEMBER 31, 2022, MORE THAN 3,000 WOMEN HAVE BEEN SCREENED FOR INFECTIONS INCLUDING SEXUALLY TRANSMITTED INFECTIONS AND URINARY TRACT INFECTIONS, MORE THAN 450 HEALTH WORKERS HAVE BEEN TRAINED IN SCREENING AND MANAGEMENT OF MATERNAL INFECTIONS, AND MORE THAN 59,000 COMMUNITY MEMBERS WERE REACHED THROUGH COMMUNITY MOBILIZATION, OUTREACH, AND SENSITIZATION ACTIVITIES OR MASS MEDIA CAMPAIGNS FOR DEMAND CREATION. IN LAOS, PATH CONTINUED SERVING AS A SHORT-TERM TECHNICAL ASSISTANCE PARTNER TO JOHN SNOW INC. (JSI) ON A USAID MATERNAL, NEWBORN, AND CHILD HEALTH PROJECT OPERATING FROM SEPTEMBER 2021 TO AUGUST 2026 ACROSS FIVE PROVINCES IN THE NORTH, CENTRAL, AND SOUTH REGIONS OF THE COUNTRY. PATH'S CORE TECHNICAL RESPONSIBILITIES FOCUS ON NEWBORN AND CHILD HEALTH, NUTRITION, AND EARLY CHILDHOOD DEVELOPMENT. THE PATH SOUTHEAST ASIA REGIONAL HUB PROVIDES ADMINISTRATIVE SUPPORT, WHILE THE MNCHN TEAM PROVIDES TECHNICAL LEADERSHIP, INCLUDING TRAVEL TO LAOS TO WORK WITH THE LOCAL JSI TEAM. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. TOGETHER WITH PATH'S CLIMATE CHANGE COMMUNITY OF PRACTICE, PATH'S NUTRITION TEAM CONTINUED TO ADVOCATE FOR SUSTAINABLE CLIMATE-FRIENDLY ALTERNATIVES, SUCH AS CULTURED PROTEINS AND EDIBLE INSECTS. WHERE POLICY OR GUIDELINES SUPPORTING FORTIFIED RICE ALREADY EXISTED, PATH CONTINUED ITS WORK WITH GOVERNMENTS, PRIVATE SECTOR, WORLD FOOD PROGRAM, AND NONGOVERNMENTAL ORGANIZATIONS (NGOS) ON ROLLOUT. AS A PARTNER IN THE DEMOGRAPHIC AND HEALTH SURVEYS PROGRAM, PATH SUPPORTED BIOMARKER DATA COLLECTION INCLUDING BOTH STANDARDIZED, ROUTINE MONITORING OF KEY NUTRITION INDICATORS LIKE STUNTING AND ANEMIA AND INNOVATIONS TO EXPAND BIOMARKER MEASUREMENT IN HOUSEHOLD-BASED SURVEYS CONDUCTED AROUND THE WORLD. WE ALSO CONCLUDED WORK ON A DATA REPOSITORY TRACKING THE STATUS TO SCALE UP OF KEY MNCHN INTERVENTIONS, INCLUDING SEVERAL THAT WOULD IMPROVE NUTRITION. FINALLY, PATH CONCLUDED THE BRIDGE COLLABORATIVE TO ADDRESS HUMAN AND PLANETARY HEALTH. EARLY CHILDHOOD DEVELOPMENT IN 2022, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO SCALE UP ECD SERVICE PROVISION AS AN ESSENTIAL COMPONENT OF PRIMARY HEALTH CARE, REACHING UNPRECEDENTED BLANKET COVERAGE IN TWO LARGE SUBNATIONAL GEOGRAPHIES IN KENYA AND MOZAMBIQUE AND EXPANSION INTO ADDITIONAL SUBNATIONAL GEOGRAPHIES. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. WITH A CONSTELLATION OF PARTNERS, PATH CONTINUED TO FACILITATE COLLECTIVE ACTION AT NATIONAL AND SUBNATIONAL LEVELS TO PROMOTE ECD THROUGH ENHANCED PLANNING, COORDINATION, AND RESOURCING, WHILE ALSO TRANSITIONING KEY IMPLEMENTATION WORKSTREAMS TO GOVERNMENT OWNERSHIP. PATH ALSO COMMENCED EFFORTS TO IMPROVE THE QUALITY OF ECD SERVICE DELIVERY BY ENGAGING COMMUNITIES, SERVICE PROVIDERS, AND KEY STAKEHOLDERS TO DETERMINE SPECIFIC TOUCHPOINTS AND SOLUTIONS THAT MAXIMIZE EXPOSURE TO ECD MESSAGES AND IMPROVE ADOPTION OF KEY BEHAVIORS. HEALTH SYSTEMS THE HEALTH SYSTEMS TEAM SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS AND CONTRIBUTE TO STRONGER PRIMARY HEALTH CARE. BOTH WITHIN PATH AND IN COLLABORATION WITH EXTERNAL PARTNERS, THE TEAM LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES INTERVENTION SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2022, MAJOR ACTIVITIES INCLUDED (1) CONTINUED LEADERSHIP OF MONITORING, EVALUATION, AND LEARNING WITHIN USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PORTFOLIO ACROSS SEVERAL COUNTRIES IN AFRICA AND SOUTHEAST ASIA; (2) LAUNCHED A NEW PHASE OF THE GATES FOUNDATION-SUPPORTED MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION ASSET TRACKER; (3) SUPPORTED PATH'S SENEGAL COUNTRY PROGRAM IN STARTING UP THE USAID URBAN HEALTH SYSTEM STRENGTHENING PROJECT IN DAKAR; AND (4) CONDUCTED SEVERAL LANDSCAPING ASSESSMENTS IN PARTNERSHIP WITH OTHER PATH TEAMS, INCLUDING THE PHC POLICY TRACKER (WITH THE ADVOCACY AND PUBLIC POLICY PROGRAM), BARRIERS AND OPPORTUNITIES IN THE NCD RESPONSE AT THE PHC LEVEL IN LMICS (WITH THE NCD TEAM), AND INTEGRATED COMMUNITY CASE MANAGEMENT ASSESSMENT IN SEVERAL COUNTRIES IN AFRICA (WITH THE MACEPA TEAM). HIV, TUBERCULOSIS, AND VIRAL HEPATITIS AS COVID-19 CONTINUED TO DISRUPT ACCESS TO ESSENTIAL HEALTH SERVICES, PATH'S HIV, TB, AND VIRAL HEPATITIS TEAM FOCUSED ON ADVANCING PERSON-CENTERED HEALTH CARE ACROSS AFRICA, CENTRAL ASIA, AND SOUTHEAST ASIA FOR GENERAL, KEY, AND PRIORITY POPULATIONS. METHODS INCLUDED PROMOTING INTEGRATED SERVICE DELIVERY MODELS PARTICULARLY WITHIN PRIMARY HEALTH CARE, ACCELERATING SELF-CARE INITIATIVES, AND LEVERAGING DIGITAL HEALTH TOOLS TO ENSURE EQUITABLE AND HIGH-QUALITY ACCESS TO HEALTH SERVICES. PATH IS A PARTNER UNDER THE USAID-FUNDED MICROBICIDE RESEARCH AND DEVELOPMENT TO ADVANCE HIV PREVENTION TECHNOLOGIES THROUGH RESPONSIVE INNOVATION AND EXCELLENCE (MATRIX) CONSORTIUM, AN INVESTMENT FOCUSED ON ADVANCING THE RESEARCH AND DEVELOPMENT OF A RANGE OF ACCEPTABLE, AFFORDABLE, SCALABLE, AND DELIVERABLE HIV PREVENTION PRODUCTS TO MEET THE UNMET NEEDS OF WOMEN AT RISK OF HIV. PATH SERVES AS THE CO-LEAD FOR THE BUSINESS MARKET DYNAMICS AND COMMERCIALIZATION ACTIVITY HUB, WHICH HELPS PRODUCT DEVELOPERS UNDERSTAND MARKET DYNAMICS AND HOW TO STRUCTURE PARTNERSHIPS TO ACCELERATE EVENTUAL ACCESS TO ESSENTIAL HIV PREVENTION AND DUAL PREVENTION PRODUCTS. PATH ALSO LEADS THE TECHNOLOGY ACCELERATOR ACTIVITY HUB, WHICH PROVIDES SEED GRANTS TO FUND PROOF-OF-CONCEPT OR FEASIBILITY STUDIES FOR POTENTIAL GAME-CHANGING HIV PREVENTION OR DUAL PREVENTION PRODUCTS. IN 2022, PATH LAUNCHED SOLICITATION PROCESSES TO IDENTIFY CONCEPTS FOR SEED FUNDING, RESULTING IN AN AWARD TO THE UNIVERSITY OF THE WITWATERSRAND TO CONDUCT EARLY PRODUCT DEVELOPMENT WORK ON A DISSOLVING VAGINAL TABLET TO PROTECT AGAINST HIV AND SEXUALLY TRANSMITTED INFECTIONS. PATH, WITH FUNDING FROM UNITAID THROUGH THE STAR-III PROJECT, CONTINUED TO SCALE UP ACCESS TO HIV SELF-TESTING (HIVST) IN INDIA, INDONESIA, AND UGANDA. IN 2022, THE PROJECT CONTINUED PROVIDING DIRECT TECHNICAL SUPPORT TO IN-COUNTRY PARTNERS TO DISTRIBUTE HIVST THROUGH DIVERSIFIED DISTRIBUTION MODELS, INFORMED BY A PROJECT-LED ASSESSMENT AND CO-DESIGN PROCESS. THE PROJECT TEAM ALSO SUPPORTED WILLINGNESS-TO-PAY ASSESSMENTS TO GENERATE MARKET-SHAPING DATA TO INFORM NATIONAL GUIDELINES AND PLANS FOR SUSTAINING HIVST. IN 2022 ALONE, THE PROJECT ASSISTED WITH THE DISTRIBUTION OF MORE THAN 170,000 HIVST KITS ACROSS INDIA, UGANDA, AND INDONESIA.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	PATH ALSO WORKED TO ADVANCE SELF-TESTING FOR HEPATITIS C (HCVST)IN INDIA AND VIETNAM WITH FUNDING FROM UNITAID. 2022 ACTIVITIES INCLUDED: KICKING OFF PROCUREMENTS OF HCVST KITS AND WORKING WITH LOCAL RESEARCH PARTNERS TO SUBMIT AND ADVANCE STUDY PROTOCOLS THROUGH RESEARCH APPROVAL PROCESSES IN INDIA, COORDINATING WITH LOCAL DISTRIBUTORS AND MANUFACTURERS TO IMPORT TWO HCVST PRODUCTS (ONE BLOOD-BASED AND ONE ORAL FLUID) INTO VIETNAM, AND ENGAGING WITH STAKEHOLDERS AND COMMUNITY ENTITIES TO CREATE DEMAND-GENERATION MATERIALS FOR HCVST IN VIETNAM. AS A PARTNER ON THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH WORKED TO ESTABLISH A GLOBAL MARKET FOR DIGITAL ADHERENCE TECHNOLOGIES (DATS) AND COMPLETED A MARKET ACCESS COUNTRY STAKEHOLDER SURVEY AND AN ANALYSIS OF DAT PLATFORMS. WE COMPLETED ENROLLMENT FOR DAT RESEARCH IN FOUR REGIONS OF UKRAINE, SCALED UP THE USE OF DATS IN SIX ADDITIONAL REGIONS THROUGH SUCCESSFUL ADVOCACY WITH THE UKRAINIAN GOVERNMENT, AND INITIATED A QUALITATIVE STUDY OF HEALTH WORKER EXPERIENCE WITH DATS. IN PARTNERSHIP WITH THE TB ALLIANCE, PATH WORKED TO ADVANCE A SHORTER TREATMENT (BEDAQUILINE, PRETOMANID, AND LINEZOLID, KNOWN AS BPAL) FOR MULTIDRUG-RESISTANT TB, COMPLETING ROADMAPS TO INTRODUCE BPAL IN PERU AND UKRAINE. IN DRC, PATH CONTINUED TO ADVANCE PERSON-CENTERED APPROACHES FOR HIV AND TB PREVENTION, TESTING, TREATMENT, AND MONITORING SERVICES THROUGH THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA. IN 2022, PATH FACILITATED THE INTRODUCTION OF A SHORTER REGIMEN FOR TB PREVENTIVE THERAPY, ENABLING MORE PEOPLE TO SUCCESSFULLY COMPLETE THEIR REGIMEN. PATH ALSO INTRODUCED A HUB-AND-SPOKE NETWORKING MODEL TO EXTEND THE REACH OF VERTICAL MOTHER-TO-CHILD TRANSMISSION OF HIV PREVENTION BY TRAINING PROVIDERS AT NON-PROJECT SUPPORTED MATERNITY HOSPITALS TO OFFER HIV TESTING SERVICES AND REFERRING THOSE TESTING POSITIVE FOR TREATMENT INITIATION. THE PROJECT ALSO CONTINUED TO OPTIMIZE THE PROVISION OF VIRAL LOAD MONITORING SERVICES, INTRODUCING A MONTHLY TRACKER TO CLOSELY MONITOR VIRAL LOAD SAMPLES ACROSS VARIOUS STAGES OF THE ANALYSIS AND RESULTS RETURN PROCESS AND MORE QUICKLY DEPLOY TECHNICAL ASSISTANCE TO ADDRESS BACKLOGS DELAYING RESULTS RETURN. USE OF THIS TOOL DECREASED THE OVERALL TURNAROUND TIME FOR VIRAL LOAD RESULTS BY SEVEN DAYS WITHIN SEVEN MONTHS. IN INDIA, PATH EXPANDED OUR FOOTPRINT IN SUPPORTING THE NATIONAL AIDS CONTROL PROGRAM WITH THEIR HIV RESPONSE, BUILDING ON OUR WORK TO STRENGTHEN NATIONAL- AND STATE-LEVEL (MUMBAI AND ANDRA PRADESH) STRATEGIC INFORMATION MANAGEMENT AND DATA USE SYSTEMS TO INTEGRATE HIV PREVENTION AND TESTING PROGRAMMING FOR KEY POPULATIONS AND MIGRANTS IN THREE NORTHEAST STATES OF INDIA. THIS WORK INCLUDED INTRODUCING INNOVATIVE MODELS FOR DECENTRALIZED PREVENTION AND TESTING SERVICES, SUCH AS DEPLOYING MOBILE UNITS ON MOTORBIKES TO OFFER HIV TESTING, LINKING TO PREVENTION AND TREATMENT SERVICES IN RURAL AREAS, AND ESTABLISHING STANDALONE CENTERS THAT PROVIDE A TAILORED PACKAGE OF HIV AND PHC SERVICES FOR YOUNG PEOPLE, PEOPLE WHO INJECT DRUGS, AND TRANS PEOPLE. IN SUPPORT OF TB PROGRAMMING IN INDIA, PATH INTRODUCED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION OF TREATMENT. WITH SUPPORT FROM USAID, PATH FACILITATED A NEEDS ASSESSMENT FOR TECHNICAL SUPPORT UNITS TO FOSTER LOCAL PRIVATE-SECTOR ENGAGEMENT ACROSS FIVE INDIAN STATES. PATH ALSO SUPPORTED REVISIONS AND UPDATES TO TB CONTROL STANDARDS IN PARTNERSHIP WITH WHO AND THE NATIONAL TB PROGRAM. IN 2022 IN KENYA, PATH CONTINUED TO PROVIDE A COMPREHENSIVE PACKAGE OF HEALTH, SOCIAL, AND ECONOMIC STRENGTHENING SERVICES FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE THROUGH THE PEPFAR-FUNDED NURU YA MTOTO PROJECT SUPPORTING 327 HEALTH FACILITIES TO DELIVER: CLINICAL SERVICES TO PREVENT VERTICAL TRANSMISSION OF HIV, TB/HIV COINFECTION SERVICES, CERVICAL CANCER SCREENING AND TREATMENT, AND VIRAL LOAD MONITORING. PATH ALSO IMPLEMENTED THE CHAK A CHAKA PROJECT, WHICH STRENGTHENS ECONOMIC SKILLS AMONG YOUNG WOMEN IN KISUMU, HOMA BAY, AND MIGORI COUNTIES TO REDUCE HIV RISK AND VULNERABILITY. IN 2022, PATH HELPED 1,225 YOUNG WOMEN BUILD SAVINGS AND ENTREPRENEURIAL SKILLS THROUGH ACCESS TO BUSINESS DEVELOPMENT AND VOCATIONAL TRAININGS, BUSINESS COMMUNITY CONNECTIONS, AND INSURANCE FUNDS. PATH PROVIDED CLINICAL EXPERTISE TO CREATE AND REVISE NATIONAL GUIDELINES AND PROTOCOLS FOR DRUG-SENSITIVE AND DRUG-RESISTANT TB IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN; DEVELOPED A TEXTBOOK FOR TB HEALTH CARE PROVIDERS IN TAJIKISTAN; AND REVISED INFECTION PREVENTION AND CONTROL GUIDELINES IN UZBEKISTAN. IN TANZANIA, THE USAID-FUNDED IDDS PROJECT SUPPORTED QUALITY MANAGEMENT AT ZONAL LABORATORIES, EQUIPMENT UPGRADES, AND PREPARATION OF THE LABORATORY NETWORK FOR THE INTRODUCTION OF THE TRUENAT TB TEST. TWENTY-ONE ZONAL LABORATORY STAFF WERE TRAINED ON QUALITY MANAGEMENT SYSTEMS, 50 ROUTERS WERE INSTALLED TO IMPROVE CONNECTIVITY FOR DATA REPORTING, AND 36 PEOPLE WERE TRAINED ON TRUENAT, ACHIEVING A PRE- TO POST-TEST KNOWLEDGE ASSESSMENT INCREASE FROM 51.9 PERCENT TO 80.4 PERCENT. THROUGH IDDS IN VIETNAM, PATH SUPPORTED THE NATIONAL TB PROGRAM BY ASSESSING THE IMPLEMENTATION OF DIAGNOSTIC INTERVENTIONS INCLUDING PEDIATRIC STOOL TESTING, HANDHELD PORTABLE X-RAY INTRODUCTION, AND THE APPLICATION OF ARTIFICIAL INTELLIGENCE FOR READING CHEST X-RAYS. IN DECEMBER 2022, PATH, IN COLLABORATION WITH THE UGANDA MOH AND YOUTH LEADERS, KICKED OFF WORK TO DEVELOP DIFFERENTIATED AND INTEGRATED HIV AND FAMILY PLANNING SERVICE DELIVERY MODELS, WITH A FOCUS ON EXPANDING ACCESS TO A RANGE OF HIV PREVENTION INCLUDING PRE-EXPOSURE PROPHYLAXIS (PREP) AND CONTRACEPTIVE OPTIONS FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN UGANDA. THIS PROJECT AIMS TO APPLY HUMAN-CENTERED DESIGN TO ENGAGE YOUNG WOMEN (18-24 YEARS OF AGE) AND HEALTH WORKERS TO DESIGN AND PROTOTYPE MODELS, WITH A GOAL OF DOCUMENTING AND SHARING MODELS AS WELL AS RECOMMENDATIONS FOR HOW TO OFFER THE EXPANDING RANGE OF PREP PRODUCTS THROUGH SERVICE DELIVERY POINTS WHERE ADOLESCENT GIRLS AND YOUNG WOMEN ACCESS CONTRACEPTION. IN UKRAINE, PATH COMPLETED THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCED TB, HIV, AND HEPATITIS C TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. IN 2022, SEVERAL PROJECT INTERVENTIONS WERE SUCCESSFULLY TRANSITIONED TO GOVERNMENT LEADERSHIP, INCLUDING MEDICATION-ASSISTED THERAPY, PROVISION OF PSYCHOSOCIAL AND HIV SERVICES FOR PRE-TRIAL DETAINEES, AND INDEX CASE TESTING FOR CONTACTS OF DETAINEES NEWLY DIAGNOSED WITH HIV. PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2022, STBCEU IMPLEMENTED INDEX CASE TESTING FOR PATIENTS WITH TB IN PROJECT REGIONS: AMONG 8,276 INDEX PATIENTS, 19,521 CONTACTS WERE IDENTIFIED AND OF THESE 563 STARTED ON TB TREATMENT AND 7,589 ON TB PREVENTIVE TREATMENT (TPT). THE PROJECT ALSO: PROMOTED SHORTER TPT REGIMENS LEADING TO AN INCREASE IN USE OF THE REGIMENS FROM 60 PERCENT TO 78 PERCENT; SUPPORTED QUANTIFERON-GOLD TESTING TO DIAGNOSE LATENT TB INFECTION; INTRODUCED PORTABLE X-RAY MACHINES TO SUPPORT CASE FINDING IN REMOTE AREAS; AND, SUPPORTED CONFLICT-RELATED RESPONSE INCLUDING TRANSPORTATION, EMERGENCY SUPPLY PROCUREMENT, AND INTEGRATED HEALTH SCREENINGS FOR INTERNALLY DISPLACED PERSONS. IN VIETNAM, PATH CONTINUED EFFORTS TO REDUCE NEW HIV INFECTIONS IN PURSUIT OF ENDING AIDS BY 2030 THROUGH THE USAID SUPPORT FOR TECHNICAL EXCELLENCE AND PRIVATE SECTOR SUSTAINABILITY IN VIETNAM (STEPS) PROJECT. 2022 EFFORTS WERE INTENSIVELY FOCUSED ON ENSURING ACCESS TO KEY HEALTH TOOLS FOR HIVST DURING THE COVID-19 OMICRON SURGE, SCALING UP PREP, AND DELIVERING AN INTEGRATED KEY POPULATION AND CLIENT-CENTERED PACKAGE OF SERVICES THROUGH ONE-STOP-SHOP CLINICS, BUILDING ON SYSTEMS AND APPROACHES ADVANCED BY THE USAID/PATH HEALTHY MARKETS PROJECT (20142021). IN ZAMBIA, PATH COMPLETED THE USAID-FUNDED ERADICATE TB PROJECT IN 2022. THE PROJECT SUCCESSFULLY INSTITUTIONALIZED SEVERAL TB INTERVENTIONS, INCLUDING TECHNICAL SUPPORTIVE SUPERVISION TOOLS AT HEALTH FACILITIES, AN INTEGRATED TB/HIV SPECIMEN COURIER SYSTEM IN 30 HIGH-VOLUME TB NOTIFICATION DISTRICTS, ENHANCED ACCESS TO LABORATORY TESTING FOR TB, DECENTRALIZED DRUG-RESISTANT TB SERVICES, ONE-STOP TB/HIV CLINICS, AND MOBILE CLINICS IN REGIONS WITH LIMITED ACCESS TO TB SERVICES.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES, CARDIOVASCULAR DISEASE, AND MENTAL HEALTH IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2022, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LMICS. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT AND IMPLEMENTATION OF A FORECASTING PROGRAM FOR NCD MEDICINES AND PRODUCTS IN KENYA AND UGANDA AND BEGAN EXPANSION INTO GHANA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, MALI, MOZAMBIQUE, RWANDA, SENEGAL, TANZANIA, UGANDA, AND VIETNAM THAT BUILD STRONGER PHC SYSTEMS, GREATER ACCESS TO ESSENTIAL NCD MEDICINES AND PRODUCTS, AND DATA-DRIVEN DECISION-MAKING ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY. OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING AND IMPLEMENTATION OF THE NCD NAVIGATOR, A FIRST-OF-ITS-KIND, LOCALLY MANAGED, NCD DIGITAL INFORMATION SYSTEM FOR RESOURCE PLANNING AND ALLOCATION IN ALL OF GHANA'S 16 REGIONS. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT CONDUCTED MORE THAN 700,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN KENYA, PATH IMPLEMENTED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MINISTRY OF HEALTH BUT CONTINUED TO PROVIDE TECHNICAL ASSISTANCE. WE ALSO BEGAN IMPLEMENTING SEVERAL INNOVATIONS TO STRENGTHEN SUPPLY CHAINS SUCH AS A STOCK TRACKER, AN ELECTRONIC MEDICAL RECORDS MODULE FOR NCD FACILITY DATA, AND LAST-MILE DISTRIBUTION. ADDITIONALLY, PATH IMPLEMENTED AN HIV-HYPERTENSION INTEGRATION PROJECT IN THREE FACILITIES IN WESTERN KENYA TO INCREASE ACCESS TO CARE. OUR PRIMARY HEALTH CARE MODEL IN VIETNAM USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENING AND LINKAGES TO CARE. IN 2022, WE DISSEMINATED RESULTS FROM A SUPPLY CHAIN ASSESSMENT TO DETERMINE THE AVAILABILITY AND AFFORDABILITY OF NCD MEDICINES AT THE PHC LEVEL AND TRAINED HEALTH CARE AND SUPPLY CHAIN PERSONNEL TO SUPPORT SUPPLY MANAGEMENT. IN SENEGAL, TANZANIA, AND RWANDA, PATH IMPLEMENTED THE HEALTHY HEART AFRICA PROJECT FOCUSED ON HYPERTENSION MANAGEMENT AT THE COMMUNITY LEVEL. PATH ALSO CONTINUED TO IMPLEMENT AND EXPAND THE DIABETES CAREPAK IN KENYA, MALI, MOZAMBIQUE, TANZANIA, AND UGANDA AN INNOVATIVE BUNDLING SOLUTION OF THE COMMODITIES NEEDED FOR SAFE ADMINISTRATION OF INSULIN AND DIABETES SELF-CARE. PATH HAS ALSO CONDUCTED SEVERAL RESEARCH AND LANDSCAPING ASSESSMENT PROJECTS. WE COMPLETED AN NCD SITUATIONAL ANALYSIS AND LANDSCAPING ASSESSMENT OF CHALLENGES AND OPPORTUNITIES, SPECIFICALLY FOCUSED ON HYPERTENSION AND DIABETES. WE ALSO INITIATED A SECONDARY RESEARCH PROJECT ON THE MENTAL HEALTH LANDSCAPE OF 22 COUNTRIES TO OUTLINE THE RESEARCH, POLICIES, AND PRACTICES AROUND MENTAL HEALTH IN A VARIETY OF LOW, MIDDLE, AND HIGH-INCOME COUNTRIES. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE AND GROUNDED IN AN UNDERSTANDING OF THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF SRH THROUGHOUT THE LIFE CYCLE. WE BUILD EVIDENCE, CREATE TOOLS AND RESOURCES, AND PROVIDE SERVICES THAT ARE CO-DESIGNED WITH AND FOR WOMEN AND GIRLS TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES, REDUCE BARRIERS, AND EXPAND OPTIONS. IN 2022, PATH RENEWED ITS COMMITMENT TO FAMILY PLANNING (FP) THROUGH THE FP2030 INITIATIVE AMPLIFYING A RIGHTS-BASED APPROACH TO ADVANCING HEALTH EQUITY. WE BELIEVE ALL PEOPLE HAVE THE RIGHT TO INFORMATION, PRODUCTS, AND QUALITY FAMILY PLANNING SERVICES REGARDLESS OF WHERE THEY LIVE, THEIR AGE, THEIR MARITAL STATUS, OR THEIR WEALTH. WITH ASSISTANCE FROM PATH AND PARTNERS, COUNTRIES HAVE CONTINUED TO ACCELERATE SCALE-UP OF THE CONTRACEPTIVE INNOVATION, SELF-INJECTION WITH SUBCUTANEOUS DMPA (DMPA-SC). LED BY PATH IN PARTNERSHIP WITH JSI, THE DMPA-SC ACCESS COLLABORATIVE IN 2022 PROVIDED TECHNICAL ASSISTANCE TO 18 COUNTRIES AND COLLECTED DATA FROM 13 COUNTRIES SHOWING MORE THAN 1 MILLION CLIENT SELF-INJECTION VISITS SINCE 2018. IN UGANDA, PATH AND THE MOH CONTINUE TO IMPLEMENT GROUNDBREAKING PERSON-CENTERED PROGRAMS TO DEMONSTRATE HOW SELF-INJECTION CAN BE OFFERED AT SCALE. IN ZAMBIA, PATH COLLABORATED WITH THE MOH TO DEVELOP PERSON-CENTERED SERVICE DELIVERY MODELS FOR INTEGRATING FP SERVICES INTO CHILDHOOD IMMUNIZATION PROGRAMMING. ACROSS 40 FACILITIES IN FOUR DISTRICTS, PUBLIC-SECTOR HEALTH WORKERS REACHED POSTPARTUM WOMEN WHO WISHED TO SPACE OR LIMIT BIRTHS AND RARELY INTERACTED WITH THE HEALTH SYSTEM. PATH'S LIVING LABS TEAM FACILITATED HUMAN-CENTERED PROGRAM DESIGN WORKSHOPS WITH WOMEN, THEIR MALE PARTNERS, AND LEADERS IN PHC, FP, AND IMMUNIZATION. TOGETHER, WE REIMAGINED THE INTEGRATION OF SERVICES THROUGH NINE APPROACHES TO MEET THE NEEDS OF MOTHERS AND INFANTS MORE HOLISTICALLY. PLANS ARE UNDERWAY WITH THE MOH TO MOBILIZE SCALE-UP OF THE APPROACHES DEVELOPED AND PILOTED THROUGH THE PROJECT. PATH CONTINUES TO BE A LEADER IN THE SELF-CARE MOVEMENT, SUPPORTING INDIVIDUALS AND FAMILIES WHO CHOOSE TO MANAGE THEIR OWN HEALTH. THROUGH THE SELF-CARE PIONEERS COALITION IN SENEGAL, THE MOH, PATH, AND PARTNERS DEVELOPED AND SECURED APPROVAL OF SENEGAL'S SELF-CARE GUIDELINES IN 2022. THESE ARE AMONG THE FIRST NATIONAL SELF-CARE GUIDELINES IN THE WORLD, AND THE FIRST IN FRANCOPHONE AFRICA. PATH'S TECHNICAL EXPERTISE WAS ALSO INSTRUMENTAL IN THE DEVELOPMENT OF AND ADVOCACY FOR RECENTLY APPROVED NATIONAL REPRODUCTIVE HEALTH SELF-CARE GUIDELINES IN KENYA, WHICH AUTHORIZE SELF-INJECTION OF DMPA-SC FOR THE FIRST TIME. WE ALSO PROVIDED TECHNICAL SUPPORT AND LEADERSHIP TO DEVELOP, SCALE UP, AND MAINSTREAM EVIDENCE-DRIVEN INNOVATIONS, INCLUDING THOSE RESPONSIVE TO DIVERSE ADOLESCENT AND YOUTH POPULATIONS. MEANINGFUL ADOLESCENT AND YOUTH ENGAGEMENT UNDERPINS OUR WORK. PATH CONTINUED SERVING AS A MEMBER OF WHO'S TECHNICAL ASSISTANCE COORDINATION MECHANISM ON ADOLESCENT AND YOUTH SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (AYSRHR) HELPING TO ENSURE THAT YOUNG PEOPLE ARE ABLE TO ACCESS SRH INFORMATION AND SERVICES; THAT AYSRHR PROGRAMS ARE WELL-DESIGNED, IMPLEMENTED, MONITORED, AND DOCUMENTED; AND THAT POLITICAL PROCESSES AND STRUCTURES ARE BETTER PREPARED TO INCLUSIVELY ADDRESS THE UNIQUE SRH NEEDS OF YOUNG PEOPLE. IN 2022, PATH'S TECHNICAL ASSISTANCE INCLUDED SUPPORT TO MINISTRIES OF HEALTH TO MEANINGFULLY ENGAGE ADOLESCENTS AND YOUTH THROUGHOUT THE POLICY CYCLE. PATH ALSO CONTINUED TO PARTICIPATE IN THE GUIDELINE DEVELOPMENT GROUP TO SUPPORT UPDATED WHO GUIDELINES ON PREVENTING CHILD MARRIAGE, RESPONDING TO THE NEEDS OF MARRIED GIRLS, AND INCREASING ACCESS TO AND UPTAKE OF CONTRACEPTION AMONG ADOLESCENTS. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NGOS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FP SUPPLIES AND SERVICES.
FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:	IN ADDITION, WE COMPLETED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS AND BEGAN DATA ANALYSIS. FINALLY, WE PARTNERED WITH LMICS ON THE PLANNING, IMPLEMENTATION, AND ONGOING MONITORING OF NATIONAL HPV VACCINATION PROGRAMS. PATH PUBLISHED SEVERAL ARTICLES ON THE ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG INFANTS IN LMICS. ADDITIONALLY, PATH UPDATED OUR RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT, WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE, AND OUR CLINICAL TRIAL TRACKER, WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS. DRUG DEVELOPMENT THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE FROM EARLY RESEARCH TO INTRODUCTION. IN 2022, WE CONTINUED DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WITH OUR COMMERCIAL MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE CONTINUED TO IMPLEMENT THE MICRONUTRIENT AND EED ASSESSMENT TOOL (MEEDAT), A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. MEEDAT WAS USED IN STUDIES OF CHILDREN IN ZAMBIA AND TANZANIA, WITH ADDITIONAL STUDIES PLANNED IN KENYA AND MALAWI. PATH ALSO EXPLORED NEW USES AND PARTNERSHIPS FOR IOWH032, A DRUG CANDIDATE WE PREVIOUSLY DEVELOPED FOR TREATMENT OF CHOLERA, WHICH ALSO HAS POTENTIAL FOR TREATING OTHER DISEASES.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	ALSO, UNDER THE MEBCI 2.0 PROJECT, PATH WORKED WITH GHS TO DEVELOP A TRAINING MANUAL FOR PROVIDERS AT THE PHC LEVEL ON THE CARE, EFFECTIVE COMMUNICATION WITH MOTHERS, AND REFERRAL PROTOCOLS FOR CRITICALLY ILL AND SMALL BABIES TO THE FOUR PROJECT HOSPITALS. AFTERWARD WE SUPPORTED THE TRAINING OF 126 HEALTH PROVIDERS FROM 24 PHC FACILITIES. WITH APPROVAL FROM GLOBAL HEALTH MEDIA, PATH ALSO TRANSLATED VIDEOS ON CARING FOR SMALL AND SICK NEWBORNS INTO TWO POPULAR LOCAL LANGUAGES FOR USE IN EDUCATION AND AWARENESS RAISING AT THE POINT OF CARE AND IN COMMUNITIES. PATH ALSO WORKED TO STRENGTHEN IMMUNIZATION PROGRAMS IN GHANA IN 2022. WITH FUNDING SUPPORT FROM OPEN PHILANTHROPY RECOMMENDED TO PATH FROM GIVEWELL, WE SUPPORTED THE EXPANSION OF THE RTS,S MALARIA VACCINE TO 51 NEW DISTRICTS IN GHANA. PATH'S OTHER AREAS OF FOCUS TO SUPPORT IMMUNIZATION PROGRAMMING INCLUDED CONTINUING TO SUPPORT THE NATIONAL RESPONSE TO COVID-19, SUPPORTING THE INTRODUCTION OF HPV VACCINATION INTO ROUTINE IMMUNIZATION PROGRAMS, EXPANDING THE USE OF GEO-ENABLED DIGITAL MICROPLANNING, AND SUPPORTING THE LAUNCH OF NATIONAL GUIDELINES FOR INTRODUCING IMMUNIZATION SERVICE DELIVERY THROUGH COMMUNITY PHARMACISTS. WITH FUNDING SUPPORT FROM ASTRAZENECA, PATH SUPPORTED NCD PROGRAMMING IN GHANA THROUGH THE HEALTHY HEART AFRICA PROGRAM. IN 2022, PATH HELPED IMPROVE THE QUALITY OF HYPERTENSION SERVICE DELIVERY IN ASHANTI AND BONO EAST REGIONS BY SUPPORTING 11 DISTRICTS AND 50 HEALTH FACILITIES WITH OVER 300 BLOOD PRESSURE DEVICES AND TRAINING OVER 200 HEALTH WORKERS ON HYPERTENSION PREVENTION AND MANAGEMENT. WE ALSO SUPPORTED THE INTEGRATION OF HYPERTENSION CARE ACROSS MULTIPLE POINTS OF CARE WITHIN FACILITIES INCLUDING CHILD WELFARE CLINICS, FAMILY PLANNING UNITS, WELLNESS CLINICS, AND NATIONAL IMMUNIZATION DAYS TO IMPROVE ACCESS TO HYPERTENSION CARE AND REDUCE MISSED OPPORTUNITIES FOR SCREENING. PATH ALSO CONDUCTED TARGETED COMMUNITY ADVOCACY CAMPAIGNS AND SCREENINGS FOR PRIORITY GROUPS. AS PART OF THESE EFFORTS, WE SUPPORTED THE DEVELOPMENT OF THE HYPERTENSION CHAMPIONS PROGRAM, WHICH LEVERAGED INFLUENTIAL COMMUNITY MEMBERS AS AGENTS FOR HYPERTENSION AWARENESS, PREVENTION, AND CONTROL. PATH WORKED WITH THE GHS NCD PROGRAM TO INTRODUCE AND SCALE THE USE OF THE NCD NAVIGATOR TOOL TO ALL 16 REGIONS OF THE COUNTRY. PATH ALSO SUPPORTED THE MULTISTAKEHOLDER HIGH-LEVEL NCD ROUNDTABLE FORUM HELD IN GHANA IN APRIL 2022 AND DELIVERED A PRESENTATION ON FINANCING NCDS ON BEHALF OF GHANA'S NCD STEERING COMMITTEE. PATH WORKED TO STRENGTHEN SUPPLY CHAIN LEADERSHIP AND GOVERNANCE WITH FUNDING FROM THE ACCESS ACCELERATED PARTNERSHIP. WE INTRODUCED A FORECASTING TOOL AND TRAINED KEY HEALTH PROVIDERS AROUND PROCUREMENT, MEDICINES AND SUPPLIES, HEALTH INFORMATION AND DATA MANAGEMENT, AND FORECASTING FOR CLINICIANS. PATH ALSO CONDUCTED A BASELINE STUDY ON INSULIN INTEGRATION INTO GHANA'S COLD CHAIN SYSTEM AND SUPPORTED AN ONGOING PILOT OF THIS INTERVENTION AT THE GA-WEST MUNICIPALITY IN THE GREATER ACCRA REGION. KENYA THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT IS A FOUR-YEAR PROJECT (JULY 2019-MARCH 2024) FUNDED BY UNITAID. THE PRIMARY GOALS ARE TO IMPROVE PHC WORKERS' ABILITY TO DIAGNOSE SEVERE DISEASE BY EQUIPPING THEM WITH PULSE OXIMETRY (POX) AND CLINICAL DECISION SUPPORT ALGORITHMS (CDSA) AND TO ACCELERATE THE DEVELOPMENT OF NONINVASIVE DEVICES THAT AUGMENT THE FEATURES OF STANDARD PULSE OXIMETERS WITH ONE OR MORE ADDITIONAL VITAL SIGN MEASUREMENTS. THE TIMCI PROJECT IMPLEMENTATION PHASE WAS ROLLED OUT IN 2022 IN THREE COUNTIES: KAKAMEGA, KITUI, AND UASIN GISHU. SIXTY HEALTH FACILITIES COLLECTED ROUTINE POX AND CDSA CASE DATA ON SICK CHILDREN, WHILE THE UNIVERSITY OF NAIROBI CONDUCTED RESEARCH ON POX AND CDSA FEASIBILITY AND COST-EFFECTIVENESS IN 19 PHC FACILITIES. ONCE THE DATA ANALYSIS IS COMPLETED, PATH AIMS TO USE THE RESULTS TO INFORM COUNTY LEADERSHIP ENGAGEMENT FOR PRIORITIZATION AND BUDGETING FOR POX, HEALTH CARE PROVIDER TRAINING AND SCALE-UP OF PULSE OXIMETRY AND CDSA, AND ENGAGEMENT OF CIVIL SOCIETY ORGANIZATIONS FOR ADVOCACY AND AWARENESS CREATION ON USE OF POX AND CDSA. PATH'S NONCOMMUNICABLE DISEASES TEAM SUPPORTED SCALE-UP OF THE AFYA KIJIJINI PRIMARY HEALTH CARE PROJECT IN MAKUENI COUNTY WITH 26 SITES AND OVER 14,000 PATIENTS LINKED TO CARE THROUGH THE ACCESS ACCELERATED PROJECT, A MULTICOUNTRY INITIATIVE IN KENYA, GHANA, AND VIETNAM. PATH ALSO SUPPORTED STRENGTHENING OF MEDICINES DATA AVAILABILITY AND END-TO-END VISIBILITY DASHBOARDS WITH THE KENYA MEDICAL SUPPLIES AUTHORITY (KEMSA) WITH THE SAME FUND. WITH INTERNATIONAL FEDERATION OF PHARMACEUTICALS MANUFACTURERS & ASSOCIATIONS AND NOVO NORDISK FUNDING, PATH SUPPORTED THE CO-CREATION OF A DIABETES SELF-CARE BUNDLE TO BE USED BY PATIENTS LIVING WITH DIABETES IN PARTNERSHIP WITH THE MOH'S DEPARTMENT ON NCDS, PATH'S LIVING LABS, AND PATIENT GROUPS. OUR WORK CONTRIBUTED TO THE DEVELOPMENT OF PROTOTYPE KITS, PATIENT MANUALS, AND TRAINING MATERIALS. ADDITIONALLY, PATH SUPPORTED A PILOT PROJECT ON HIV AND HYPERTENSION WITH RESOLVE TO SAVE LIVES (RTSL) FUNDING IN KISUMU AND NYAMIRA COUNTIES. THROUGH THE NCD PROGRAM, PATH PROVIDED TECHNICAL STAFF EMBEDDED WITHIN MOH TO SUPPORT NCD PROGRAMMING INCLUDING FOR CANCER. THE ECD PROJECT IN KENYA SUPPORTED THE DEVELOPMENT OF POLICY DOCUMENTS THAT ENTRENCH ECD AS A PRIORITY PROGRAM NATIONALLY AND SUBNATIONALLY. THE PROJECT ALSO SUCCESSFULLY ADVOCATED FOR GOVERNMENT LEADERSHIP AND INVESTMENT IN ECD THROUGH THE LAKE REGIONAL ECONOMIC BLOC, ENSURING THAT COUNTY GOVERNMENTS ALLOCATE RESOURCES IN SECTORAL BUDGETS TO PROMOTE CHILD DEVELOPMENT. UNDER THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, THE DETERMINED, RESILIENT, EMPOWERED, AIDS-FREE, MENTORED, AND SAFE (DREAMS) PROGRAM AIMS TO REDUCE NEW HIV INFECTIONS AMONG ADOLESCENT GIRLS AND YOUNG WOMEN (AGYW) BY DELIVERING HIGH-QUALITY, COMPREHENSIVE, AND YOUTH-FRIENDLY PREVENTION SERVICES TO AGYW ENROLLED IN THE PROGRAM. THE PROGRAM ALSO AIMS TO REDUCE GENDER-BASED VIOLENCE (GBV) AND IMPROVE THE HEALTH SYSTEM RESPONSE TO POST-GBV CARE FOR AGYW. THE PROJECT ENROLLED AND HAS AN ACTIVE AGYW BASE OF 37,575 AND AN 87 PERCENT ACHIEVEMENT AGAINST TARGETS. THE ORPHANS AND VULNERABLE CHILDREN (OVC) INTERVENTION AIMS TO SAFEGUARD THE HEALTH, RIGHTS, AND WELFARE OF CHILDREN AND ADOLESCENTS, WORKING WITH COUNTY GOVERNMENTS, STAKEHOLDERS, AND LOCAL IMPLEMENTING PARTNERS. WE DELIVER HIGH-QUALITY HEALTH AND SOCIAL SERVICES TO OVC AND HOUSEHOLDS AFFECTED BY HIV AND HELP STRENGTHEN CHILD PROTECTION SYSTEMS AND SERVICE DELIVERY IN CLOSE COLLABORATION WITH THE DEPARTMENT OF CHILDREN SERVICES AND MOH. THE PROJECT ADMINISTERED CASE PLAN ACHIEVEMENT READINESS ASSESSMENTS (CPARAS) FOR 27,863 HOUSEHOLDS AND DEVELOPED CASE PLANS FOR 64,675 OVC, WHICH IS A 100 PERCENT ACHIEVEMENT FOR HHS WITH CASE PLANS. PATH'S MARKET DYNAMICS TEAM BEGAN IMPLEMENTING TWO PROJECTS IN KENYA DURING 2022 THAT WILL RUN THROUGH 2025: STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) AND SCALING ACCESS TO LIFESAVING EQUIPMENT (SCALE). PATH HAS CONDUCTED COUNTIES' NEEDS ASSESSMENTS IN THE SEVEN IMPLEMENTATION COUNTIES IN KENYA. WE CONDUCTED WORKSHOPS ON FINANCIAL PLANNING, PROCUREMENT TRAINING, AND BUDGETING TO SUPPORT EQUIPMENT AND INFRASTRUCTURE RELATED TO MEDICAL OXYGEN PRODUCTION, STORAGE, AND DISTRIBUTION. PATH ALSO SUPPORTED CAPACITY-BUILDING EFFORTS FOR COUNTY BIOMEDICAL ENGINEERS AND CLINICIANS ON DETERMINATION OF OXYGEN NEEDS AND ON RATIONAL USE OF OXYGEN. PATH LED ADVOCACY TRAINING WITH THE GOAL OF INCREASING DOMESTIC FINANCING TO ENSURE A SUSTAINABLE AND RESILIENT SUPPLY CHAIN FOR EQUIPMENT, SPARE PARTS, AND EQUIPMENT CONSUMABLES. UNDER THE SOURCE PROJECT WE HAVE SUPPORTED THE MOH IN THE DEVELOPMENT OF GUIDELINES ON PRODUCTION, DELIVERY, AND MANAGEMENT OF MEDICAL OXYGEN AND DEVELOPMENT OF OXYGEN INDICATORS TO BE INCORPORATED INTO THE NATIONAL HEALTH INFORMATION SYSTEM. UNDER THE SCALE PROJECT, PATH FOCUSED ON INCREASING ACCESS TO MNCH/PHC DEVICES, VIRAL LOAD TESTING, AND COLD CHAIN EQUIPMENT. PATH CONTINUED SUPPORTING THE EXPANSION OF IMMUNIZATION SERVICES IN KENYA. DISTRIBUTION OF THE RTS,S MALARIA VACCINE EXPANDED TO AN ADDITIONAL 26 HIGH-RISK SUBCOUNTIES IN 2022, MAKING A TOTAL OF 52 SUBCOUNTIES PROVIDING THE RTS,S VACCINE AS PART OF THE COUNTRY'S ROUTINE IMMUNIZATION. THROUGH GAVI TCA AND COVID-19 DELIVERY SUPPORT FUND, PATH HAS BEEN ABLE TO PROVIDE TECHNICAL SUPPORT AT NATIONAL AND SUBNATIONAL LEVELS ON COVID-19 VACCINATION. THROUGH USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PROJECT, PATH SUPPORTED THE COUNTRY IN REDUCING THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNIZED CHILDREN.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	WITH FINANCIAL SUPPORT FROM THE GATES FOUNDATION, PATH'S LIVING LABS PROJECT PARTNERED WITH HEALTH CARE WORKERS USING A HUMAN-CENTERED DESIGN APPROACH TO CO-CREATE SOLUTIONS FOR IMPROVING HEALTH WORKER MOTIVATION AND INCREASING VACCINE COVERAGE. PATH LIVING LABS ALSO COLLABORATED WITH ADOLESCENT GIRLS AND YOUNG WOMEN AND PREP SERVICE PROVIDERS IN HOMA BAY COUNTY TO JOINTLY DEVELOP FIVE SOLUTIONS AIMED AT ENHANCING AGYW ADHERENCE TO PREP. PATH LIVING LABS HAS, THROUGH USER ENGAGEMENT, ESTABLISHED THE SIGNIFICANCE OF THE MOTHER-CHILD HEALTH BOOKLET IN PROMOTING NURTURING CARE FOR EARLY CHILDHOOD DEVELOPMENT (NCFECD). IN 2022, WE CONTINUED TO FOCUS ON THE DEVELOPMENT OF TRAINING GUIDES AND OPERATING PROCEDURES AIMED AT EMPOWERING HEALTH CARE WORKERS AND COMMUNITY HEALTH VOLUNTEERS TO EFFECTIVELY INTEGRATE NCFECD AT FACILITY AND COMMUNITY LEVELS AND ENSURE HIGH-QUALITY IMPLEMENTATION. OUR LIVING LABS AND M-RITE TEAMS COLLABORATED TO REVIEW AND EVALUATE THE M-RITE CRISTA FRAMEWORK, WHICH FOCUSES ON ASSESSING THE TRANSFERABILITY OF COVID-19 DIGITAL SYSTEMS TO ROUTINE IMMUNIZATION. THIS FRAMEWORK PROVIDES A SYSTEMATIC PROCESS FOR COLLECTING EVIDENCE AND GENERATING RECOMMENDATIONS TO SUPPORT THE TRANSFER OF DIGITAL SYSTEMS FROM COVID-19 TO ROUTINE IMMUNIZATION PROGRAMS. TO ASSESS THE TOOL, THE LIVING LABS TEAM CONDUCTED EXPERT INTERVIEWS AND DESK REVIEWS AND PROVIDED VALUABLE FEEDBACK ON THE USABILITY AND EFFECTIVENESS OF THE TOOL, AIMING TO ENHANCE ITS OVERALL FUNCTIONALITY. IN COLLABORATION WITH THE NATIONAL VACCINES AND IMMUNIZATION PROGRAM (NVIP) TEAM, WE UNDERTOOK THE TASK OF REDESIGNING HPV MATERIALS WITH CONSIDERATION OF THE FEEDBACK RECEIVED FROM 16 COUNTIES WITH LOW PERFORMANCE IN HPV VACCINATION. THE GOAL WAS TO IMPROVE THE EFFECTIVENESS AND RELEVANCE OF THE MATERIALS, ENSURING THEY ADDRESS THE SPECIFIC CHALLENGES FACED BY THESE COUNTIES. BY INCORPORATING THE VALUABLE INSIGHTS GATHERED FROM A WORKSHOP WITH REPRESENTATIVES FROM LOW-PERFORMING COUNTIES, WE AIMED TO CREATE REDESIGNED HPV MATERIALS THAT ARE BETTER SUITED TO MEET THE NEEDS AND OVERCOME THE BARRIERS ENCOUNTERED IN PROMOTING HPV VACCINATION. PATH LIVING LABS, IN COLLABORATION WITH THE DIGITAL SQUARE TEAM, WAS INVOLVED IN ENHANCING THE MOH'S CHANJO KE PORTAL FOR COVID-19 VACCINATION SERVICES. AS PART OF THIS INITIATIVE, WE CONDUCTED AN ASSESSMENT OF CHANJO KE UTILIZATION IN KAJIADO AND NAKURU COUNTIES. THE ASSESSMENT YIELDED VALUABLE INSIGHTS THAT WILL GUIDE THE ENHANCEMENT PROCESS. ADDITIONALLY, WE FACILITATED A WORKSHOP INVOLVING KEY STAKEHOLDERS SUCH AS THE NVIP, MOH DIGITAL HEALTH TEAMS, COUNTY HEALTH MANAGEMENT TEAMS (CHMT), AND HEALTH CARE WORKERS. THIS COLLABORATIVE WORKSHOP WAS HOSTED TO REVIEW THE UTILIZATION FINDINGS, DEFINE WHAT NEEDS TO BE ENHANCED, AND CO-CREATE AND REFINE SYSTEM FEATURES FOR ENHANCEMENT. LIVING LABS ALSO PARTNERED WITH OTHER PATH TEAMS TO DESIGN A NEWBORN NUTRITION DIGITAL ADAPTION KIT (NNDAK) THAT PROVIDES DATA-INFORMED GUIDANCE TO OPTIMIZE CRITICAL FEEDING ACCORDING TO CLINICAL CARE GUIDELINES. THE NNDAK HAS THE POTENTIAL TO REDUCE HOSPITAL STAYS, IMPROVE NEWBORN NUTRITION, AND REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH LACK OF OPTIMAL NUTRITION EARLY IN LIFE. MALAWI IN 2022, PATH WORKED CLOSELY WITH THE HEALTH EDUCATION SERVICES (HES) IN THE MINISTRY OF HEALTH TO DEVELOP THE COMMUNICATION STRATEGY; MESSAGES; AND INFORMATION, EDUCATION, AND COMMUNICATION MATERIALS FOR THE INTRODUCTION OF THE RTS,S MALARIA VACCINE IN MALAWI. AS PART OF THE ADVOCACY, COMMUNICATION AND SOCIAL MOBILIZATION SUBCOMMITTEE, PATH ALSO WORKED WITH HES AND OTHER PARTNERS IN GETTING THE MESSAGES TO COMMUNITIES THROUGH POSTERS, LEAFLETS, FLYERS, COMMUNITY MEETINGS, AND VOLUNTEERS. WITH FUNDING FROM OPEN PHILANTHROPY, PATH SUPPORTED THE EXPANSION OF RTS,S FROM THE INITIAL 147 PILOT FACILITIES TO 281 HEALTH FACILITIES. WE ALSO WORKED WITH PARTNERS IN DEVELOPING AND DISTRIBUTING MESSAGES AND MATERIALS FOR THE INTRODUCTION OF THE TYPHOID CONJUGATE VACCINE. THROUGH THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) GLOBAL PROJECT, PATH SUPPORTED THE MOH IN IMPROVING ACCESS TO MEDICAL OXYGEN THROUGH THE IMPLEMENTATION OF THE MEDICAL OXYGEN ECOSYSTEM ROADMAP. WORKING WITH THE MOH, WE PROVIDED TECHNICAL ASSISTANCE IN THE DEVELOPMENT OF OXYGEN INDICATORS AND OXYGEN USAGE GUIDELINES AND CONTINUED TO SUPPORT A PILOT TESTING THEIR EFFECTIVENESS PRIOR TO NATIONAL SCALE-UP. PATH CONDUCTED MALAWI'S FIRST NATIONAL-SCALE MEDICAL EQUIPMENT INVENTORY ASSESSMENT, WHICH INCLUDED EVALUATING THE STATE OF AVAILABLE MEDICAL EQUIPMENT, QUANTIFYING THE GAPS IN AVAILABILITY AND FUNCTIONALITY OF MEDICAL EQUIPMENT, AND SUPPORTING THE DEVELOPMENT OF AN ESSENTIAL SPARE PARTS LIST FOR RESPIRATORY CARE EQUIPMENT (RCE) IN MALAWI TO SUPPORT THE MOH IN PLANNING BULK PROCUREMENT FOR RCE SPARE PARTS. OUR MARKET DYNAMICS TEAM ALSO LAUNCHED A MARKET LANDSCAPE SURVEY TO UNDERSTAND THE AVAILABILITY OF RCE SPARE PARTS ON THE LOCAL MARKET AND HOW TO BEST SUPPORT MARKET STIMULATION. MOZAMBIQUE 2022 MARKED PATH'S TENTH ANNIVERSARY IN MOZAMBIQUE. OVER THE LAST DECADE, THE CONRAD N. HILTON FOUNDATION HAS FUNDED PATH'S TECHNICAL ASSISTANCE TO INTEGRATE EARLY CHILDHOOD DEVELOPMENT (ECD) INTO THE HEALTH SYSTEM IN MOZAMBIQUE. AS PART OF THE HILTON PHASE IV ECD GRANT, PATH CONTINUED ITS LONG-TERM ADVOCACY AND SOCIAL MOBILIZATION EFFORTS TO ELEVATE NURTURING CARE FOR ECD IN THE GOVERNMENT'S AGENDA AT NATIONAL AND SUBNATIONAL LEVELS, WHICH RESULTED IN THE DEVELOPMENT OF GOVERNMENT-OWNED ECD ACTION PLANS IN NAMPULA AND MAPUTO PROVINCES; ENGAGEMENT OF SPOUSES OF GOVERNORS AND SECRETARIES OF STATE AS ECD CHAMPIONS IN THOSE TWO PROVINCES; AND INTEGRATION OF ECD INTO SEVERAL MNCHN POLICIES, GUIDELINES, AND TOOLS FOR INCREASED REACH OF NURTURING CARE INTERVENTIONS THROUGH INTEGRATED PHC SERVICE DELIVERY FOR THE YOUNGEST CHILDREN IN MOZAMBIQUE. PATH COLLABORATED WITH THE WORLD FOOD PROGRAMME (WFP) IN MOZAMBIQUE TO STRENGTHEN THE INTEGRATION OF NURTURING CARE, INCLUDING NUTRITION, EARLY LEARNING, AND RESPONSIVE CAREGIVING INTERVENTIONS INTO WFP'S EMERGENCY RECOVERY NUTRITION-SENSITIVE PROGRAMMING IN BUZI DISTRICT, SOFALA PROVINCE. THE NINE-MONTH PROJECT, IMPLEMENTED FROM OCTOBER 2021 TO JUNE 2022, RESULTED IN INCREASED CAPACITY OF 64 COMMUNITY HEALTH ACTORS TO IMPLEMENT THE MOH'S PACKAGE OF NUTRITION INTERVENTIONS (PIN); INCREASED QUALITY OF PIN SERVICE DELIVERY; AND INCREASED KNOWLEDGE OF OPTIMAL EARLY LEARNING AND RESPONSIVE CAREGIVING BEHAVIORS AMONG APPROXIMATELY 4,125 CAREGIVERS OF CHILDREN 0-24 MONTHS OF AGE, REACHED WITH NURTURING CARE FOR ECD BEHAVIOR CHANGE INTERVENTIONS. IN 2022, THE PATH TEAM IN MOZAMBIQUE LAUNCHED THE DIABETES CAREPAK PROJECT, A MULTICOUNTRY PROJECT FUNDED BY THE HELMSLEY CHARITABLE TRUST AND PHASE III OF THE PMI-FUNDED DIGITAL COMMUNITY HEALTH INITIATIVE (DCHI), IMPLEMENTED THROUGH DIGITAL SQUARE IN SEVERAL COUNTRIES. AS PART OF PHASE III OF THE DCHI, THE MOZAMBIQUE MOH SELECTED ONE PRIORITY AREA FOR STRENGTHENING THE COMMUNITY DIGITAL HEALTH ECOSYSTEM AMONG THE VARIOUS NEEDS IDENTIFIED THROUGH AN ASSESSMENT CONDUCTED IN PREVIOUS PHASES OF THE PROJECT. TO STRENGTHEN GOVERNANCE OF COMMUNITY DIGITAL HEALTH PLATFORMS, PATH SECONDED A COMMUNITY DIGITAL HEALTH ADVISOR TO THE PHC DEPARTMENT OF THE MOH TO DEVELOP A STRATEGIC PLAN FOR THE IMPLEMENTATION OF A COMMUNITY HEALTH INFORMATION SUBSYSTEM AND TO STRENGTHEN COORDINATION AMONG VARIOUS COMMUNITY DIGITAL HEALTH STAKEHOLDERS. SENEGAL IN 2022, PATH WAS SELECTED TO LEAD USAID'S INVESTMENT IN URBAN HEALTH PROJECT TO STRENGTHEN LOCAL URBAN HEALTH SYSTEMS AND IMPROVE HEALTH EQUITY IN DAKAR IN THREE HEALTH DISTRICTS: GUDIAWAYE, YEUMBEUL, AND KEUR MASSAR. PATH LEADS A CONSORTIUM OF PARTNERS IN THIS PROJECT, INCLUDING OPEN DEVELOPMENT, ACTION ET DEVELOPPEMENT (ACDEV), ALLIANCE DU SECTEUR PRIVE DE LA SANTE DU SENEGAL (ASPS), AND ENDA SANTE. PATH SUPPORTED USAID'S ENGAGEMENT WITH SEVERAL NATIONAL, REGIONAL, AND DISTRICT LEVEL STAKEHOLDERS, INCLUDING THE DAKAR REGIONAL MEDICAL OFFICER (RMO), THE DISTRICT HEALTH OFFICES (DHOS), THE DIRECTION GENERALE DE LA SANTE PUBLIQUE (DGSP), THE DIRECTION OF MATERNAL AND CHILD HEALTH (DSME), THE COORDINATOR OF THE TUBERCULOSIS PROGRAM, THE DIRECTION OF PLANIFICATION AND RESEARCH (DPRS), AND THE DIRECTION OF PRIVATE-SECTOR HEALTH FACILITIES. PATH ISSUED PRE-AWARD CONTRACTS TO PARTNERS IN OCTOBER 2022 TO KICK OFF THE INCEPTION PHASE ACTIVITIES. TO FACILITATE COORDINATION AND PLANNING, A TECHNICAL WORKING GROUP WAS ESTABLISHED, AND EACH PARTNER DEVELOPED A YEAR-ONE ACTION PLAN TO PROVIDE TECHNICAL SUPPORT TO THE DISTRICTS AND RMOS. UNDER THIS PLAN, PATH AND OPEN DEVELOPMENT CONDUCTED A FINANCIAL AND MANAGERIAL RISK ASSESSMENT TO EVALUATE THE CAPACITY OF DHOS AND RMOS TO RECEIVE AND ADEQUATELY MANAGE EXTERNAL FUNDING.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	PATH CONTINUED SUPPORTING THE SENEGALESE GOVERNMENT IN CONDUCTING TWO BIOMEDICAL EQUIPMENT INVENTORIES IN HEALTH FACILITIES AND COVID-19 TREATMENT CENTERS TO COLLECT DATA ON EXISTING MEDICAL EQUIPMENT, INCLUDING OXYGEN DEVICES, AND IDENTIFY GAPS IN OXYGEN ACCESS AND UTILIZATION. PATH DONATED THROUGH THE ACCESS TO COVID-19 TOOLS ACCELERATOR INITIATIVE OXYGEN DEVICES WORTH $1 MILLION TO SUPPORT THE MOH IN COVID-19 RESPONSE. WE ALSO SUPPORTED THE ASSESSMENT OF THE ONLINE MAINTENANCE MANAGEMENT SYSTEM TO IDENTIFY CHALLENGES THAT MAY DETER FUTURE SCALE-UP OF ACCESS AND UTILIZATION OF OXYGEN DEVICES AND DEVELOPED A VALUE-BASED PROCUREMENT GUIDE TO SUPPORT THE PROCUREMENT OF MEDICAL EQUIPMENT. PATH ALSO CONTRIBUTED TO THE DEVELOPMENT OF A MANUAL OF STANDARD OPERATING PROCEDURES TO SUPPORT PROCUREMENT AND MANAGEMENT OF NTD DRUGS TO RATIONALIZE RESOURCES DURING MASS DRUG ADMINISTRATION IN SENEGAL. PATH, THROUGH ITS MACEPA PROGRAM, CONTINUED SUPPORTING SENEGAL'S NATIONAL MALARIA CONTROL PROGRAM (NMCP) DURING 2022 IN THE IMPLEMENTATION OF MALARIA SURVEILLANCE AND ELIMINATION ACTIVITIES IN ELIGIBLE AREAS. THE MACEPA TEAM SUPPORTED SENEGAL'S HEALTH CARE SYSTEM IN THE TIMELY DETECTION, DOCUMENTATION, AND TREATMENT OF MALARIA CASES. PATH ALSO SUPPORTED DATA QUALITY AUDITS AND SUPERVISIONS OF THE DHIS2 TRACKER TO IMPROVE DATA QUALITY AND STRENGTHEN THE CAPACITY OF PROIVIDERS TO USE OF THE TOOL TO CAPTURE MALARIA CASE INVESTIGATION DATA. IN 2022 UNDER THE MACEPA IV PROJECT, PATH'S SENEGAL STAFF ALSO PROVIDED TECHNICAL AND FINANCIAL SUPPORT TO NMCP FOR THE INTRODUCTION OF CASE-BASED MALARIA SURVEILLANCE IN THE NORTH BANK REGIONS OF THE GAMBIA. KEY ACCOMPLISHMENTS INCLUDE THE DEVELOPMENT AND VALIDATION OF CASE-BASED MALARIA SURVEILLANCE GUIDELINES, STANDARD OPERATING PROCEDURES, AND DATA COLLECTION TOOLS. EIGHTY-TWO HEALTH CARE WORKERS WERE TRAINED ON CASE-BASED MALARIA SURVEILLANCE AND 31 HEALTH CARE WORKERS ON THE DHIS2 TRACKER. FIELD TESTING OF THE DHIS2 TRACKER WAS CONDUCTED TO ASCERTAIN THE EFFECTIVE FUNCTIONING OF THE APP. AS PART OF CROSS-BORDER COLLABORATION BETWEEN SENEGAL AND THE GAMBIA, PATH SUPPORTED A JOINT WORKSHOP WHERE A COMMON DATA VISUALIZATION PLATFORM WAS SET UP FOR THE SYNCHRONIZED MASS LONG-LASTING INSECTICIDAL NETS (LLIN) CAMPAIGN CONDUCTED IN 2022 FOR THE TWO COUNTRIES. IN PARTNERSHIP WITH RESOLVE TO SAVE LIVES, PATH SUPPORTED ESTABLISHMENT OF THE PUBLIC HEALTH EMERGENCY OPERATION CENTRE (PHEOC) THROUGH THE DEVELOPMENT OF THE LEGAL FRAMEWORK; SUPPORTED PROVISION OF INFORMATION AND COMMUNICATION TECHNOLOGY EQUIPMENT TO SUPPORT WATCH, ALERT, AND RESPONSE FUNCTIONS; AND SUBSEQUENTLY SUPPORTED THE RESPONSE TO ACUTE KIDNEY INJURY OUTBREAK (JULOCT 2022). WE FACILITATED MONTHLY COLLABORATION CALLS BETWEEN SENEGAL AND THE GAMBIA PHEOC FOR CROSS-BORDER LEARNING AND PUBLISHED MONTHLY EXPANDED PROGRAMME ON IMMUNIZATION (EPI) BULLETINS USING THE DHIS2 DASHBOARD. FOLLOWING SUCCESSFUL INTRODUCTION OF THE HPV VACCINE IN THE GAMBIA, PATH SIGNED A SERVICE AGREEMENT WITH GAVI FOR THE VACCINE VISIBILITY SYSTEM AND ONGOING HPV VACCINE TECHNICAL ASSISTANCE AND IMPLEMENTATION (TO BEGIN IN 2023). THE DIGITAL SQUARE TEAM CARRIED OUT VARIOUS ACTIVITIES AS PART OF THE GLOBAL VAX INITIATIVE IN SENEGAL. THESE INCLUDED THE DEVELOPMENT AND VALIDATION OF THE WORK PLAN AND BUDGET, AS WELL AS PARTICIPATION IN COORDINATION BODIES FOR COVID-19 CONTROL AND ROUTINE IMMUNIZATION. THE MAIN OBJECTIVE WAS TO SUPPORT THE AVAILABILITY OF QUALITY DATA FOR BETTER IMMUNIZATION MANAGEMENT. DIGITAL SQUARE PARTICIPATED IN COORDINATION MEETINGS WITH USAID PARTNERS AND THE KAFFRINE MEDICAL REGION TO DISCUSS THE RESULTS-BASED FINANCING INITIATIVE. IN ADDITION, A VIRTUAL MEETING WAS HELD WITH USAID IMPLEMENTING PARTNERS, THE PERMANENT SECRETARIAT OF ONE HEALTH SENEGAL, AND GOVERNORS TO OFFICIALLY LAUNCH COVID-19 IMMUNIZATION SCALE-UP ACTIVITIES AT THE REGIONAL LEVEL. A KEY FOCUS OF THIS WORK WAS THE RETROSPECTIVE ENTRY OF COVID-19 VACCINATION DATA INTO THE NATIONAL DHIS2 PLATFORM. DIGITAL SQUARE ORGANIZED WORKSHOPS TO ELIMINATE DATA ENTRY DELAYS IN 20 HEALTH DISTRICTS SPREAD ACROSS 10 MEDICAL REGIONS. ADDITIONALLY, DIGITAL SQUARE PROVIDED SUPPORT TO THE MINISTRY OF HEALTH THROUGH ITS EPI WITH THE ACQUISITION OF 624 SMARTPHONES FOR HEALTH FACILITY WORKERS IN SIX MEDICAL REGIONS. THESE SMARTPHONES WERE USED TO FACILITATE THE MANAGEMENT OF COVID-19 DATA AND STOCKS IN THE DHIS2 AND LOGISTIMO SYSTEMS. IN ADDITION, WE CONDUCTED INTERVIEWS TO ANALYZE THE ROOT CAUSES OF DATA ENTRY DELAYS IN SIX HEALTH FACILITIES IN THE KDOUGOU MEDICAL REGION. PATH CONTINUED WORKING WITH THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT IN SENEGAL. THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN IN 2022 WITH IMPLEMENTATION OF PULSE OXIMETRY AND CLINICAL DECISION SUPPORT ALGORITHMS (CDSA) AT 60 INTERVENTION SITES. SERVING AS THE LEAD PARTNER ON THE TIMCI PROJECT, PATH SUPPORTED THE MOH REVISION OF THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS. THROUGH THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT, PATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE THIRD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE TECHNICAL GUIDELINES, A KEY TOOL DEVELOPED BY THE WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR AFRICA (WHO AFRO) FOR THE IDENTIFICATION, MANAGEMENT, AND MITIGATI0N OF INFECTIOUS DISEASE OUTBREAKS. PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE. PATH ALSO WORKED WITH THE DIRECTORATE OF LABORATORIES IN DECENTRALIZING BACTERIOLOGY TESTING CAPACITIES BY INCLUDING SEVEN TIER 1 DIAGNOSTIC FACILITIES INTO THE NETWORK. PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF PRIVATE HEALTH FACILITIES IN INCORPORATING 12 PRIVATE CLINICS INTO THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM. THE ORGANIZATION COMPLETED THE EXPANSION OF THE COMMUNITY-BASED SURVEILLANCE OF PRIORITY HUMAN AND ZOONOTIC DISEASES IN THE TAMBACOUNDA REGION. WE ALSO PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF PREVENTION IN UPGRADING THE EARLY WARNING SYSTEM BY INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS. PATH'S DIGITAL SQUARE PROGRAM CONTINUED SUPPORTING SENEGAL'S MINISTRY OF HEALTH AND SOCIAL ACTION (MSAS) THROUGH USAID'S DIGITAL HEALTH COMMUNITY INITIATIVE (DCHI). IN 2022, DIGITAL SQUARE SUPPORTED THE MSAS IN DEVELOPING A COMMON VISION FOR COMMUNITY HEALTH DIGITIZATION USING THE COUNTRY PROFILE FINDINGS, THE DIGITAL HEALTH STRATEGIC PLAN, NMCP NATIONAL STRATEGIC PLAN, AND THE NATIONAL STRATEGIC COMMUNITY HEALTH PLAN. DIGITAL SQUARE ALSO SUPPORTED A HUMAN-CENTERED APPROACH TO DESIGNING THE DIGITAL COMMUNITY HEALTH TOOL BY CONDUCTING A USER NEEDS ASSESSMENT, A COLLABORATIVE REQUIREMENTS DEVELOPMENT METHODOLOGY (CRDM) WORKSHOP WITH KEY MSAS STAKEHOLDERS TO IDENTIFY 13 BUSINESS PROCESSES AND WORKFLOWS FOR COMMUNITY HEALTH AND 213 SYSTEM FUNCTIONAL REQUIREMENTS TO DEVELOP OR ADAPT THE DIGITAL TOOL. DIGITAL SQUARE SUPPORTED THE MSAS TO SELECT AN APPROPRIATE DIGITAL TOOL TO BE ADAPTED FOR COMMUNITY HEALTH DIGITIZATION IN A COLLABORATIVE WAY, INCLUDING THE HEALTH MANAGEMENT INFORMATION SYSTEMS (HMIS) EXPERTS FROM THE MSAS. THE DIGITAL SQUARE TEAM ALSO CONDUCTED A TWO-DAY WORKSHOP WITH A HEALTH ENTERPRISE ARCHITECTURE (HEA) EXPERT TO INTRODUCE THE CONCEPT OF HEA TO THE MSAS. NINE DIGITAL HEALTH EXPERTS FROM THE MSAS WERE SELECTED FOR THE OPEN GROUP ARCHITECTURE FRAMEWORK (TOGAF) TRAINING TO SUPPORT THE FUTURE DEVELOPMENT OF HEA IN SENEGAL. DIGITAL SQUARE'S SENEGAL TEAM ALSO WORKED TO STRENGTHEN THE USE OF COVAX DHIS2 AND IMPROVE THE MANAGEMENT OF COVID-19 VACCINATION DATA IN MALI. WE HOSTED ESSENTIAL TRAINING COURSES ON USE OF THE DHIS2 COVAX PACKAGE IN VARIOUS MEDICAL REGIONS, INCLUDING KAYES, SIKASSO, MOPTI, AND SGOU, AS WELL AS IN THE BAMAKO HEALTH DISTRICT. A TOTAL OF 104 HEALTH WORKERS, INCLUDING DATA MANAGERS AND COVID-19, VACCINATION, AND SURVEILLANCE FOCAL POINTS, WERE TRAINED IN THE COLLECTION AND MANAGEMENT OF DATA RELATING TO COVID-19 VACCINATION. PATH ALSO ORGANIZED DATA REVIEW MEETINGS IN THE MEDICAL REGIONS OF KAYES, SIKASSO, MOPTI, AND SGOU. THESE MEETINGS, WHICH USED DHIS2 AS A DATA VISUALIZATION AND ANALYSIS TOOL, WERE ATTENDED BY 188 REGIONAL AND DISTRICT STAFF. THEY PROVIDED AN OPPORTUNITY TO REVIEW IMMUNIZATION DATA IN DETAIL AND MONITOR PROGRESS IN EACH REGION. SUPERVISING VISITS WERE MADE TO THE KAYES AND KOULIKORO REGIONS TO PROVIDE PERSONALIZED SUPPORT TO 14 PEOPLE WHO HAD ALREADY BEEN TRAINED IN USE OF THE DHIS2 COVID-19 MODULE AND TO GUARANTEE THE QUALITY OF THE DATA COLLECTED AND ENTERED.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	TO FACILITATE RAPID AND SECURE DATA TRANSMISSION, DIGITAL SQUARE PROVIDED 180 INTERNET CONNECTIVITY KITS (KNOWN AS FLYBOXES) WITH 6-MONTH INTERNET PACKAGES TO THE MOH TO SUPPORT THE NATIONAL IMMUNIZATION CENTER AND HEALTH DISTRICTS IN SIX MEDICAL REGIONS (BAMAKO, KAYES, SIKASSO, KOULIKORO, SGOU, AND MOPTI) RESPONSIBLE FOR COVID-19 VACCINATION DATA COLLECTION. DIGITAL SQUARE ALSO HELPED UPDATE DHIS2 FORMS, ENSURING THEIR RELEVANCE AND ALIGNMENT WITH THE SPECIFIC NEEDS OF COVID-19 IMMUNIZATION DATA COLLECTION. THE TEAM DEVELOPED A USER GUIDE FOR THE COVAX DHIS2 PACKAGE, AS WELL AS A SPECIFIC GUIDE FOR DATA ANALYSIS. THESE GUIDES PROVIDE DETAILED INSTRUCTIONS ON HOW TO USE THE COVAX DHIS2 AND INTERPRET VACCINATION DATA. SOUTH AFRICA IN 2022 PATH ESTABLISHED A TECHNICAL ASSISTANCE PARTNERSHIP WITH THE PRIVATE OFFICE OF THE PRESIDENT (POP) IN SOUTH AFRICA, WHICH GREW FROM OUR SUPPORT TO THE PRESIDENT IN HIS LEADERSHIP ROLE WITH THE AFRICAN UNION (AU) COVID-19 COMMISSION. WE ADVISED THE PRESIDENT ON GLOBAL AND REGIONAL POLICY PROCESSES AIMED AT INCREASING ACCESS TO HEALTH TECHNOLOGIES, ESPECIALLY SUSTAINABLE MANUFACTURING. FOR EXAMPLE, WE DRAFTED A CONCEPT NOTE FOR POSITIONING SOUTH AFRICA AS HOST FOR A REGIONAL CENTRE OF REGULATORY EXCELLENCE (RCORE), A PARTNERSHIP BETWEEN THE POP AND THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY (SAHPRA). WE ALSO ADVOCATED THROUGH THE AU COVID-19 COMMISSION, TARGETING MULTILATERAL PROCUREMENT AGENCIES SUCH AS GAVI AND UNICEF TO PURCHASE AT LEAST 30 PERCENT OF VACCINES FROM AFRICAN MANUFACTURERS. ADDITIONALLY, ALONG THE SIDELINES OF THE WORLD HEALTH SUMMIT, PATH CO-CONVENED A SESSION IN PARTNERSHIP WITH THE POP THAT BROUGHT TOGETHER HIGH-PROFILE DELEGATES, INCLUDING THE SOUTH AFRICA DEPUTY MINISTER OF HEALTH, REPRESENTATIVES FROM GAVI, AND THE PRESIDENT OF THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) TO DELIBERATE ON MATTERS AFFECTING SUSTAINABLE MANUFACTURING SUCH AS POOLED PROCUREMENT OF AFRICAN-MANUFACTURED MEDICAL PRODUCTS, OFFSET GUARANTEES, AND MECHANISMS FOR EFFECTIVE TECHNOLOGY TRANSFER. STEMMING FROM PATH'S RELATIONSHIP WITH THE POP IN SOUTH AFRICA AS WELL AS PATH'S MEMORANDUM OF UNDERSTANDING WITH THE AFRICA CDC, PATH DRAFTED A PROPOSAL FOR THE HARMONISED ENTITY OF AFRICAN LEADERS IN TECHNOLOGIES FOR HEALTH (HEALTH), WHICH WILL BE HOUSED BY THE AFRICA CDC AND THE AU COVID-19 COMMISSION WITH A MANDATE TO ENSURE COORDINATED EFFORTS ON SUSTAINABLE PHARMACEUTICAL MANUFACTURING IN AFRICA AND REDUCE IMPORTATION OF BIOTECHNOLOGY AND HEALTH TECHNOLOGY. AS PART OF OUR PRIORITY TO ADVANCE MANUFACTURING POLICIES AND INCREASE DEMAND FOR LOCAL PRODUCTS, PATH SECURED A SEAT ON THE SOUTH AFRICA HEALTH PRODUCTS MASTER PLAN WORKING GROUP. THIS GROUP ENABLES PATH TO DIRECTLY INFLUENCE AND PROVIDE SUPPORT TO SOUTH AFRICA'S PLANS, THEREFORE SUPPORTING SKILLS TRANSFER AND STRENGTHENING THE RESEARCH AND DEVELOPMENT (R&D) POLICY ENVIRONMENT. WE ALSO PARTICIPATED IN THE SAMRC SUB-SAHARAN AFRICA FUNDERS FORUM WHERE WE DISSEMINATED RESEARCH AND REFLECTIONS FROM PATH'S DIAGNOSTICS AND CENTER FOR VACCINES INNOVATION AND ACCESS TEAMS TO INFORM THIS GROUP'S PRIORITIES. WE CONTINUED TO ADVOCATE ON THE AFRICAN MEDICINES AGENCY (AMA) RATIFICATION. IN SOUTH AFRICA, WE SAW THE CABINET APPROVE THE AMA TREATY AND INITIATE THE PROCESS OF SUBMITTING DOCUMENTS TO PARLIAMENT FOR RATIFICATION. TO ACHIEVE THIS MILESTONE, PATH PROVIDED TECHNICAL ASSISTANCE TO THE SOUTH AFRICAN NATIONAL DEPARTMENT OF HEALTH'S DIRECTORATE OF INTERNATIONAL HEALTH, INCLUDING PREPARING TECHNICAL BRIEFS AND TALKING POINTS. PATH HAS WORKED OVER THE PAST SEVERAL YEARS WITH SAHPRA TO IMPROVE ITS REGULATORY CAPACITY AND TO IMPROVE TRANSPARENCY AND COMMUNICATIONS. TO SUSTAIN VIBRANT R&D ADVOCACY AT COUNTRY AND REGIONAL LEVEL, PATH CONTINUED TO PROVIDE TECHNICAL ASSISTANCE AND CAPACITY STRENGTHENING TO A LOCAL COALITION, THE SOUTH AFRICA HEALTH TECHNOLOGIES ADVOCACY COALITION. TANZANIA IN 2022, THE DATA USE PARTNERSHIP PROJECT AN INITIATIVE LED BY THE GOVERNMENT OF TANZANIA WITH SUPPORT FROM THE GATES FOUNDATION THROUGH PATH FINALIZED THE RENOVATION OF THE CENTER OF DIGITAL HEALTH PREMISES, PAVING THE WAY FOR GOVERNMENT AND PARTNERS TO COLLABORATE AND COORDINATE DIGITAL HEALTH IMPLEMENTATION IN THE COUNTRY. PATH ALSO SUPPORTED THE DEVELOPMENT AND REVIEW OF THE DATA USE TOOL KIT AND DIGITIZATION OF THE TANZANIA HEALTH ENTERPRISE ARCHITECTURE (TZHEA) COMPLIANCE ASSESSMENT TOOL. THROUGH THE PEPFAR-CDC FUNDED HEALTH INFORMATION SYSTEM STRENGTHENING INITIATIVE FOR HIV AND TB PROJECT, PATH SUPPORTED INTEGRATION OF THE ELECTRONIC SAMPLE REFERRAL SYSTEM WITH THE SAMPLE TRANSPORTATION ON THE COURIER LOGISTIC SYSTEM (POSTA KIGANJANI) TO IMPROVE THE SAMPLE TRACKING MECHANISM FROM THE POINT OF COLLECTION TO TESTING. FURTHERMORE, WE ALSO SUPPORTED DEVELOPMENT OF THE ZANZIBAR LABORATORY INFORMATION SYSTEM AND UPGRADED THE TANZANIA HIV/AIDS CARE AND TREATMENT PATIENT RECORD SYSTEM TO INCLUDE BIOMETRIC FINGERPRINT. THE PATH-LED DIGITAL SQUARE PROJECT IN TANZANIA FACILITATED HEALTH INFORMATION MEDIATORS, DEVELOPED THE ZANZIBAR HEALTH INTEROPERABILITY LAYER FOR DATA EXCHANGE, AND SUPPORTED MOH HEALTH PROMOTION SERVICES IN IDENTIFYING, RELOCATING, AND MANAGING COMMUNITY-BASED WORKFORCES. PATH'S IDDS PROJECT TEAM SUPPORTED THE MOH IN REVIEWING THE AMR NATIONAL ACTION PLAN 2017-2022, ENHANCING TB DIAGNOSTIC CONNECTIVITY THROUGH SERVER INTEGRATION, DATA MIGRATION, AND GX-ALERT UPGRADES. PATH WITH SUPPORT FROM ASTRAZENECA SUCCESSFULLY LAUNCHED THE HEALTHY HEART AFRICA PROJECT IN DODOMA WITH STRONG INVOLVEMENT AND ATTENDANCE OF HIGH-LEVEL GOVERNMENT OFFICIALS. THROUGH THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) PROJECT, PATH SUPPORTED THE NATIONAL MEDICAL OXYGEN SCALE-UP PLAN, CORRECTIVE MAINTENANCE OF BIOMEDICAL EQUIPMENT, AND ROLLOUT OF MEDICAL EQUIPMENT AND INFRASTRUCTURE MANAGEMENT INFORMATION SYSTEM (MEIMIS)IN SEVEN REGIONS. UGANDA THROUGH THE USAID-FUNDED AND ICF-LED IDDS PROJECT, PATH SUPPORTED THE MINISTRY OF AGRICULTURE, ANIMAL INDUSTRIES, AND FISHERIES (MAAIF) TO IMPROVE DIAGNOSTIC CAPACITY IN THE ANIMAL HEALTH SECTOR BY IMPLEMENTING LABORATORY QUALITY MANAGEMENT SYSTEMS BASED ON THE INTERNATIONAL ORGANIZATION FOR STANDARDIZATION (ISO) 17025:2017 STANDARD AT FOUR ANIMAL HEALTH REGIONAL LABORATORIES. THIS WAS UNDERTAKEN AS PART OF THE PROCESS TO SUPPORT THE FIRST LABORATORY IN THE ANIMAL HEALTH SECTOR TO ACHIEVE ISO 17025 ACCREDITATION. PATH SUPPORTED THE NATIONAL ANIMAL DISEASES DIAGNOSTICS AND EPIDEMIOLOGY CENTER AND THE ANIMAL HEALTH NATIONAL REFERENCE LABORATORY WITHIN MAAIF TO DEVELOP AND ROLL OUT A MACRO-ENABLED EXCEL-BASED DATA ENTRY AND ANALYSIS TOOL TO ALL DISTRICTS AS A MEANS TO IMPROVE DATA ENTRY, QUALITY, ANALYSIS, AND REPORTING FOR ANIMAL HEALTH SURVEILLANCE SITES, WHICH HAD PREVIOUSLY BEEN USING A PAPER-BASED SYSTEM. THE IDDS PROJECT ALSO STRENGTHENED TB DIAGNOSIS CAPACITY OF THE LABORATORY NETWORK THROUGH THE PROCUREMENT AND INSTALLATION OF 38 TRUENAT TRUELAB MOLECULAR MACHINES WITH PORTABLE, BATTERY-OPERATED DEVICES THAT CAN RUN TESTS FOR RAPID TB DIAGNOSIS. THESE WERE INSTALLED AT 38 HIGH-VOLUME HEALTH FACILITIES TO IMPROVE PATIENT ACCESS TO TB AND RIFAMPICIN-RESISTANT DETECTION. PATH ALSO SUPPORTED THE DEVELOPMENT OF STANDARD OPERATING PROCEDURES AND WASTE MANAGEMENT GUIDELINES FOR COVID-19 VACCINATION ROLLOUT AND PROVIDED REGULATORY SUPPORT TO THE MOH TO EXPEDITE COVID-19 VACCINE AUTHORIZATION AND SHIPMENT INTO THE COUNTRY. THROUGH THE UNITAID-FUNDED HIV STAR III INITIATIVE, UGANDA HAS ACHIEVED SIGNIFICANT SCALE-UP IN HIV SELF-TESTING (HIVST) SERVICES. THE COUNTRY IS SET TO DISTRIBUTE 3.5 MILLION HIVST KITS ANNUALLY, MAKING IT THE LARGEST HIVST MARKET GLOBALLY. IN 2022, PATH DEVELOPED THE POST-MARKET SURVEILLANCE NATIONAL PLAN AND STANDARD OPERATING PROCEDURES FOR HIVST AND INTRODUCED THREE WHO-PREQUALIFIED BLOOD-BASED KITS INTO THE COUNTRY TO EXPAND CHOICE AND ACCESS. THESE CHANGES HAVE BEEN INTEGRATED INTO THE SUPPLY CHAIN AND OTHER SYSTEMS, LEADING TO THE GOVERNMENT'S REVIEW AND ADOPTION OF HIVST TRAINING MATERIALS FOR HEALTH CARE WORKERS AND DEVELOPMENT OF TRAINING MATERIALS FOR PEER HIVST DISTRIBUTORS. IN 2022 PATH ALSO PILOTED FOUR HIVST SERVICE DELIVERY MODELS IDENTIFIED THROUGH A USER-CENTERED APPROACH, TWO OF WHICH HAVE BEEN ADOPTED BY UGANDA'S MOH WITH SUPPORT FROM THE GLOBAL FUND. IN ADDITION, PATH HAS SUPPORTED THE BUNDLING OF SELF-CARE PRODUCTS BY PARTNERING WITH SOCIAL MARKETING ORGANIZATIONS, WHICH RESULTED IN INCREASED DEMAND FOR HIVST IN PRIVATE AND PUBLIC SECTOR.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	THE UGANDA SELF-INJECTION (SI) SCALE-UP PROJECT MADE SIGNIFICANT PROGRESS IN COLLABORATION WITH THE MOH AND PARTNERS TO SCALE UP SELF-INJECTION NATIONWIDE, WITH SELF-INJECTION AVAILABLE IN 85 PERCENT OF PUBLIC-SECTOR FACILITIES. PATH ADDRESSED GAPS IN SI SCALE-UP TRAINING, SUPERVISION, AND MONITORING, AND DISTRIBUTED TOOLS AND GUIDELINES IN 20 DISTRICTS THAT LACKED PARTNER SUPPORT. PATH ALSO SUPPORTED INTEGRATION OF DMPA-SC AND SI INTO THE NATIONAL PRE-SERVICE TRAINING CURRICULUM IN UGANDA AND ORIENTED 197 INSTRUCTORS ON THE CONTENT, WHO THEN TRAINED OVER 3,000 HEALTH WORKERS. IN PARTNERSHIP WITH INSUPPLY KENYA, PATH CONDUCTED A DMPA-SC SUPPLY CHAIN ANALYSIS AS PART OF THE REGIONAL TECHNICAL ASSISTANCE MECHANISM. THIS LED TO THE DEVELOPMENT OF AN ACTION PLAN TO ADDRESS KEY GAPS AND RECOMMENDATIONS WITH THE MOH AND PARTNERS, WHICH ARE PART OF THE UPDATED 20222024 NATIONAL DMPA-SC SELF-INJECTION SCALE-UP PLAN. PATH ACTIVELY PARTICIPATED IN THE DEVELOPMENT AND PILOTING OF THE SELF-CARE GUIDELINES USING SELF-INJECTION AS A SPRINGBOARD TO OTHER SELF-CARE INTERVENTIONS. THROUGH THE ADVOCACY AND PUBLIC POLICY PROGRAM, PATH SUPPORTED THE MOH, ALONGSIDE WHO AND UNICEF, TO DRAFT AND COST THE NATIONAL IMMUNIZATION STRATEGY (NIS) 2022-2026. IN 2022, PATH FACILITATED REESTABLISHMENT OF THE UGANDA PARLIAMENTARY FORUM ON IMMUNIZATION (UPFI) AND SUPPORTED DEVELOPMENT OF A FIVE-YEAR STRATEGIC PLAN INCLUDING A SET OF KEY PERFORMANCE INDICATORS TO GUIDE THEIR WORK. PATH ALSO TRAINED AND MENTORED 25 LOCAL IMMUNIZATION PARTNERS AND FACILITATED OPPORTUNITIES FOR THEM TO INPUT INTO KEY POLICY PROCESSES, SUCH AS THE NIS. ADDITIONALLY, WE SUCCESSFULLY LED THE ADVOCACY EFFORTS FOR THE GOVERNMENT TO FULFILL ITS CO-FINANCING OBLIGATIONS TO GAVI. PATH SUPPORTED THE COUNTRYWIDE ROLLOUT OF COLD CHAIN INFORMATION SYSTEM (CCIS), AN ODK-X BASED TOOL, TO DIGITIZE THE COLD CHAIN EQUIPMENT (CCE) INVENTORY AND GENERATE ACTIONABLE DATA FOR THE MAINTENANCE, MANAGEMENT, AND REPAIR OF CCE ASSETS. PATH ALSO SUCCESSFULLY TRAINED OVER 150 DISTRICT COLD CHAIN TECHNICIANS FROM 136 DISTRICTS AND 25 NATIONAL-LEVEL TECHNICIANS/SUPER USERS, EQUIPPED THEM WITH MOBILE DEVICES WITH THE APP INSTALLED, AND FACILITATED THEM TO CONDUCT CCE INVENTORY UPDATES. THROUGH THE COVID-19 DELIVERY SUPPORT PROJECT, PATH SECONDED TWO TECHNICAL OFFICERS TO THE MOH IMMUNIZATION PROGRAM TO FILL THE HUMAN RESOURCES CAPACITY GAP DUE TO THE COVID-19 PANDEMIC. AS PART OF THE HILTON-FUNDED AQUA STREAM PROJECT, PATH CONDUCTED JOINT MONITORING VISITS WITH THE MOH TO OBSERVE THE FUNCTIONALITY OF THE AQUA STREAM ONSITE CHLORINE DEVICES AND THE BENEFITS THAT THE DEVICES OFFERED TO THE TEN PILOT HEALTH FACILITIES. NUMEROUS STRONG USER TESTIMONIES ON HOW THE AQUA STREAM HAS CONTRIBUTED TO INFECTION PREVENTION AND CONTROL AT THE TEN PILOT HEALTH FACILITIES WERE OBTAINED. WITH RECOMMENDATION FROM THE HEALTH POLICY ADVISORY COMMITTEE AFTER A PRESENTATION OF AQUA STREAM PILOT PROJECT RESULTS, PATH CONDUCTED A JOINT EVALUATION VISIT WITH THE NATIONAL ADVISORY COMMITTEE ON MEDICAL EQUIPMENT TO HEALTH FACILITIES WHERE THE AQUA STREAM WAS DEPLOYED AND DETERMINED THAT THE AQUA STREAM CHLORINE WAS FOUND TO BE NON-CORROSIVE TO MEDICAL INSTRUMENTS AND FURNITURE. IN NOVEMBER 2022, PATH WORKED WITH THE MOH'S CLINICAL SERVICE DEPARTMENT ON THE DEPLOYMENT OF TWO AQUA STREAM DISINFECTANT GENERATORS TO SUPPORT THE NATIONAL EBOLA VIRUS DISEASE RESPONSE EFFORTS. ZAMBIA IN 2022, PATH CONTINUED TO COLLABORATE WITH ZAMBIA'S MOH. TO ACCELERATE ZAMBIA'S JOURNEY TO ELIMINATION, PATH'S MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA SUPPORTED THE MOH, THROUGH THE NATIONAL MALARIA ELIMINATION PROGRAMME, TO LAUNCH MALARIA CASE INVESTIGATION (MCI) AS PART OF ITS ONGOING EFFORTS TO END LOCAL TRANSMISSION OF MALARIA. MCI BUILDS ON A CENTRAL PLANK OF THE COUNTRY'S NATIONAL STRATEGY: TRAINING COMMUNITY HEALTH WORKERS (CHWS) TO TEST, TREAT, AND TRACK MALARIA IN THEIR HOME COMMUNITIES. PATH AND THE MOH CONTINUED TRAINING HEALTH FACILITY STAFF AND CHWS ON THE INTERVENTION AND HOW TO STRENGTHEN THEIR SKILLS IN THE FIELD AS PART OF THE MCI INTRODUCTION IN THE CHIKANKATA AND MAZABUKA DISTRICTS THAT BEGAN IN SEPTEMBER 2021. NEARLY 900 CASES OF MALARIA HAVE BEEN IDENTIFIED SINCE MCI BEGAN IN LATE 2021, WITH A MAJORITY OF THOSE INFECTIONS IN PEOPLE WHO HAD TRAVELED FROM OUTSIDE OF THE PROVINCE. PATH CO-FACILITATED A RELIGIOUS LEADER ORIENTATION FOR MUCHINGA, CENTRAL, AND COPPERBELT PROVINCES WITH FAITH LEADER ADVOCACY FOR MALARIA ELIMINATION (FLAME). FLAME CONDUCTED SUBNATIONAL ORIENTATIONS TO ESTABLISH FLAME CHAPTERS IN EACH OF THE COUNTRY'S TEN PROVINCES. PATH'S MACEPA TEAM PARTNERED WITH FLAME TO HOST ORIENTATIONS IN CENTRAL, COPPERBELT, AND MUCHINGA PROVINCES, SUCCESSFULLY ORIENTING ABOUT 250 RELIGIOUS LEADERS TO THE LOCAL MALARIA SITUATION, THE NATIONAL STRATEGY, KEY MALARIA MESSAGES, AND THEIR ROLE IN ZAMBIA'S PUSH TO END MALARIA. FAITH LEADERS ARE WELL POSITIONED TO DISSEMINATE MALARIA MESSAGES AND SUPPORT THE DEVELOPMENT OF COORDINATED NETWORKS AND STRATEGIC PARTNERSHIPS TO PRIORITIZE MALARIA AND STRENGTHEN HEALTH SYSTEMS AMONG INTERFAITH COMMUNITIES WITHIN THEIR PROVINCES. THE PAMO PLUS PROJECT IN ZAMBIA SUPPORTED THE NATIONAL MALARIA ELIMINATION PROGRAM (NMEP) TO TRAIN 1,723 CHWS AND 139 CHW SUPERVISORS IN MALARIA CASE MANAGEMENT AT THE COMMUNITY LEVEL IN THE FOUR SUPPORTED PROVINCES OF EASTERN, LUAPULA, MUCHINGA, AND NORTHERN. THE AIM IS TO TAKE MALARIA SERVICES CLOSER TO THE PEOPLE BY REDUCING TRAVEL TIME TO THE POINT OF CARE THEREBY ENCOURAGE EARLY CARE SEEKING. ADDITIONALLY, 2,423 COMMUNITY CHANGE AGENTS AND 400 FAITH LEADERS WERE TRAINED TO INFLUENCE BEHAVIOR CHANGE IN THEIR COMMUNITIES FOR INCREASED UPTAKE AND USE OF PROVEN MALARIA INTERVENTIONS. TO INCREASE UPTAKE OF SULFADOXINE-PYRIMETHAMINE (SP) AND INSECTICIDE-TREATED NETS, PAMO PLUS ORIENTED 1,405 SAFE MOTHERHOOD ACTION GROUPS THAT ENCOURAGE WOMEN TO GO FOR EARLY ANTENATAL CARE (ANC) BOOKING AND ADHERE TO RECOMMENDED SUBSEQUENT ANC VISITS. PAMO PLUS CONTINUED CONDUCTING A QUALITATIVE ASSESSMENT FOR THE PROACTIVE COMMUNITY CASE MANAGEMENT FOR MALARIA IN ZAMBIA (PROACT) STUDY TO DESCRIBE THE FEASIBILITY, CHALLENGES, AND BENEFITS OF PROACTIVE COMMUNITY CASE MANAGEMENT FROM THE PERSPECTIVE OF HEALTH FACILITY STAFF, CHWS, AND COMMUNITY MEMBERS. THE STUDY ALSO AIMS TO DESCRIBE COMMUNITY PERCEPTIONS OF THE DESIRABILITY, BENEFITS, AND EXPERIENCES OF THE CARE OFFERED THROUGH PROACTIVE CASE DETECTION. THE PROACT STUDY IS A THREE-YEAR RANDOMIZED CONTROL TRIAL (2021-2023) WITH THE GOAL OF COMPARING PASSIVE MALARIA CASE MANAGEMENT TO PROACTIVE MALARIA CASE MANAGEMENT TO DETERMINE WHICH OF THE TWO APPROACHES CAN REDUCE MALARIA INCIDENCE AND DEATHS QUICKER. THE PROACT STUDY ALSO CONDUCTED A BARRIER ANALYSIS TO EXPLORE BEHAVIORAL BARRIERS AND FACILITATING FACTORS AMONG SEGMENTED POPULATION GROUPS FOR THE ADOPTION, USE, AND MAINTENANCE OF PRIORITY BEHAVIORS. THE RESEARCH COMPRISED A QUALITATIVE COMPONENT THAT INCLUDED 160 INTERVIEWS (KEY INFORMANT INTERVIEWS AND FOCUS GROUP DISCUSSIONS WITH RELEVANT TARGET GROUPS). THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) PROJECT SUPPORTED DEVELOPMENT OF THE NATIONAL MEDICAL OXYGEN STRATEGIC PLAN 20222026. THE MOH COMPLETED DEVELOPMENT IN NOVEMBER 2022 AND IS EXPECTED TO LAUNCH THE PLAN IN MAY 2023. DMPA-SC ACCESS COLLABORATIVE (AC) CONTINUED SUPPORTING THE FAMILY PLANNING TECHNICAL WORKING GROUP (FPTWG), INCLUDING HOSTING MEETINGS AND LEADING ON ADVOCACY FOR REPRODUCTIVE HEALTH POLICY. THE AC SUCCESSFULLY SUPPORTED THE SCALE-UP AND INTRODUCTION OF DMPA-SC AND SELF-INJECTION IN PRIVATE PHARMACIES IN ZAMBIA. THE PROJECT BUILT QUALITY ASSURANCE AND EVALUATION ACTIVITIES INTO THE INITIAL PRIVATE PHARMACY INTRODUCTION TO INFORM ADVOCACY FOR FUTURE SCALE-UP. THE AC ALSO WORKED WITH THE PHARMACEUTICAL SOCIETY OF ZAMBIA AND OTHER PARTNERS TO TRAIN 136 PHARMACIES AND 156 PHARMACISTS TO PROVIDE DMPA-SC AND TO TRAIN WOMEN TO SELF-INJECT. THROUGH THE CATALYTIC OPPORTUNITY FUND, PATH SUPPORTED TWO SUPERVISION AND MENTORING VISITS TO 136 PHARMACIES IN FOUR PROVINCES OF ZAMBIA. WITH FUNDING FROM THE HEWLETT FOUNDATION, PATH COMPLETED THE FP/IMMUNIZATION INTEGRATION PROJECT IN FOUR DISTRICTS OF SOUTHERN PROVINCE USING A HUMAN-CENTERED DESIGN (HCD) APPROACH. THE ZAMBIA DIGITAL COMMUNITY HEALTH PROJECT COMPLETED REQUIREMENTS GATHERING FOR THE COMMUNITY HEALTH INFORMATION PLATFORM AND CONTRACTED TWO TECHNICAL PARTNERS TO DEVELOP IT. THE PROJECT SUPPORTED THE MOH TO REVISE REPORTING INDICATORS FOR THE NATIONAL COMMUNITY HEALTH MANAGEMENT INFORMATION SYSTEM WHICH IS CURRENTLY PAPER BASED.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	FUNDED BY THE BAYER FOUNDATION, THE SUPPORT FOR COVID-19 VACCINE PREPAREDNESS, ROLLOUT, AND SURVEILLANCE PROJECT IN ZAMBIA INITIATED THE ENGAGEMENT OF TRADITIONAL LEADERSHIP WITH SUPPORT FROM THE SPECIAL ADVISOR TO THE PRESIDENT. PATH ORIENTED 57 HEADMEN (INDUNAS) AND 5 CHIEFS TO THE PROJECT. PATH ALSO HELPED DEVELOP A WASTEWATER SURVEILLANCE PROTOCOL (APPROVED BY RELEVANT RESEARCH AUTHORITIES), PROCURED A NOVEL TESTING METHOD, AND TRAINED KEY PERSONNEL ON ENVIRONMENTAL SURVEILLANCE FOR SARS-COV-2 AND OTHER PATHOGENS SAMPLING. IN 2022, QUALITATIVE INSIGHTS FROM LIVING LABS WERE AMPLIFIED WITH QUANTITATIVE ANALYSIS AND DATA VISUALIZATION TO DESCRIBE 26 ROOT CAUSES OF DEMOTIVATION AMONG FRONTLINE IMMUNIZATION PROVIDERS AND ANALYZE COMMONALITIES IN HCD-DERIVED THEORIES OF CHANGE. PATH CREATED THE INSIGHTS EXPLORER TOOL, AN INTERACTIVE DASHBOARD TO FACILITATE THE EXPLORATION OF THESE ROOT CAUSES, AND PUBLISHED IT ONLINE WITH PUBLIC ACCESS. THIS WEB-BASED INTERACTIVE COMMUNICATION PLATFORM DOCUMENTS LIVING LABS' HCD PROCESSES AND OUTPUTS IN KENYA AND ZAMBIA IN A FORMAT THAT FACILITATES EXPLORATION AND UNDERSTANDING OF KEY PROJECT QUALITATIVE INSIGHTS. THE GOAL IS TO ADVANCE PREVIOUS EFFORTS IN HCD GLOBAL HEALTH PROJECTS BY INCREASING TRANSPARENCY OF THE CONTINUUM OF CONTEXTUAL CHALLENGE THROUGH TO THE PROCESS OF GENERATING PROTOTYPES WITH END USERS. PATH'S LIVING LABS SUPPORTED THE DEVELOPMENT OF THE RELI DELIVERY SYSTEM, A LOW-COST, HYBRID PNEUMATIC-ELECTRIC INFUSION PUMP DESIGNED TO ADDRESS CHALLENGES FOUND IN RESOURCE-CONSTRAINED HEALTH SYSTEMS. IT IS A LOW-COST, RELIABLE, STURDY, AND EASY-TO-USE ALTERNATIVE TO CONVENTIONAL ELECTRIC INFUSION PUMPS. THE LIVING LABS TEAM SUPPORTED THE DESIGN OF THE RELI'S ELECTRONIC SUBSYSTEMS AND CONDUCTED A USER ASSESSMENT IN ZAMBIA TO UNDERSTAND THE CONTEXT OF USE AND USER PERCEPTIONS OF THE RELI, WHICH IS ESSENTIAL TO ACHIEVE OPTIMAL DESIGN OF THE SYSTEM. THE ASSESSMENT AIMED TO: (1) PROVIDE PROSPECTIVE USERS WITH AN OPPORTUNITY TO CONDUCT A SIMULATION OF AN INFUSION USING A PROTOTYPE OF THE RELI DELIVERY SYSTEM AND TO ASSESS USER EXPERIENCES OF THE USABILITY OF THE VARIOUS COMPONENTS OF THE DEVICE. (2) GATHER USER INPUT ON THE ACCEPTABILITY AND EASE OF USE OF THE RELI DELIVERY SYSTEM INCLUDING SETTING UP THE SYSTEM, ACTIVATING THE SYSTEM, AND COMPLETING A SIMULATION USING THE RELI DELIVERY SYSTEM. PATH AND FIND PARTNERED TO IMPROVE DATA COLLECTION AND MITIGATE CURRENT PAIN POINTS ASSOCIATED WITH COVID-19 DIAGNOSTIC TESTING IN LOW- AND MIDDLE-INCOME SETTINGS. THE TEAMS WORKED TO DEVELOP STANDARDS AND ENHANCE THE INTEROPERABILITY OF PATIENT AND DIAGNOSTIC DATA COLLECTION PLATFORMS WHILE INCORPORATING THEM INTO MOBILE HEALTH TOOLS. LIVING LABS IN ZAMBIA AND SENEGAL ENGAGED END USERS TO IDENTIFY AND VALIDATE NEEDS AND PRIORITIES AND WORKED WITH APPLICATION DEVELOPERS TO ITERATIVELY TEST AND REFINE THE DIGITAL HEALTH SOLUTION, USING OPERATIONAL RESEARCH AT COMMUNITY HEALTH FACILITIES.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM.
FORM 990, PART VI, SECTION B, LINE 12C	PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING.
FORM 990, PART VI, SECTION B, LINE 15	THE BOARD ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO AND DIVISION CHIEFS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD IN 2022. AT THE REQUEST OF THE BOARD, PATH ENGAGED FUTURE SENSE (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND DIVISION CHIEFS. FUTURE SENSE USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD REVIEWED THE FUTURE SENSE REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE DIVISION CHIEFS. ADDITIONALLY, FUTURE SENSE REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE.
FORM 990, PART VI, SECTION C, LINE 19	PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (2 entries)

Address Line1ForeignAddress/AddressLine1Txt	CityForeignAddress/CityNm	CountryForeignAddress/CountryCd	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile Foreign CountryLegalDomicileForeignCountryCd	Exempt Code SectionExemptCodeSectionTxt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt	Controlled OrganizationControlledOrganizationInd
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
207 ROUTE DE FERNEY 1218 LE GRAND-S	GENEVA	SZ	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	SZ	501(C)(3)	PATH	Yes (1)
PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA
ACS PLAZA 4TH FL LENANA RD PO BOX	NAIROBI	KE	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	KE	501(C)(3)	PATH	Yes (1)

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	0	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	Yes (1)	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	Yes (1)	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	0	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	0	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	0	DivRelatedOrganizationInd
Asset Sale To Other Org	0	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	0	AssetPurchaseFromOtherOrgInd
Asset Exchange	0	AssetExchangeInd
Rental Of Facilities To Oth Org	0	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	0	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	0	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	0	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	0	SharingOfFacilitiesInd
Paid Employees Sharing	0	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	0	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	0	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	0	TransferToOtherOrgInd
Transfer From Other Org	0	TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (4 entries)

Transaction TypeTransactionTypeTxt	InvolvedInvolvedAmt	Method Of Amount DeterminationMethodOfAmountDeterminationTxt
PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA
C	$3,713,487	FMV
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
B	$5,631,350	FMV
PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA
B	$9,001,439	FMV
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
C	$3,544,561	FMV